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Glucocorticoids are steroid hormones involved in the stress response, with a well-
established role in promoting cardiovascular risk factors including obesity and 
diabetes. The focus of glucocorticoid research has shifted from understanding control 
of blood levels, to understanding the factors that control tissue steroid concentrations 
available for receptor activation; it is disruption of these tissue-specific factors that has 
emerged as underpinning pathophysiological mechanisms in cardiovascular risk, and 
revealed potential therapeutic targets. However, the field is hampered by the inability 
at present to measure concentrations of steroid within individual tissues and indeed 
within component cell types. This research project explores the potential for steroid 
measurements using mass spectrometry-based tissue imaging techniques combining 
matrix assisted laser desorption ionization with on-tissue derivatisation with Girard T 
and Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (OTCD-MALDI-
FTICRMS). 
A mass spectrometry imaging (MSI) platform was developed and validated to quantify 
inert substrate and active product (11-dehydrocorticosterone (11DHC), corticosterone 
(CORT) respectively) of the glucocorticoid-amplifying enzyme 11-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1) in rodent tissues. A novel approach to derivatising 
keto-steroids in tissue sections using Girard T reagent was developed and validated. 
Signals were boosted (10
4 
fold) by formation of GirT hydrazones compared to non-derivatised 
neutral steroids. Active and inert glucocorticoids were detected in a variety of tissues, 
including adrenal gland and brain; in the latter, highest abundance was found in the cortex and 
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hippocampus. The MSI platform was also applied to human biopsies and murine tissues 
for the analysis of other ketosterols such as androgens and oxysterols. 
Proof-of-principle validation that the MSI platform could be used to quantify 
differences in enzyme activity was carried out by following in vivo manipulation of 
11β-HSD1. Regional steroid distribution of both substrate and product were imaged at 
150-200μm resolution in mouse brain sections, and the identification confirmed by 
collision induced dissociation/liquid extraction surface analysis (CID-LESA). To 
validate the technique, the CORT/11DHC ratios (active/inert) were determined in 11-
HSD1 deficient mice and found to be reduced (KO vs WT; cortex (49 %*); 
hippocampus (46 %*); amygdala (57 %)). Following pharmacological inhibition by 
administration of UE2316, drug levels peaked at 1 h in tissue and at this time point, a 
reduction in CORT/11DHC ratios were also determined, although to a lesser degree 
than in KO mice, cortex (22%), hippocampus (25 %) and amygdala (33 %). The 
changes in ratios appeared driven by accumulation of DHC, the enzyme substrate. In 
brains of mice with 11-HSD1 deficiency or inhibition, decreases in sub-regional 
CORT/11DHC ratio were quantified, as well as accumulation of an alternative 11-
HSD1 substrate, 7-ketocholesterol. MSI data correlated well with the standard liquid 
chromatography tandem mass spectrometry (LC-MS/MS) in whole brain homogenates. 
Subsequently, the MSI platform was also applied to measure the dynamic turnover of 
glucocorticoids by 11-HSD1 in metabolic tissues using stable isotope tracers 
(Cortisol-D4 (9,11,12,12-D4) (D4F). D4F was detected in plasma, liver and brain after 6 
h infusion and after 48 h in adipose. D3F generation was detected at 6 h in plasma and 
liver; at 24 h in brain specifically in cortex, hippocampus and amygdala; and at 48 h in 
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adipose. The spatial distribution of d3F generation in brain by MSI closely matched 
enzyme localisation. In liver, an 11β-HSD1-riched tissue, substantial generation of d3F 
was detected, with a difference in d4F/d3F ratios compared with plasma (ᴧTTRᴧ 0.18± 
0.03 (6 h), 0.27± 0.05 (24 h) and 0.38±0.04 (48 h)). A smaller difference in TTR was 
also detected between plasma and brain (ᴧTTR 0.09 ± 0.03 (24 h), 0.13±0.04 (48 h)), 
with no detectable regeneration in adipose. After genetic disruption of 11β-HSD1, d3F 
generation was not detected in plasma or any tissues, suggesting that 11-HSD1 is the 
only enzyme carrying out this reaction. After pharmacological inhibition, a similar 
pattern was seen. The circulating concentration of drug peaked at 2 h and declined 
towards 4 h, with same pattern in liver and brain. The ᴧTTR ratios 2HPD between 
plasma and liver (0.27±0.08vs. 0.45± 0.04) and brain (0.11±0.2 vs. 0.19± 0.04) were 
smaller following drug administration than vehicle, indicating less d3F generation. 
Extent of enzyme inhibition in liver responded quickly to the declining drug, with 
ᴧTTR returning to normal by 4 h (0.38± 0.06). ᴧTTR had not normalised 4HPD in 
brain (0.12±0.02, suggesting buffering of this pool. In adipose, UE2316 was not 
detected and nor were rates of d3F altered by the drug. Two possible phase I CYP450 
metabolites were identified in the brain differing in spatial distribution.  
In conclusion, MSI with on-tissue derivatisation is a powerful new tool to study the 
regional variation in abundance of steroids within tissues. We have demonstrated that 
keto-steroids can be studied by MALDI-MSI by using the chemical derivatisation 
method developed here and exemplified its utility for measuring pharmacodynamic 
effects of small molecule inhibitors of 11-HSD1. This approach offers the prospect of 
many novel insights into tissue-specific steroid and sterol biology. 
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1.1.   Steroids  
1.1.1.  Structure and function 
The steroid hormones are all derived from cholesterol. Moreover, with the exception of 
vitamin D, they all contain the same cyclopentanophenanthrene ring and atomic 
numbering system as cholesterol. The conversion of C27 cholesterol to the 18-, 19-, and 
21-carbon steroid hormones (designated by the nomenclature C with a subscript 
number indicating the number of carbon atoms, e.g. C19 for androstanes) involves the 
rate-limiting, irreversible cleavage of a 6-carbon residue from cholesterol, producing 
pregnenolone (C21) plus isocaproaldehyde (Lednicer, 2011). 
 
Figure 1.1: Steroid core and nomenclature. Adapted from (Lednicer, 2011) 
 
Common names of the steroid hormones are widely recognized, but systematic 
nomenclature is gaining acceptance and familiarity with both nomenclatures is 
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increasingly important. Steroids with 21 carbon atoms are known systematically as 
pregnanes, whereas those containing 19 and 18 carbon atoms and aromatic rings are 
known as androstanes and estranes, respectively (Carson-Jurica et al., 1990). Most of 
the steroid hormones exert their action by passing through the plasma membrane and 
binding to intracellular receptors, although in some cases, they may act directly on 
membrane receptors (Puia et al., 1990). Steroids exert their genomic action by their 
corresponding receptor which binds to specific nucleotide sequences in the DNA of 
responsive genes. These DNA sequences are identified as hormone response elements, 
(HREs). The interaction of steroid-receptor complexes with DNA leads to altered rates 
of transcription of the associated genes (Beato et al., 1995). The particular steroid 
hormone class synthesised by a given cell type depends upon its complement of 
peptide hormone receptors, its response to peptide hormone stimulation and enzymes 
transcribed and translated. The following indicates which glycoprotein is mainly 
responsible for stimulating the synthesis of which steroid hormone: Luteinizing 
Hormone (LH): progesterone and testosterone, adrenocorticotrophic hormone 
(ACTH): cortisol and corticosterone, follicle stimulating hormone (FSH): estradiol and 
angiotensin II/III: aldosterone (Leake et al., 1987). 
1.1.2.  Steroids and the adrenal cortex 
The adrenal cortex is responsible for production of three major classes of steroid 
hormones critical for health: glucocorticoids, which regulate carbohydrate metabolism; 
mineralocorticoids, which regulate the body levels of sodium and potassium; and 
androgens, whose actions are similar to that of steroids produced by the male gonads 
(Baxter, 1976). Primary adrenal insufficiency is known as Addison’s disease, and in the 
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absence of steroid hormone replacement therapy can rapidly cause death. The adrenal 
cortex is composed of three main tissue regions: zona glomerulosa, zona fasciculata, 
and zona reticularis. Although the pathway to pregnenolone synthesis is the same in all 
zones of the cortex, the zones are histologically and enzymatically distinct, with the 
exact steroid hormone product dependent on the enzymes present in the cells of each 
zone (James, 1992). Many of the enzymes of adrenal steroid hormone synthesis are of 
the class called cytochrome P450 enzymes. These enzymes all have a common, 
standardised nomenclature, using the abbreviation CYP. For example the P450 enzyme 
(also called 20, 22-desmolase or cholesterol desmolase) is identified as CYP11A1. In 
order for cholesterol to be converted to pregnenolone in the adrenal cortex, it must be 
transported into the mitochondria where CYP11A1 resides (Hanukoglu, 1992b). This 
transport process is mediated by steroidogenic acute regulatory protein (StAR). This 
transport process is the rate-limiting step in steroidogenesis (Hanukoglu, 1992a). The 





Figure 1.2: Adrenal gland steroidogenesis. (Adapted from Miller et al., 2011). DHT: 
Dyhydrotestosterone, 3β-HSD: 3β-hydroxysteroid dehydrogenase, 17β-HSD: 17β-hydroxysteroid 
dehydrogenase 
 
1.1.3.  Steroidogenesis 
Steroidogenic enzymes fall into two superfamilies. Most belong to the CYP-P450 
monooxidase gene family and are thus referred to as CYPs. These enzymes are located 
either in the inner mitochondrial matrix, where they use molecular oxygen and a 
flavoprotein electron donor, or in the smooth endoplasmic reticulum, where they use a 
different flavoprotein for electron transfer. Different CYP enzymes act as hydroxylases, 
lyases (desmolases), oxidases, or aromatases (Miller et al., 2011). Two of these 
enzymes have multiple functions. CYP17 has both a 17-hydroxylase function and a 
17,20-lyase (desmolase) function. CYP11B2, also called aldosterone synthase, has 
three functions: 11-hydroxylase, 18-hydroxylase, and 18-oxidase. The other enzymes 
involved in steroidogenesis belong to three hydroxysteroid dehydrogenase (HSD) 
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families (Gonzalez, 1988). 3β-HSDs have two isoforms that convert the hydroxyl 
group on carbon 3 of the cholesterol ring to a ketone and shift the double bond from the 
5-6 (Δ5) position to the 4-5 (Δ4) position. All active steroid hormones must be 
converted to Δ4 structures by 3β-HSD (Lorence et al., 1990). The 17β-HSDs have at 
least five members and can act as either oxidases or reductases. 17β-HSDs primarily 
act on sex steroids and can be activating or deactivating (Moghrabi et al., 1998). 
1.1.4.  Cortisol 
The zona fasciculata produces the glucocorticoid hormones, for example cortisol in 
humans. This zone is an actively steroidogenic tissue composed of straight cords of 
large cells. These cells have a "foamy" cytoplasm because they are filled with lipid 
droplets that represent stored cholesterol esters (Strain et al., 1980). These cells make 
some cholesterol de novo but also import cholesterol from blood in the form of low-
density lipoprotein (LDL) and high-density lipoprotein (HDL) particles. Free 
cholesterol is then esterified and stored in lipid droplets (Olson, 1998). The stored 
cholesterol is continually turned back into free cholesterol by a cholesterol ester 
hydrolyase, a process that is increased in response to the stimulus of cortisol synthesis 
(e.g., adrenocorticotrophic hormone [ACTH]). In the zona fasciculata, cholesterol is 
converted sequentially to pregnenolone, progesterone, 17-hydroxyprogesterone, 11-
deoxycortisol, and cortisol (Figure 1.2) (Stocco et al., 1996). A parallel pathway in the 
zona fasciculata involves the conversion of progesterone to 11-deoxycorticosterone 
(DOC) and then to corticosterone. This pathway is minor in humans, but corticosterone 
is the principle glucocorticoid in mice and rats. In the absence of active CYP11B1 (11-
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hydroxylase activity), the production of DOC is significant. Because DOC acts as a 
weak mineralocorticoid, elevated levels of DOC cause hypertension (Costanzo, 2006).  
Cortisol is transported in blood to its sites of action predominantly bound to 
corticosteroid-binding globulin [CBG] (also called transcortin), which binds about 
90%, and albumin, which binds 5- 7% of the circulating hormone (Zhou et al., 2006). 
The liver is the predominant site of steroid inactivation. It both inactivates cortisol and 
conjugates active and inactive steroids with glucuronide or sulfate so that they can be 
excreted more readily by the kidney (Basu et al., 2009). However pathways also exist 
in the liver to regenerate active cortisol. 
Cortisol has a broad range of actions and is often characterised as a "stress hormone." 
In general, it maintains blood glucose levels, CNS function, and cardiovascular 
function during fasting and increases blood glucose during stress at the expense of 
muscle protein (Andrews et al., 1999; Maclullich et al., 2005; Walker, 2007; Walker et 
al., 1995). Also, it protects the body against the self-injurious effects of unbridled 
inflammatory and immune response (Carmichael et al., 1981) and has several other 
effects on bone, skin, connective tissue, the GI tract (Mitchell et al., 1990), and the 
developing foetus (Lindsay et al., 1996) that are independent of its stress-related 
functions. Cortisol reinforces its effects on blood glucose by its positive effects on the 
cardiovascular system. It is permissive for the actions on catecholamines (Brust et al., 
1951) and thereby contributes to cardiac output and blood pressure (Connell et al., 
1987). Cortisol stimulates erythropoietin synthesis and hence increases red blood cell 
production. Anaemia occurs when cortisol is deficient, and polycythaemia occurs when 
cortisol levels are excessive (Kelly et al., 2000). 
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1.2.  Intracrinology 
Hormones form in specialised glands, called endocrine glands, and are released into the 
general circulation and transported to distant target cells. On the other hand, hormones 
released from one cell can influence neighbouring cells (paracrine activity) or can exert 
a positive or negative action on the cell of origin (autocrine activity) (Labrie et al., 
1988). The term Intracrinology was coined in 1991 by Labrie et al to focus our 
attention on the synthesis of active steroids in peripheral target tissues where steroid 
action is exerted in the same cells where synthesis takes place without release of the 
active hormones in the extracellular space and in the general circulation (Labrie, 
1991)(Figure 1.3).  
 
 
 Figure 1.3: Representation of endocrine, paracrine, autocrine and intracrine secretion. Adapted from 






1.2.1.  Intracrinology of Glucocorticoids 
It is now viewed as very important to elucidate by factors that determine intracellular 
glucocorticoid concentrations available for action. Access of glucocorticoids to 
corticosteroid receptors (MR or GR) is determined not only by the plasma pool of 
glucocorticoid but also by local metabolism of glucocorticoids (e.g. by 11β-
hydroxysteroid dehydrogenases (11β-HSDs) and 5α-reductases) (Livingstone et al., 
2014; Walker, 2007; Yang et al., 2011), and potentially by active transport of 
glucocorticoids across the cell membrane (Webster et al., 2002) and/or by the control 
of storage of glucocorticoids in the inert triglyceride pool in some tissues (Hughes et 
al., 2010).  
1.2.2.  Intracrinology of androgens 
Adrenal androgens contribute 40% of total androgens in adult men. The inactive 
precursor steroids dehydroepiandrosterone (DHEA) and DHEA-sulphate are secreted in 
large amounts by the adrenals and reach the prostate and other peripheral target tissues, 
where they are transformed into the potent androgen dihydrotestosterone (DHT) 
(Labrie, 2004). In other hands, testosterone is taken up from the systemic circulation by 
the prostatic glandular and stromal cells. Once within the prostate, testosterone is 
rapidly and irreversibly converted to dihydrotestosterone (DHT) by the enzyme 5AR. 
This leads to a five-fold higher concentration of DHT versus testosterone within the 
intracellular prostate, versus an eleven-fold higher concentration of testosterone within 
the circulation (Bartsch et al., 2002). DHT then binds to the androgen receptor within 
the cytosol, is actively transported into the nucleus, and serves as a transcription factor 
for prostatic gene expression and thus prostatic cellular function. The higher 
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concentration of intracellular DHT, in addition to its higher affinity for the androgen 
receptor, support the importance of 5AR in normal and pathologic prostate physiology 
(Labrie et al., 1993). The 5AR enzyme is responsible for converting testosterone into 
DHT. DHT is a prevalent and potent androgen in prostate tissue and is responsible for 
embryologic development of the prostate (Walsh et al., 1974), growth of the prostate 
and promotion of prostate cancer (McConnell, 1995). Finasteride inhibits 5-AR type 2, 
and dutasteride inhibits 5AR types 1 and 2. Both finasteride and dutasteride were 
designed and approved for the treatment of benign prostatic hyperplasia (BPH) and 
have proven efficacy in this regard. 
1.2.3.  11β-Hydroxysteroid dehydrogenase (11β-HSDs) 
1.2.3.1.  Structure and functions 
The interconversion of active cortisol and inert cortisone is mediated by the two 
isozymes of 11β-HSD (Figure 1.4) (White et al., 1997). Both enzymes are 
hydrophobic, membrane-bound proteins that bind cortisol/cortisone and corticosterone 
(CORT)/ 11-dehydrocorticosterone (11DHC), but otherwise their properties and 
physiological roles differ substantially (White et al., 1997) (Table 1.1). Interest in these 
enzymes extends far beyond their deficiency states because they play central roles in 





Figure 1.4:11β-HSD in rodents and humans. Adapted from (White et al., 1997). NADP: nicotinamide 
adenine dinucleotide phosphate, NAD: nicotinamide adenine. Oxid n: Oxidation. Red n: reduction. 
 
Table 1.1: Principal characteristics of the two isozymes of 11βHSD 
 11β-HSD type 1 11β-HSD type 2 
Tissues Liver, testis, lung, fat, proximal 
nephron, CNS. 
Distal nephron, placenta, 
colon 
Location Endoplasmic reticulum, facing lumen Endoplasmic reticulum, 
facing cytoplasm 
Reaction Reduction/Oxidation Oxidation 
Substrates Cortisone, 11-dehydrocorticosterone, 
cortisol, corticosterone, synthetic 








Coenzyme H6PDH  
Km 0.1–0.3/1-2 μM 0.01–0.1 μM 
Km:  Michaelis constant, NADP: nicotinamide adenine dinucleotide phosphate, NAD: nicotinamide 





1.2.3.2.  11β-HSD type 1 
11β-HSD type 1 enzyme (11β-HSD1) (Tannin et al., 1991) is a dimer of 34-kDa 
subunits expressed mainly in glucocorticoid-responsive tissues such as the liver, testis, 
lung, fat, and proximal convoluted tubule (Morton, 2010; Seckl et al., 2004a). The type 
1 enzyme catalyzes both the oxidation of cortisol to cortisone using NADP+ as cofactor 
(Km 1–2 μM) and the reduction of cortisone to cortisol using NADPH cofactor (Km 0.1–
0.3 μM), with cortisone reduction being the dominant reaction in transfected cells 
(Agarwal et al., 1989; Moore et al., 1993); the reaction catalysed depends on which 
cofactor is available (Agarwal et al., 1990). Many synthetic glucocorticoids (e.g., 
prednisone and cortisone) are 11-ketosteroids that must be reduced to their 11β-
hydroxy derivatives to attain biological activity; these transformations are performed 
mainly in the liver by 11β-HSD1. However, when recombinant 11β-HSD1 is 
expressed in vitro, oxidation of cortisol with NADP+ is more efficient, and cortisone 
reduction is only achieved if NADP+ is removed by an enzymatic NADPH regeneration 
system (Walker et al., 2001). Thus, the net flux of steroid driven by 11β-HSD1 depends 
on the relative concentrations of available NADPH and NADP+, which usually favours 
reduction in cells, especially given the high Km of the enzyme for cortisol. The 
discrepancy between the prominent oxidative preference in vitro and the reductive 
dominance in vivo derives from the localisation of 11β-HSD1 in the lumen of the 
endoplasmic reticulum (Albiston et al., 1994). In the endoplasmic reticulum, the ratio 
of NADPH to NADP+ is maintained by hexose-6-phosphate dehydrogenase (H6PDH), 
rather than by cytoplasmic NADP+-coupled dehydrogenases (e.g., glucose-6-phosphate 
dehydrogenase) (Bujalska et al., 2003). Furthermore, a balance of activities has been 
found by in vivo observations in adipose and muscle tissues (Hughes et al., 2012). 
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Early studies had addressed the hypothesis that 11β-HSD1, like 11β-HSD2, was a 
predominant dehydrogenase enzyme, which protected glucocorticoid receptors, e.g. in 
testis. However, it appears that there is an ample supply of inert substrate that can be 
reactivated by predominant 11β-reductase activity of 11β-HSD1 in many tissues in 
vivo. To explore this further, 11β-HSD1 “knock-out” mice (11β-HSD1
−/−)
 have been 
generated following genetic disruption of the Hsd1b1 allele; homozygous mice had no 
detectable 11β-HSD1 mRNA and also no 11-reductase activity as demonstrated by the 
failure to convert 11-DHC to corticosterone. The knockout mice thrived, were fertile, 
and basally did not exhibit any overt phenotypical abnormalities (Kotelevtsev et al., 
1997). However, upon closer examination, it was determined that glucocorticoid-
induced responses were attenuated in the 11β-HSD1
−/−
 mice, consistent with the 
hypothesis that 11β-HSD1 activity contributes significantly to the active intracellular 
glucocorticoid pool. For example, the 11β-HSD1 null mice are less able to induce 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (key 
glucocorticoid-inducible gluconeogenic and glycolytic enzymes) following a fast, 
compared to wild-type controls (Paterson et al., 2005). Furthermore, after 4 weeks fat 
feeding or following an acute stressor, the 11β-HSD1 knockout mice had lower levels 
of fasting plasma glucose. More detailed analysis of these mice suggest that 11β-HSD1 
deficiency produces a “cardioprotective” lipid profile due, at least in part, to increased 
beta oxidation in the liver, hepatic insulin sensitization, and reduced fibrinogen 





1.2.3.3.  11β-HSD type 2 
The 41 kDa type 2 enzyme (11β-HSD2) has only 21% sequence identity with 11β-
HSD1, whereas 11β-HSD2 and 17β-HSD2 share 37% identity and favour steroid 
oxidation in vivo. Thus, 11β-HSD1 and 2 are only distantly related members of the 
short-chain dehydrogenases/reductases (SDR) family, yet they perform physiologically 
related but opposite functions. 11β-HSD2 catalyzes only the oxidation of cortisol to 
cortisone using NAD
+
 and functions with low (nM) concentrations of steroid (Km 10–
100 nM) (Brown et al., 1993; Rusvai et al., 1993); an ability of 11β-HSD2 to catalyse 
reduction has not been demonstrated for endogenous steroids, although in vitro it can 
be demonstrated to catalyse reduction of synthetic keto-steroids (Heirholzer et al., 
1966). 11β-HSD2 is expressed in mineralocorticoid-responsive tissues and thus serves 
to “defend” the mineralocorticoid receptor by inactivating cortisol to cortisone, so that 
only “true” mineralocorticoids, such as aldosterone can exert a mineralocorticoid 
effect. 11β-HSD2 is inactive against aldosterone and 9α-fludrocortisol. Thus, 11β-
HSD2 prevents cortisol from overwhelming renal mineralocorticoid receptors (Funder, 
1993), and in the placenta and other foetal tissues 11β-HSD2 (Krozowski et al., 1995) 
also inactivates cortisol. The placenta also has abundant NADP
+
 favouring the 
oxidative action of 11β-HSD1, so that in placenta both enzymes may protect the foetus 
from high maternal concentrations of cortisol. 
11β-HSD2 disruption on an out bred background revealed mice with an apparently 
normal phenotype at birth but within 48 h, half of them exhibit motor deficiencies, 
perhaps due to hypocalcaemia, and die (Kotelevtsev et al., 1999). Survivors are fertile, 
but exhibit severe hypertension and polyuria, all typical characteristics of apparent 
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mineralocorticoid excess (AME) and thus apparent mineralocorticoid actions of 
corticosterone were revealed by 11β-HSD2 deficiency. The original strain of modified 
mice did not exhibit reduced foetal weight although this was clearly apparent in later 
studies on a 11β-HSD2 knock-out model congenic on a C57BL/6 J background 
(Holmes et al., 2006). This raises the intriguing possibility of gene interaction effects 
on feto-placental 11β-HSD2 function. 
In addition to the AME symptoms, 11β-HSD2
−/−
 mice revealed a key role for 11β-
HSD2 in brain function. Heterozygous mating have shown 11β-HSD2
−/− 
offspring have 
heightened anxiety in comparison to their wild type littermates (Wyrwoll et al., 2013), 
demonstrating a key role of feto-placental 11β-HSD2 in prenatal glucocorticoid 
‘programming’ (Kotelevtsev et al., 1999). 
1.2.3.4.  11β-HSDs in the brain 
Glucocorticoids have profound effects on pre- and post-natal brain development. They 
are essential for normal maturation in most regions of the developing CNS, initiating 
terminal maturation, remodelling axons and dendrites, and affecting neuronal and glial 
cell survival. Either inadequate or excessive glucocorticoid levels cause abnormalities 
in neuronal and glial structure and function that often impact throughout the lifespan 
(Moisan et al., 1990a). Similarly in adulthood either excessive or deficient 
glucocorticoid action affects a myriad of brain functions, altering biochemistry, 
neurotransmission and cell structure (Joels et al., 2009a; Joels et al., 2009b; Sapolsky 
et al., 1986). Thus accurate control of glucocorticoid levels and cellular action is 
critical for brain development and function. 11β-HSD1 is the main isozyme found in 
the adult mammalian CNS. It was originally described in neuronal and glial cell lines. 
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Using biochemical techniques, 11-keto oxidation of steroids was found in mouse, rat, 
dog and primate whole brain extracts, as well as foetal brain and the C6 glioma cell line 
(Moisan et al., 1990b). 11β-HSD1 is widely distributed in the CNS, albeit with an 
uneven pattern of expression. Studies have clearly demonstrated the 11β-HSD activity 
in rat cerebellum (Moisan et al., 1990b) and a broad range of CNS regions, including 
the hippocampus and neocortex, with levels some 10–30% of those in kidney and liver. 
There were higher levels in specific cells types, for instance Purkinje cells of the 
cerebellum, CA3 pyramidal cells of the hippocampus and layer V neurons of the 
neocortex (Moisan et al., 1990b). 11β-HSD is also clearly detectable in most other 
brain sub regions, including the hypothalamus, amygdala and brain stem (Lakshmi et 
al., 1991). The enzyme mRNA, protein and activity are found in neurons and in glia. . 
Whilst there is some discordance in the earlier literature on the expression of 11β-
HSD2 mRNA, and perhaps confusion generated by highly sensitive PCR-based 
methods which inevitably detect occasional transcripts, the vast majority of 11β-HSD 
mRNA and activity in the adult mammalian CNS is 11β-HSD1. The exception may be 
a few discrete nuclei in the hind brain/brain stem, notably the nucleus of the tractus 
solitarius (NTS), which expresses 11β-HSD2 mRNA in adult rodents.  
Nevertheless, manipulation of 11β-HSD1 does not always have the anticipated effects 
as studies have shown cognitive improvement with 11β-HSD1 deficiency or inhibition 
(Yau et al., 2011). However, the effects in man have been disappointing, as clinical 
trials of 11β-HSD1 inhibitors have not demonstrated any improvements in dementia.  
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These observations raise the question of how much 11β-HSD1 really contributes to GR 
activation in different tissues in mouse and in man and if there is a better way to 
document the pharmacodynamic effects of 11β-HSD1 inhibition.  
The importance to measure effects of intracrinology on tissue steroid levels, is to 
understand the relative contributions of local metabolism versus circulating levels in 
determining the concentration of steroid available to receptors 
1.2.4.  Measuring glucocorticoids action at the tissue level 
An elevated exposure to glucocorticoids at tissue level may influence metabolism, fat 
distribution and mass. Predisposition to type 2 diabetes and excess accumulation of 
abdominal fat has been clearly demonstrated in patients with Cushing’s syndrome 
(Walker et al., 1992c; Wei et al., 2004). Similar features as seen in idiopathic obesity (a 
component of the metabolic syndrome) are associated with increased risk of 
cardiovascular disease including insulin resistance and hypertension (Walker et al., 
1992b) (Wei et al., 2004). It has been shown in several studies that cortisol synthesis 
rate is increased in obese subjects. Despite the attractive hypothesis of activation of the 
hypothalamic pituitary-adrenal (HPA) axis in obesity, this is not evident when studying 
steroids in the circulation, as plasma levels of cortisol are not consistently high, being 
normal, slightly elevated or lower  (Praveen et al., 2011; Rask et al., 2001) throughout 
the day (Rosmond et al., 1998). Furthermore, after administration of dexamethasone, 
the feedback regulation of the HPA axis does not seem to differ between lean and 
obese. Furthermore, Mattson and colleagues has demonstrated that a combined receptor 
antagonist stimulation of the HPA axis revealed redundancy of MR and GR in negative 
feedback in humans. The group have found that obese men have impaired responses to 
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combined receptor antagonist stimulation, suggesting impaired negative feedback by 
endogenous cortisol (Mattson et al., 2009). Therefore, it remains unclear whether 
overweight/moderate obesity is related with a primary alteration in the HPA axis 
activity. 
An alternative hypothesis has been proposed in which an increased cortisol production 
rate in obesity reflects normal HPA axis function compensating for changes in 
peripheral cortisol clearance. This hypothesis is sustained by an increased in cortisol 
metabolic clearance rates seen in obese subject measured by isotope dilution (Strain et 
al., 1980). Data have also confirmed that an increased cortisol metabolite excretion in 
urine, as a combination of excretion of A ring reduced (especially 5α-reduced) cortisol 
metabolites (Andrew et al., 1998; Fraser et al., 1999) together with impaired hepatic 
regeneration of cortisol from cortisone, at least in men (Rask et al., 2001; Stewart et al., 
1999) and in women is associated with obesity (Rask et al., 2002). Therefore, the 
compensatory activation of the HPA axis to maintain normal levels of circulating 
cortisol by decreasing the negative feedback may be due to a combination of increased 
hepatic cortisol inactivation and impaired regeneration of cortisol. However, in contrast 
in adipose glucocorticoid regeneration may be enhanced locally by increased activity of 
11-HSD1 – the goal of a number of studies has been to quantify the contribution of 
different tissues to glucocorticoid clearance and activation in metabolic disease. 
In rodents, the levels of glucocorticods in tissues have been measured primarily by 
LC/MS using tissue homogenate (Livingstone et al., 2003; Sooy et al., 2010). In a 
study conducted by Livingstone, glucocorticods were measured in liver, adipose and 
skeletal muscle of obese and lean rats to evaluate the effects of Carbenoxolone. The 
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study shown that Carbenoxolone inhibited 11β-HSD1 activity in liver but not in 
adipose tissue or skeletal muscle.  
Glucocortiods were also measured in murine brain homogenate (Sooy et al., 2010; 
Joyce et al.,2011) to test whether lifelong or short-term decreases in 11β-HSD1 activity 
are sufficient to alter cognitive function in aged mice (Sooy et al., 2010) and to 
determine which brain receptors [high-affinity mineralocorticoid receptors (MRs) or 
low-affinity glucocorticoid receptors (GRs)] are involved in the memory deficit with 
aging (Joyce et al., 2011). The latter study supports the notion that 11β-HSD1 
deficiency in aging mice leads to lower intracellular GC concentrations in brain, 
particularly in the hippocampus, which activate predominantly MRs to enhance 
memory (Yau et al., 2011). 
Active glucocorticod activity at corticosteroid receptors is controlled by tissue-specific 
pre-receptor metabolism primarily by 11β-HSD1. These changes happened 
independently of changes in circulating levels. In male leptin-resistant Zucker obese 
rats (Livingstone et al., 2000) and in men with idiopathic obesity (Rask et al., 2001), 
11β-HSD1 activity was increased in adipose tissue potentially contributing to some 
features of obesity. Therefore, a focus of research has been to measure glucocorticoid 
regeneration in metabolic tissues by 11-HSD1. However finding techniques to 






1.2.4.1.  Whole body: 24 hour cortisol and cortisone and urinary metabolites 
There has been extensive interest in the control of local activation and inactivation of 
cortisol by the 11β-HSD enzymes in patients with common disorders, e.g. hypertension 
and obesity. One approach to measure the activity of these enzymes in human cohorts 
is based on whole-body measurements of both cortisol and cortisone in blood or the 
concentrations of their major metabolites in urine. These approaches provide limited 
information on the activities of the individual 11β-HSD as the measurements merely 
reflect the balance of their dehydrogenase and reductase activities. Typical readouts 
include the ratio of cortisol:cortisone or the same ratio of their terahydro metabolites 
(5+5 tetrahydrocortisol vs tetrahydrocortisone).  
The ratio does change predictably upon inhibition of the enzymes. Glycyrrhetinic acid 
inhibits cortisol inactivation by 11β-HSD2 in vivo and increases the ratios of cortisol to 
cortisone metabolites (Best et al., 1997; Stewart et al., 1990). In subjects unable to 
reduce cortisone to cortisol through genetic mutation in either 11HSD1 (Jamieson et 
al., 2000) or H6PDH (Draper et al., 2003; Lavery et al., 2006), the opposite change is 
seen. By way of example of the use of this approach, in some clinical studies, subjects 
with AME presented with elevated urinary 11β-hydroxy metabolites of cortisol 
(cortols, tetrahydrocortisol (THF) and C19 steroids) while the 11-oxo metabolites 
(cortolones and tetrahydrocortisone THE) were diminished (Stewart et al., 1988). From 
this information, however, it cannot be interpreted whether the change lies with 11-
HSD 1 or 2.   
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Urinary metabolite ratios may therefore give false negative results. Carbenoxolone (a 
non-selective inhibitor), which inhibits both isozymes does not alter the ratio of 
metabolites of cortisol and cortisone due to inhibition of both cortisol inactivation and 
reactivation (Stewart et al., 1990). However, carbenoxolone results in marked 
inhibition of turnover in the 11β-HSD pathways, with increased cortisol concentrations 
in kidney and decreased cortisol levels in the liver and in the brain (Stewart et al., 
1990). As the isozymes possess distinct physiological roles and are altered in different 
pathologies, determination of their separate activities is desirable (Stewart et al., 1990). 
A number of more refined approaches has been attempted 
1.2.4.2.  Tritiated tracers not labelled on C11 position 
Approaches using tritium labelled cortisol (Figure 1.5) to tackle the selectivity issues 
found during determination of cortisol metabolites have been presented. Several radio 
labelled isotopomers of cortisol have been used to measure cortisol metabolism and to 
further evaluate 11β-HSD activities. These may be infused or injected and clearance of 
the endogeous pool assessed. 
3
H radio labelled corticosteroids were used to study either 
11β-HSD1 (conversion of [1,2] 
3
H2 cortisone to [1,2] 
3
H2 cortisol) or 11β-HSD2 
(conversion of [1,2] 
3
H2 cortisol to [1,2] 
3
H2 cortisone) usually detected by liquid 
scintillation counting but, as with endogenous steroids, these are not truly selective as 
they can be interconverted and only initial rates may be discriminatory. [1,2] 
3
H2 
cortisol was applied to measure the conversion in normal and inflamed human gingiva 
biopsies and detection of other 20-α/β dehydrogenation metabolites (Leloup-Hatey, 
1976). In vivo human studies conducted by Sandeep and colleagues (Sandeep et al., 
2005) used [1,2] 
3
H2 cortisone to infer the differences in 11β-HSD1 activity in adipose 
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obese subjects using microdialysis. In this study the infusion of substantial 
concentrations of [1,2] 
3
H cortisone (50 nmol/L; similar to normal blood cortisone 
levels) was required to ensure reliable detection. Under these conditions, the [1,2] 
3
H2 
cortisone infused was not a “tracer” because it contributed substantially to the local 
substrate concentration (Sandeep et al., 2005). Furthermore, since high concentrations 
are needed to achieve a reliable detection, this restricts the use for in vivo experiments 
in humans due to ethical and safety concerns. 
In order to increase the sensitivity in the assessment of cortisol metabolism another 
tracer [1,2,6,7] 
3
H4 cortisol, with higher specific activity was used, but this still lacks 
selectivity due to regeneration. Klemcke and colleagues used this approach while 
conducting an in vivo experiment in pigs to evaluate the foetal cortisol metabolism 
during gestation. The study found that the major contribution of maternal cortisol to 
fetal cortisone strongly suggested the presence of porcine placental hydroxysteroid 
dehydrogenase. However, accurate assessment of 11β-HSD2 activity could not be 
achieved as [1,2,6,7] 
3
H4 cortisone can be also formed in the foetus may also be derived 
from the plasma [1,2,6,7] 
3
H4 cortisone pool (Klemcke et al., 1996). Moreover, the 
placenta also expresses some 11-HSD1 confounding quantitation of rates. Another 
study conducted by Bocchi attempted to provide evidence of 11β-HSD2 deficiency in 
aldosterone-sensitive sweat gland ducts biopsies from subject with essential 
hypertension (Bocchi et al., 2004). The [1,2,6,7] 
3
H4 tracer has been extensively used 
by others (Bujalska et al., 2008). However, as with previous tracers, the main 
drawbacks is the lack of selectivity due to cross-reactivity with other metabolites in 
radioactivity measurement using liquid scintillation counting, lack of discrimination of 





























[1,2,6,7] 3H4 cortisol 
[1,2] 3H2 cortisol  
Figure 1.5: Structures of [1,2] 
3
H2 (a) and  [1,2,6,7] 
3
H4 cortisol tracer. Radioactive tritium labelled is 
highlighted in red. 
 
1.2.4.3.  Arteriovenous sampling of endogenous corticosteroids 
Another approach to measure enzyme 11β-HSDs activity was by measuring both 
endogenous cortisol and cortisone by arteriovenous (A-V) sampling; this approach 
measures the change in substrate and product in blood entering and leaving a tissues. 
An in vivo study of the cortisol–cortisone shuttle in subcutaneous abdominal adipose 
tissue was conducted by Katz et al in where (A-V) differences in serum cortisol and 
cortisone across subcutaneous human abdominal adipose tissue and forearm muscle 
were measured. In this study, serum cortisol and cortisone were measured in samples 
from a radial artery, superficial epigastric vein and deep forearm vein and 11β-HSD 
oxo-reductase activity in subcutaneous abdominal adipose tissue was inferred from and 
increased cortisol/cortisone ratio, which increased in obesity (Katz et al., 1999a). 
Walker and co-workers applied A-V measurements of cortisol and cortisone in patients 
with valvular or ischaemic heart disease and with Cushing's syndrome to evaluate if 
11β-HSD is inhibited by ACTH, and prove that cortisol induces hypokalaemic alkalosis 
in ectopic ACTH syndrome (Walker et al., 1992a). In this study, the principal sources 
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of plasma cortisone were assessed by selective venous catheterisation with 
measurement of cortisol and cortisone by radioimmunoassay. The study found that 
peripheral conversion of cortisol to cortisone occurs mainly in the kidney and is 
inhibited by ACTH. In ectopic ACTH syndrome the characteristic mineralocorticoid 
excess can be accounted for by a combination of increased secretion of cortisol, 
corticosterone and of 11-deoxycorticosterone and decreased inactivation of cortisol and 
corticosterone by 11β-HSDs, but this approach did not distinguish activity in the liver 
from the contribution of visceral adipose tissue which in vitro studies suggested is 
substantial (Bujalska et al., 1997). Unfortunately, measuring cortisol in the portal vein 
is only achievable during surgery, when high stress would probably obscure the local 
regeneration (Aldhahi et al., 2004). Furthermore, the errors associated with A-V 
measurement are wide and A-V is an invasive methodology. Most importantly again 
dehydrogenase and reductase activities could not be separately measured. 
1.2.4.4.  Ex vivo biopsies 
Ex vivo studies have been conducted on tissue homogenate biopsies to measure the 
velocities and transcript abundance of the individual isozymes of 11-HSD1. This is 
achievable since 11-HSD2 accepts NAD
+
 as a co-factor, whereas 11-HSD1 requires 
NADPH, allowing harnessing of either isozyme through experimental conditions. 
Cortisol metabolism within different adipose tissue depots was studied by (Bujalska et 
al., 1997) in cultured omental and subcutaneous adipose stromal cells from 16 patients 
undergoing elective abdominal surgery. By analysing activity of the two isozymes of 
11β-HSDs, the study found than adipose stromal cells from omental fat, but not 
subcutaneous fat, generated active cortisol from inactive cortisone through the 
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expression of 11β-HSD1. Another group studied the tissue-specific disruption of 
cortisol metabolism in subcutaneous fat biopsies, showing that enhanced reactivation of 
cortisone to cortisol in subcutaneous adipose tissue was observed (Rask et al., 2001). 
The approach reports on the amount and activity of protein present but does not 
account for the availability and concentration of enzyme substrate. Although tissue-
specific, this method does not usually provide spatial localisation information within 
different cell population, without cell sorting. This is very important in tissue like brain 
in which the enzyme expression varies across the tissue. 
1.2.4.5.  11α-tritiated cortisol 
To allow specific dehydrogenation of cortisol to be assessed, other studies were 
conducted using a tritiated labelled cortisol tracer, 11α-
3
H-cortisol (Figure 1.6), which 
is metabolised by 11β-HSD2, yielding unlabeled cortisone and tritiated water. This 
tracer is more selective than those mentioned previously in section 1.1.1.2 as the 
radioactive tag is strategically place on the C11 position (site of enzyme 
dehydrogenation). Therefore clearance of this tracer reflects dehydrogenation. The 
clearance of this tracer is more rapid than with cortisol alone (Hellman et al., 1971). 
Using this tracer in vivo, Walker and co-workers showed impaired clearance of the 
radio tracer, in spite of no change in endogenous plasma steroids. Furthermore, normal 
ratios were observed after carbenoxolone administration in patient with essential 
hypertension against healthy volunteers (controls) suggesting that 11β-reductase 
conversion of cortisone to cortisol was also defective (Walker et al., 1993). The tracer 
was also use by Stewart and colleagues in patients with 11β-HSD2 deficiency (Stewart, 
1988). The downside of this method is that is only provides information about 
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dehydrogenation and is again less desirable due to the ethical and safety concerns of 























Figure 1.6: Structure of 11α-3H-cortisol tracer. Radioactive tritium labelled is highlighted in red. 
 
1.2.4.6.  Stable isotope tracers 
To tackle the aforementioned issues of non-selectivity and radiolabelling, Andrew and 
colleagues developed a novel, approach to measure the turnover of the 11β-HSDs 
pathways and further distinguish dehydrogenase and reductase activities using a stable 
isotope tracer of cortisol (9,11,12,12-[
2
H]4-cortisol (d4F)) (Figure 1.7). The tracer, 
analogous to that prepared by Ulick et al (Ulick et al., 1991), contains four deuteriums 
in the steroid skeleton, one of which is in the 11 position. By using this tracer, cortisol 
and other metabolites can be distinguished from the endogenous contribution by their 
respective molecular masses. The deuterium at the 11 position is lost on metabolism by 
dehydrogenation, yielding a labelled cortisone molecule [trideuterated cortisone (d3E)] 
with a mass 3 greater than that of the endogenous cortisone. Then on reactivation by 
11β-HSD1/reductase, d3E is converted to a labelled cortisol species [trideuterated 
cortisol (d3F)], which can be distinguished from the [9,11,12,12-2H4]cortisol (d4F) 
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infused. Therefore, by using this approach it was possible to distinguish “cortisol” 





































Figure 1.7: Schematic of metabolism of deuterated cortisol tracer (9,11,12,12-[
2
H]4-cortisol (d4F) by 






The first in vivo application of the tracer in humans to distinguish the dehydrogenase 
and reductase activities following carbenoxolone administration was presented by 
Andrew and colleagues (Andrew et al., 2002). D4F and its metabolites were measured 
in plasma and urine during a steady state infusion. Inhibition of 11β-HSDs by 
carbenoxolone was measured by increased steady state concentrations of d4F and a fall 
in the rate of appearance of d3F. 11β-HSD1 reductase activity was measured as dilution 
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of d4F by d3F whereas 11β-HSD2 was measured by initial rates of appearance of d3E 
or from urinary ratios of d4F/(d3E + d3F). This study confirms that carbenoxolone 
inhibits both isozymes of 11β-HSD (Andrew et al., 2002) and that d3F was a useful 
measure of 11β-HSD1 activity. Using this approach in combination with tissue-specific 
sampling can be used to elucidate tissue-specific changes in 11β-HSD1 activity in a 
disease context. 
In a subsequent application, in vivo whole body kinetics of cortisol using d4F tracer 
infusion, were examined in obesity. The study found that the obese men had no 
difference in their whole-body rate of regenerating cortisol. Possibly the contribution of 
subcutaneous adipose 11β-HSD1 to d3F generation was too small to cause a significant 
change in measured whole body rates of appearance. Again carbenoxolone inhibited 
whole-body cortisol regeneration, but did not significantly inhibit adipose 11β-HSD1. 
Therefore, this study suggested that efforts in the development of selective 11β-HSD1 
inhibitors should address drug delivery in order to inhibit the enzyme more effectively 
in adipose tissue (Sandeep et al., 2005). 
Following with in vivo applications, the magnitude of regeneration of cortisol in 
different tissues in humans several studies have been inferred by sampling arterio-
venous blood across tissue beds. In one study, d4F was infused in men and tracer 
enrichment in the hepatic vein compared with that in arterialised blood as an indicator 
of total splanchnic cortisol generation. Modelling from this study suggested that tissues 
draining into the hepatic vein contribute substantially to the regeneration of cortisol. 
Thus, the hepatic vein may deliver cortisol to the liver (Andrew et al., 2005). Basu and 
colleagues likewise found that the splanchnic production of cortisol occurs in 
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nondiabetic humans at rates approximating that which occurs in the remainder of the 
body (Basu et al., 2004). 
From whole-body to tissue-specific regeneration, a study has been conducted in 
adipose to directly studying the release of cortisol by 11β-HSD1 from visceral adipose 
tissue and its effect on portal vein concentrations. D4F infusion was conducted on both 
healthy and stable chronic liver disease subjects and blood samples were taken from 
superficial epigastric vein (healthy) and from the portal, hepatic and peripheral veins 
(liver disease). Significant cortisol and d3F release from subcutaneous adipose tissue 
was detected, but with splanchnic release of cortisol and d3F accounted entirely by the 
liver (Stimson et al., 2009). This finding was supported by another study in which it 
was found that the liver accounts for all splanchnic production; cortisol from visceral 
tissues into portal vein was not detected (Basu et al., 2006). Therefore, visceral adipose 
11β-HSD1 activity appears insufficient to increase portal vein cortisol concentrations 
and hence is unlikely to influence intrahepatic glucocorticoid signalling or be an 
effective drug target (Stimson et al., 2009). 
Another study was carried out to evaluate the dynamics of turnover of cortisol within 
adipose tissue and the circulating pool, Hughes et al (Hughes et al., 2010) measured the 
rate of exchange of cortisol and d3F  between plasma and adipose for comparison with 
rates of intracellular cortisol generation by 11β-HSD1, using adipose biopsies. In 
plasma, d4F concentrations and appearance rates of cortisol and d3E (reflecting 11β-
HSD1 activity) did not change during the experiments. In both omental and sc adipose, 
the tracer was detected later than plasma and enrichment with d4F in the adipose 
cortisol pool was low. The contribution of 11β-HSD1 to this turnover could not be 
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quantified because very little substrate d3E accumulated in adipose during infusion, but 
can be considered slow. The slow turnover observed in the adipose glucocorticoid pool 
demonstrated that the rapid acute fluctuations in circulating cortisol are not likely to be 
reflected in adipose (Hughes et al., 2010). 
Stable isotope tracer approaches have also allowed evaluation of effects of factors 
regulating metabolism (nutrition/insulin sensitivity) on cortisol generation. Wake and 
colleagues have demonstrated that hyperinsulinemia increased the rate of appearance of 
d3F, indicating increased whole-body 11β-HSD1. Within adipose, the predominant 
reaction was reductase conversion of cortisone to cortisol and insulin increased 
reductase activity (Wake et al., 2006). The effects of dietary macronutrients (high fat-
low carbohydrate (HF-LC) vs. moderate fat-moderate carbohydrate (MF-MC) on 
cortisol metabolism have been evaluated in obese men. This study found that both HF-
LC and MF-MC diets induced weight loss. During d4F infusion, HF-LC but not MF-
MC increased 11β-HSD1 activity (measured as rates of appearance of cortisol and d3F) 
along with a reduction in urinary excretion of 5α- and 5β- reduced d4F metabolites and 
clearance. Nevertheless, in sub-cutaneous abdominal adipose tissue, 11β-HSD1 mRNA 
and activity were unaffected by diet implicating the liver source of enzyme in the 
findings (Stimson et al., 2007). 
A recent study conducted by the same group showed that plasma cortisol was similarly 
increased after all macronutrient meals compared with placebo. With carbohydrate-
based diet the adrenal secretion and extra-adrenal regeneration of cortisol was 
stimulated to a similar degree. The adrenal cortisol secretion following protein and fat 
meals was greater than extra-adrenal cortisol regeneration with postprandial cortisol 
30 
 
rise not accounted for by decreased cortisol clearance. Therefore, food-induced 
circadian variation in plasma cortisol is mediated by adrenal secretion and extra-
adrenal regeneration of cortisol (Stimson et al., 2014). 
Isotope traces have also been applied to assess drug-efficacy on several targets. In one 
study, peroxisome proliferator-activated receptor (PPAR) agonists (rosiglitazone 
(PPARγ) and fenofibrate (PPARα) was tested to see whether cortisol secretion and 
peripheral regeneration by 11β-HSD1 were altered in humans receiving these drugs and 
whether reduced cortisol action contributes to metabolic effects of PPARγ agonists. 
Neither PPARα nor PPARγ agonists down-regulate 11β-HSD1 or cortisol secretion 
acutely in humans and the early insulin-sensitizing effect of rosiglitazone was not 
dependent on reducing intracellular glucocorticoid concentrations (Wake et al., 2007). 
Another application by (Sigurjonsdottir et al., 2009) evaluated the acute effects of 
growth hormone (GH) on 11β-HSD1 in liver and adipose tissues in vivo in men with 
benign pituitary disease. Cortisol kinetics during d4F infusion was measured. In this 
study, subjects on stable GH replacement therapy for >6 months were studied after GH 
withdrawal for 3 weeks, and after either placebo or GH injections were reintroduced for 
another 3 weeks. Results found that d3F appearance was not changed after GH 
withdrawal and reintroduction and d4F clearance increased after GH withdrawal, hence, 
GH did not regulate 11β-HSD1 rapidly in vivo in humans (Sigurjonsdottir et al., 2009).  
In a disease context, single nucleotide polymorphisms (SNPs) in HSD11B1, the gene 
encoding 11β-HSD1, have been associated with type 2 diabetes and hypertension and 
with hyperandrogenism in patients with the polycystic ovary syndrome (PCOS). The 
functional consequences of these single nucleotide polymorphisms (SNPs) in 11β-
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HSD1 expression and activity were evaluated using d4F in patient with polycystic 
ovary syndrome (PCOS). Using an in vivo setting, the study shown that women with 
and without PCOS, alleles of HSD11B1 containing the two SNPs rs846910 A and 
rs12086634 T confer increased 11β-HSD1 expression and activity (Gambineri et al., 
2011). Another study conducted by (Boonen et al., 2013) used d4F cortisol to measure 
the plasma cortisol clearance and production in critically ill patients in the intensity 
care unit (ICU). In the patients, as compared with the controls, endogenous cortisol and 
rate of appearance were increased and no significant difference in cortisol production 
between patients was found in patients who were treated with catecholamines and those 
who were not treated. By using isotope tracer, cortisol production in patients with 
adrenal insufficiency could be evaluated and levels were indistinguishable from that in 
controls, whereas it was elevated in patients with a normal response to corticotropin. 
Tracer analysis also allowed dissection of the contribution of 11β-HSD enzymes to 
altered cortisol clearance. The patients had a lower net rate of appearance of cortisone 
than the controls). However, there was no significant between-group difference in the 
level of regeneration of cortisol by 11β-HSD1, as measured by the rate of appearance 
of d3F (Boonen et al., 2013) 
As the development of novel and selective 11β-HSD1 inhibitors has focussed on 
treatment of type 2 diabetes and the pharmacological effects may be reduced if hepatic 
11β-HSD1 is similarly decreased in obese patients with type 2 diabetes (Stimson et al., 
2011) evaluated this hypothesis by quantifying in vivo whole-body, splanchnic, and 
hepatic 11β-HSD1 activity in obese type 2 diabetic subjects by infusion of both cortisol 
and d4F. D3F appearance rate in the arterialised blood was increased, splanchnic d3F 
production was not reduced  and cortisol appearance in the hepatic vein after oral 
32 
 
cortisone was unchanged. These data supported the concept that inhibitors of 11β-
HSD1 are likely to be most effective in obese type 2 diabetic subjects (Stimson et al., 
2011). 
While d4F infusion has allowed measurement of 11-reductase activity, a strand of 
literature has suggested that this enzyme may also proceed as dehydrogenase under 
given circumstances. Further tracers may be employed to address this. In vivo 
assessment of the bidirectionality activity of 11β-HSD1 in human metabolic tissues 
was carried out by (Hughes et al., 2012). In this study, 1,2-[2H]
2
-cortisone (d2E) was 
used to measure 11β-dehydrogenase activity and d4F for 11β-reductase activity. 11β-
Reductase and -dehydrogenase activities were detected in muscle and splanchnic 
circulation and in adipose, dehydrogenase was higher readily detected than reductase 
(Hughes et al., 2012).  
However, in these studies the glucocorticoid turnover in individual tissues was inferred 
from measurements either in vivo (whole-body, AV sampling) or ex vivo (enzyme 
activities/mRNA and tissue steroid concentrations in whole tissue homogenates), 
therefore, the reliably to measure tissue- or cell-specific steroid concentrations is still 
needed for understanding tissue-specific pharmacodynamics of novel enzyme 
inhibitors, interactions between 11β-HSD1 and other determinants of intracellular 
glucocorticoid concentrations, and the relative importance of 11β-HSD1 in specific 





1.2.4.7.  New approaches 
Ongoing efforts are being focused in the development of non-invasive tools of tissue-
specific activity of 11-HSD1, Magnetic resonance spectroscopy (MRS) has been 
explored using fluorinated steroids for in vivo studies. Coherent anti-Stokes Raman 
spectroscopy (CARS) microscopy is being investigated for in vitro measurements of 
steroid trafficking at sub-cellular level in cell cultures using deuterated steroids and the 
technique has the potential for in vivo imaging application by incorporation in 
multiphoton in vivo confocal microscopy.  
However, a limiting factor for all of the above is sensitivity, requiring either large 
samples (from mass spectrometry analysis stable isotope tracer), high non-
physiological tracer concentrations (for MRS and CARS microscopy) and synthesis of 
radioactive tags (tritiated steroids). Furthermore, standard tissue-homogenate analysis 
assumes homogeneity across the tissue section and in most of the cases (e.g. tumour 
tissue biopsies) this assumption is incorrect, as tissues have different histological 
features due to different cell population. Therefore, our research group in Edinburgh 
has continued to explore alternative technological solutions such as mass spectrometry 
imaging (MSI) as an approach to overcome current limitations. The main advantage of 
using MSI over conventional tissue-based analysis is that MSI can generate molecular 
distribution maps across the tissue section based on the mass/charge (m/z) of molecules 
with acceptable spatial resolution (100-10µm) and great sensitivity (up to femtomole). 
The methodology is also capable of performing both targeted (e.g. drugs) and 
untargeted (endogenous metabolites) multiplex analysis. This technique may 
potentially be used to study steroid molecular histology in the tissue microenvironment, 
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as biochemical-based assays (e.g. immunohistochemistry) lack of reproducibility and 
multiplex identification. Thus, in this thesis, MSI will be explored as a potential 
technique to study steroid biology at the tissue level. 
1.3.  Mass Spectrometry Imaging  
1.3.1.  Introduction 
The concept of MSI has its origins in the field of physics, where it was used to study 
semiconductor surfaces (Benninghoven et al., 1978).
 
The introduction of matrix 
assisted laser desorption ionization (MALDI)-MSI in 1997 by Caprioli et al (Caprioli et 
al., 1997) led to a significant development and optimisation of instrumentation and data 
analysis platforms for the analysis of biological samples. The technologies were rapidly 
applied to the fields of biology, chemistry and pharmaceutical analysis using the label-
free strategy to generate molecular maps aligned with histology images (Heeren et al., 
2010; Nilsson et al., 2010; Stoeckli et al., 2007). MSI has the ability to detect 
endogenous and exogenous analytes across a wide mass range. The analysis of lower 
molecular weight drugs and endogenous compounds through to lipids, peptides and 
large proteins directly from tissue samples (Castellino et al., 2011; Falth et al., 2006; 
Groseclose et al., 2008) is leading to an important contribution in fields such as 
molecular histology, drug distribution, lipidomics and proteomics (Fletcher et al., 
2011). It is important to again reiterate that as MSI can, by accurate mass measurement, 
differentiate between molecular species such as drugs and their metabolites; hence the 
technique overcomes the limitations of non-specificity encountered with using 
radioactive analogues. In addition, as labelled compounds are not required, it is 
possible to dose test animals with multiple compounds (cassette dosing) (White et al., 
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2001) increasing the throughput of compounds in discovery or enabling the study of 
combination therapies. To successfully, accurately, and reproducibly analyse the 
abundance and distribution of a molecules directly from tissue sections, a robust 
workflow is required. Variations and fluctuations in technical aspects can affect 
subsequent stages leading to erroneous or misleading data. The following section will 
describe the commonly available ionisation processes and mass analysers. Also the 
steps in sample preparation (focus primarily on MALDI-MSI), processing and analysis 
required for successful MSI analysis will be reviewed.  
1.3.2. Principle and instrumentation 
MSI is a multi-step process, involving sample preparation, analyte desorption and 
ionisation, mass analysis, and image registration (Figure 1.8). Briefly, tissue 
cryosections are placed, commonly under vacuum, into an MS instrument and analyte 
molecules are desorbed and ionised from the surface (Zimmerman et al., 2008). With 
ionisation being performed from known positions across a sample, the collated mass 
spectral information can be used to generate distribution data on the molecules present. 
The resulting ion distributions are typically presented as 2D ion images showing 
relative abundance of selected molecular masses. The sample processing pipeline for 
MSI, while simple, does offer multiple stages for optimisation and modification. In 
MSI,  spatial resolution is determined by the size of the probe beam (affected by laser 
spot size and sample positioning) and mass resolving power is defined by (m/Δm50%) 
where Δm is the resolution (The minimum peak separation ΔM which allows to 
distinguish two ion species: at 50% peak height) and m is the mass of the second peak. 
 Another important aspect is the pixel size, which is defined by the speed of the stage 
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movements, acquisition rate of the mass spectra and distance between two lines of 
acquisitions (Heeren et al., 2010). 
There are two major types of MALDI-TOF MSI; microprobe and microscope mode 
experiments. In MALDI microprobe MSI, a highly focused pulsed 
desorption/ionization laser beam probes the sample surface. A full mass spectrum is 
generated at every raster point. An image is reconstructed after the experiment with a 
pixel resolution equivalent to the beam size (provided the stepping size/accuracy of the 
sample/beam movement is not limiting) (Spengler et al., 2002). Disadvantages of small 
surface probe areas include long measurement times and loss of sensitivity due to low 
laser fluence for desorption and ionization. (Bradshaw et al., 2009) 
MALDI microscope mode MSI is an alternative approach to microprobe mode imaging 
(Luxembourg et al., 2004). In the microscope mode, a large surface probe desorbs and 
ionizes surface molecules over a large sample area, typically 200-300 µm in diameter. 
The large field of view in microscope mode MSI enables fast, large area image 
acquisition at high spatial resolution (Luxembourg et al., 2004). An ion microscope 
uses ion optics to project the desorbed/ionized surface compounds onto a position-
sensitive detector. Importantly, the initial ion distribution is magnified and the lateral 
spatial organization of the surface molecules is retained on the flight path to the 
detector. While the ionization spot size determines the obtainable spatial resolution in 
microprobe mode, the spatial resolution in microscope mode is decoupled from the 
ionization spot size. Rather, the spatial resolution is determined by the quality and the 
capabilities of the ion optics in combination with a position- (and time-) sensitive 
detector. Spatial resolving powers on the order of 4 µm have been achieved where a 10 
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µm charge-coupled device (CCD) camera pixel probed 1 µm on the sample surface pot 
size has been demonstrated by over-sampling (Jurchen et al., 2005). Presented here is 
an overview of several key stages for MALDI-MSI, the focus of this thesis. 
 
Figure 1.8: Mass spectrometry imaging (MSI) workflow. MSI involves sample preparation, analyte 
desorption and ionization, mass analysis, and image registration. In briefly, cryo-sections of tissue of 
interest are coated with a suitable MALDI matrix and then introduced into an MSI instrument. A 
specified area of the tissue section is analysed and mass spectral information collected. The resulting ion 
distributions are presented in the form of ion images. ITO = Indium Titanium oxide; MS = Mass 
















1.3.3.  Ionisation techniques 
There are a number of ionisation methods capable of performing MSI, with MALDI the 
most commonly used and the primary focus of this thesis. The next most commonly 
utilised are secondary ion mass spectrometry (SIMS) and more recently desorption 
electrospray ionisation (DESI) and Liquid extraction surface analysis (LESA) all 
described briefly (Table 1.2). The alternative ionisation methods prove advantageous 
for certain studies depending on target analyte, abundance of analyte, or spatial 
resolution of analysis. Detailed reviews have been published that compare the 
advantages and optimisation of the various methods (Klinkert et al., 2007).  
Table 1.2: MSI ionisation methods adapted from (Caprioli, 2007) 
Ionisation Techniques Ionisation Source Matrix 
LESA Nano-ESI Direct  Analysis 
LDI/MALDI Laser beam MALDI Matrices 
Me-nSIMS (HV) Ion beam  (Ag,Au,Pt) + MALDI 
DESI (AP) Charged electro-sprayed droplets Direct  Analysis 
MALDI: Matrix assisted laser desorption ionisation, Me-nSIMS: Metal-nano secondary ion mass spectrometry, 
DESI: Desorption electrospray ionisation AP: Atmospheric pressure. LDI: Laser desorption ionisation. LESA: 
Liquid extraction surface analysis. Nano-ESI: nano-electrospray ionisation 
 
1.3.3.1.  Liquid extraction surface analysis (LESA)   
A recent development in the context of MSI is Liquid Extraction Surface Analysis 
Mass Spectrometry (LESA-MS) (Kertesz et al., 2010) which obtains information from 
biological tissue sections via liquid extraction of analytes from the solid surface 
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followed by nano-electrospray ionisation (Figure 1.9). The LESA-MS approach has 
potential advantages over other MSI approaches in that no additional sample 
preparation is required (which compared to e.g. MALDI could also eliminate potential 
low molecular weight MALDI matrix mass interferences), the ionisation process is 
soft, potentially revealing labile molecules or metabolites and it allows analysis of 
negatively or positively charged analytes by simple exchange of the modifier used in 
the extraction solvent. However, LESA is a fairly new analysis tool available for 
ambient surface analysis and its extraction process on thin tissue sections is not well 
characterised or understood. Its sensitivity might be compound-dependent and affected 
by ion suppression of co-extracted matrix molecules. Differences in extraction and ion 
suppression from different tissues might also limit the ability for relative quantification 
across a thin section. Another limiting factor of LESA is the spatial resolution, as it can 
only be optimised to approximately 1 mm not suitable for high resolution tissue 




Figure 1.9: Liquid Extraction Surface Analysis workflow. Solvent is deposited using a precise micro 
pipette into an area of interest of the tissue (spot), the spot is then extracted several times and transferred 
to an Electrospray nano-chip device in which the tissue components and analyte ionised and ions are 
finally guided to the mass analyser. 
1.3.3.2.  Matrix assisted laser desorption ionisation (MALDI)   
MALDI is a development of the established laser desorption/ionization mass 
spectrometry (LDI-MS) introduced in 1988 by Karas and Hillenkamp (Karas et al., 
1988). It is a powerful technique that allows the analysis and detection of a wide range 
of molecules directly from a surface, including from a tissue section. MALDI-MSI has 
the ability to detect multiple biomolecules generated as intact ions directly from 
individual, localised pulsed laser spots in matrix-coated tissue sections. In traditional 








matrix to analyte ratio of 100-1000:1 (Dreisewerd, 2003), whereas for MALDI-MSI, 
the matrix is coated as an even surface layer as described above. MALDI possesses low 
femtomole to attomole sensitivity and can ionise molecules across a wide mass range 
up to 300 kDa, lending itself to applications from large biomolecules down to small 
molecular weight drugs. As such, it has been used for the analysis of proteins, peptides, 
lipids and pharmaceutical compounds (Franck et al., 2009).   
 
Figure 1.10: A schematic diagram of the mechanism of MALDI. Adapted from (Nygren et al., 2007) 
In a MALDI-MSI experiment the laser beam is rastered across the surface of the 
matrix covered tissue. The matrix crystal surface is irradiated with pulsed laser light of 
sufficient fluence (Karas et al., 2003) and the matrix molecules absorb the laser 
energy, resulting in the explosive desorption of matrix and analyte molecules (Figure 
1.10). This phenomenon can be explained and quantified by using the Coupled 
Physical and Chemical Dynamics (CPCD) model. This name is intended to reflect the 
fact that it explicitly covers everything from the condensed phase, through a very dense 
fluid, and the expansion of that fluid, to the state of isolated ions. In particular, it 
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includes the way chemical and physical processes interact to determine the final 
result. The concepts of CPCD model can be cast into quantitative form, making them 
much more useful for prediction and understanding of MALDI spectra (Knochenmuss, 
2002). The unimolecular and bimolecular (pooling) processes involved can be 
quantified using one order differential equations as described in equation 1. The 
bimolecular processes are scaled by D (expansion factor), the rate of collisions in the 
expanding plume. Because the plume begins at very high pressures and the external 
environment is vacuum (or at most 1 atm), it is can be well described as an isentropic 
expansion (Knochenmuss, 2002). 
 
Equation 1: MALDI ionization mechanism: IP (free molecule);IP (large clusters) S1 state energy starting 
temperature σ:S0—>S1 absorption coefficient; σ: S0-<-S1 stimulated emission; σ: S,—>S, absorption 
coefficient; σ: S,—>S decay rate; τ1:(t=0)= solid state lifetime; τ': limiting plume S1 lifetime;(I)(t)= 
fluorescence quantum yield; f= internal degrees of freedom; γ= C,/CV for plume expansion density; Kf = Ion 
recombination Fraction clusters in plume laser spot diameter. Pooling rate constants: K11 = S, + S1—>Sn + 
80K1n = S, + S,,—>lons + 80; D: expansion scaling factor 
 
The depth of the ablation crater is estimated around 1 μm or more, depending on laser 
fluence (Knochenmuss, 2014). Although this has traditionally been a slow process, the 
introduction of the new N2 (337 nm) or neodymium-doped yttrium aluminium garnet 
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(Nd:YAG) (355 nm) lasers with repetition rates of 200-5000 Hz and typical pulse 
lengths of 3 ns or less has shortened the data acquisition process (Dreisewerd, 2003). 
To make MALDI-MSI a more practical application for biological cellular imaging the 
lasers spot size have been reduced from >100 to <20 μm. Focusing of the laser beam to 
the diameter of a single cell (approximately 7 μm) has also been reported by Holle et 
al. (Holle et al., 2006). However, although such improvements greatly enhance spatial 
resolution, they also dramatically decrease the sensitivity and are only suitable for high 
abundance species (e.g. membrane lipids (Fuchs et al., 2007) 
1.3.3.3.  Secondary Ion Mass Spectrometry (SIMS)  
SIMS is a desorption-ionisation technique which has been used for the characterisation 
of biomaterials by physicists and now is being extended into biomedicine. 
        
                              (Equation 2) 
The basic equation (Equation 2) for the SIMS phenomena is described by equation1 
where Im is the secondary ion current of species m, Ip it is the primary particle flux, ym 
is the sputter yield, α is the ionisation probability to positive ions, θ is the fractional 
concentration of the chemistry in the surface layer and ή is the transmission of the 
analysis system. Ionisation occurs at, or close to, emission of the particles from the 
surface with the consequence that the matrix participates in the electronic processes 
involved. This means that the yield of secondary ions is strongly influenced by the 
electronic state of the material being analysed with consequent complications for 
quantitative analysis. (John C. Vickerman and David Briggs, 2nd edition, IM 
Publications, 2013)  
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Its key benefit over MALDI is in achieving higher spatial resolution and a matrix is not 
required, reducing opportunities for diffusion and analyte delocalisation. SIMS uses a 
primary ion beam (e.g. metal ions) capable of producing secondary ions from the 
surface of the sample (Figure 1.11) (Jones et al., 2007). An ion column is used to 
produce, accelerate and steer a primary ion beam onto the tissue surface, can be 
focussed as sharply as 50 nm, depending on the primary ion beam current, molecular 
weight, and its charge state (Altelaar et al., 2005). The energy of the primary ions is 
substantially higher than the energy of a MALDI laser beam; SIMS thus often yields 
extensive fragmentation of surface molecules. However, as ion beams can be focused 
with higher precision than lasers, SIMS offers a unique tool for high spatial resolution 
MSI of abundant inorganic elements and small organic molecules in cellular organelles 
(Altelaar et al., 2007). Furthermore, the depth of SIMS imaging can be refined to nm as 
opposed to µm layers (Chandra et al., 2002).  
However, since 2001, the introduction of cluster and polyatomic ion beams has resulted 
in a sea change in the technique of molecular SIMS. The wide introduction of 
polyatomic ion beams such C60+ and (H2O)
n+
 cluster ions (n= 500-10,000) has had an 
even more dramatic effect on molecular SIMS (Sheraz et al., 2015). Not only did these 
beams increase ion yield, it was also discovered that, for many materials, the degree of 
observable bombardment-induced damage was very significantly reduced, so that 
analysis could be carried out well beyond the static limit; indeed, in some cases, the 
whole sample could be consumed during analysis and the chemical information was not 
compromised. This was a revolutionary development for molecular SIMS because, in 
principle, it allowed molecular depth profiling of organic materials (John C. Vickerman 




Figure 1.11: A schematic diagram of the mechanism of SIMS. Adapted from (Vickerman et al., 2005). 
SIMS is used to analyze solid surfaces and thin films by sputtering the surface with a focused 
primary ion beam and collecting and analysing ejected secondary ions. 
 
1.3.3.4.  Desorption Electrospray Ionisation (DESI) 
DESI, an atmospheric pressure ionisation method developed by R.G. Cooks in 2004 
(Takats et al., 2004), has been suggested as an alternative MSI platform. In contrast to 
MALDI and SIMS, DESI operates under atmospheric pressure (AP), being derived 
from a combination of two MS ionisation methods: electrospray ionisation (ESI) and 
desorption ionization (DI). Instead of a laser beam or a primary ion beam, DESI uses 
energetic, charged electrosprayed solvent droplet to release the molecules from the 
surface (Takats et al., 2004). Molecular ion formation from secondary droplets occurs 
either by ion emission (ion evaporation model) (Parvin et al., 2005) or by evaporation 
of neutral solvent molecules (charged residue model) (Figure 1.12). Solid samples 
analysed by DESI produce multiply charged ions like pure ESI. For DESI imaging, the 
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sample can be placed onto a target (e.g. microscope glass slide). The main advantage of 
DESI over the others MSI ionisation techniques is that it offers the unique possibility of 
in situ analysis (Dill et al., 2009). In terms of spatial lateral resolution, an study 
conducted using DESI achieved 400 μm in rat brain (Ifa et al., 2007). However; a 
recent spray design theoretically predicts an improvement in achievable lateral 
resolution of 40 μm. Although improvements are still required for this, it holds the 
promise of soft, local, liquid atmospheric desorption and ionisation, already being 




Figure 1.12: DESI mechanism. Adapted from (Takats et al., 2004). DESI is a combination 
of electrospray (ESI) and desorption (DI) ionisation methods. Ionisation takes place by directing an 
electrically charged mist to the sample surface that is a few millimetres away. The electrospray mist is 
attracted to the surface by applying a voltage on the sample holder and transfer to the mass analyser. 
1.3.4.  Tissue preparation for MALDI-MSI analysis 
Sample collection and preparation are the first stages of any MSI experiment. The 
protocols must ensure that histological integrity of the tissue sections are retained so 
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that spatial localisation of any target molecule is uncorrupted by analyte 
degradation/diffusion (rapid proteolytic activity has been reported in tissue sections 
when analysed by MSI (Goodwin, 2012; Goodwin et al., 2008). Put simply, the quality 
of an MSI image is only ever as good as the starting tissue section. To achieve the 
highest quality sections, the following steps need to be optimised for the particular 
target tissues being analysed: sectioning, sample transfer, and washing and 
application/deposition of the MALDI matrix.   
1.3.4.1.  Preparation of Tissue Sections  
1.3.4.1.1. Pre-sectioning steps 
It is most common to conduct MSI using snap-frozen cryosections cut from dissected 
tissues or organs, rather than conventionally embedded/fixed tissues. For analysis of 
small drug molecules, it is important to avoid processes which delocalise the analytes, 
specifically lengthy soaking in fixative or washing with graded ethanol, although these 
processes may be compatible with analysis of structural components such as proteins. 
Even so, proteomic analysis from formalin-fixed paraffin embedded tissues is fraught 
with difficulty, involving multistage process to reverse cross-linking and remove 
paraffin (Groseclose et al., 2008). An alternative procedure using RCL2/CS100, a non-
volatile and non-cross-linking fixative reagent, has been reported as suitable for tissue 
MSI of proteins and peptides, introduced by Mange and colleagues (Mange et al., 
2009); however this is not suitable for small molecules, again due to washing out of 
analyte.  Ideally tissues are collected by rapid freezing in liquid nitrogen, and 
cryosections prepared specifically for MSI analysis. It is worth collecting consecutive 
tissue sections for traditional histology, allowing MSI and histology images to be 
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aligned. If the morphological assessment is performed using the same MSI sample, 
histological staining must be performed with MSI-compatible stains such as methylene 
blue or cresyl violet (Chaurand et al., 2004a), i.e. stains not causing ion suppression.  
“Ion suppression” is a common problem encountered in biological mass spectrometric 
analyses, whereby high abundance analytes (e.g. fixative embedding agents) ionise 
preferentially to low abundance species, masking the signal and swamping mass 
analyser detectors. Haematoxylin and eosin staining can also be performed after MSI 
analyses by washing off the MALDI matrix with a suitable solvent, as the histological 
features of the tissue remain intact (Heeren et al., 2010). In conventional histology, 
tissues are usually mounted using an optimal cutting temperature polymer (OCT) to 
allow easier and precise cryosectioning. However, the presence of OCT causes 
suppression of the MS ion signal (Todd et al., 2001). If samples cannot be mounted 
with just a small drop of water on the reverse side of the sample, then mounting the 
sample in gelatine or ice, rather than OCT, can be attempted.   
1.3.4.1.2. Sectioning and tissue pre-treatment 
During sectioning, the sample stage temperature is maintained between -10 and -25ºC 
and sections are usually cut at 10-20µm, comparable to the thickness of a mammalian 
cell diameter, so that the majority of cells are cut open. This allows MALDI matrix 
(described below) to co-crystallise with cell contents. For some MALDI mass 
spectrometers, the sample must be ionised from a conductive surface, either a metal 
plate or a metal coated microscope slide. If tissue sections are much thicker than 30-50 
µm then the tissue surface can start to become insulated from the underlying electrical 
field and hence ionisation will be less efficient. Tissue attachment can be carried out by 
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the use of an adhesive double-sided conductive tape or by thaw-mounting (Schwartz et 
al., 2003). Multiple sections from different tissues can be placed on the same MALDI 
target to allow inter-sample comparison e.g. with vehicle controls. Cell debris, 
compounds, and salts from the surface of the tissue (Todd et al., 2001) that can cause 
ion suppression or formation of unstable adducts can be removed by washing. Several 
solvents have been used, ethanol being preferred due to the fixative dehydration 
properties (Lemaire et al., 2007). This approach is suitable for proteins or structural 
components of the tissue, but in the case of small molecular weight drugs care must be 
taken, as washing with ethanol may lead to the removal of small molecules, particularly 
hydrophobic ones (e.g. steroids). Therefore, the washing step is target compound-
dependent and usually avoided for all small molecule analysis unless optimised 
specifically. Samples and sections should be stored at -80
o
C prior to analysis, with all 
transfers performed on dry ice. Prior to matrix application, samples should be removed 
from storage and dried using a stream of nitrogen or under vacuum in a desiccator. 
1.3.4.2.  Matrix deposition 
The role of the MALDI matrix is to absorb laser energy in the MALDI source, leading 
to the explosive desorption of analytes (often neutral species) held within matrix 
crystals, into the gas-phase without significant degradation (Karas et al., 1988). Matrix 
application must enable homogenous co-crystallisation of the analytes from the tissue 
within the matrix on the section surface, without causing any diffusion or disruption of 
the tissue morphology. This step is crucial for achieving reproducible high quality data. 
Non-optimal matrix selection can obviate detection of target analytes. Furthermore, 
poorly applied matrix can prevent effective high spatial resolution analysis as analytes 
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may delocalise in the matrix solvent during deposition and prior to matrix 
crystallisation. The matrix solution consists of: (a) an organic solvent (commonly 
ethanol, methanol or acetonitrile), (b) an organic acid (matrix) and (c) trifluoroacetic 
acid (TFA) or another strong organic acid (when performing positive mode ionisation). 
The function of the organic solvent is to rapidly extract target compounds from the 
tissue, followed by fast solvent release by evaporation at room temperature. This allows 
co-crystallisation of the molecules of interest within the growing crystals of the matrix 
at the tissue surface (Goodwin et al., 2008). The addition of TFA promotes the 
ionisation of analytes by enriching the media with available protons, thus, allowing 
protonated mass formation (ions formed by gain of a proton). The choice of matrix 
depends on the mass range and physicochemical properties of the target compounds: 



















Sugars, peptides and 
nucleotides, 
crystalline 
α-Cyano-4-hydroxycinnamic acid CHCA Peptide and small proteins crystalline 
3,5-Dimethoxy-4-hydroxycinnamic SA Oligonucleotides crystalline 
2,4,6-Trihydroxyacetophenone THAP Oligonucleotides and 
glycoprotein 
crystalline 
3-Hydroxypicolinic acid 3-HPA Phospholipids crystalline 
2,6-Dihydroxyacetophenone DHA FFPE tissues reactive 
2,4-Dinitrophenylhydrazine 2,4 DNPH Peptides ionic solid 
 
The size of the droplets and subsequent crystals formed by the different matrices 
influences the spatial resolution possible. Matrix deposition can be performed as 
individual droplets (spotted) or as a homogeneous layer (coated). The coating can be 
performed by either spray-based (e.g. TLC-sprayer) or solvent-free (e.g. sublimation) 
based methods dependent on the spatial resolution that is required. The advantages and 
disadvantages of the most commonly used deposition techniques are summarised in 
Table 1.4 (Kaletas et al., 2009). To limit diffusion of the analyte molecules during 
matrix deposition, alternative solvent-free matrices have been developed and 
successfully applied for small molecule MSI analysis (Goodwin et al., 2010). 
However, the main issue of the “dry-coating” technique is the lack of sensitivity of the 
low abundance molecules due to poor extraction of analytes from the tissue (Goodwin 
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et al., 2011). The formation of matrix adducts can mask the detection of a target mass 
and therefore the use of a deuterated matrix can help in avoiding interference while 
retaining the ionisation efficient of the MALDI matrix (Shariatgorji et al., 2012).  
Table 1.4: Matrix deposition techniques adapted from (Kaletas et al., 2009) 
Technique Advantages Disadvantages 
Acoustic multi-spotter Uniform, fast, good 
reproducibility 




Homogenous Limited time for analyte matrix 
interaction 
Pneumatic Sprayer Homogenous  Droplet size not constant 
Image Prep
®
 Controlled conditions, automated Droplet size not constant, expensive 
Dry-coating Cheap, high purity matrix Poor analyte–matrix extraction 
Sublimation Homogenous, reproducible, fast Poor analyte–matrix  extraction 
Desktop inkjet printer Uniform droplets, (multichannel) Slow and poor solvent compatibility 
 
1.3.5.  Mass Analysers 
Technological improvements in MS instrumentation started with high throughput 
peptide and protein screening applications, followed by the innovative technological 
improvement in the field of proteomics. MSI has applied these technological 
developments in tissue analysis and imaging. Table 1.5 provides an overview of the 
most commonly used mass spectrometers for MSI together with their characteristic 
performance indicators. The ions generated by the different ions sources are then 
detected by their mass/charge ratios (m/z) and a range of potential detection systems are 
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available. Each mass analyser has its own special characteristics and applications, 
benefits and limitations (Jaroslav et al., 2010) and the choice is based upon the 
application and cost. A single imaging experiment in the MS-mode can yield multiple 
ion images within a narrow mass range of only a few hundred Da and therefore mass 
analysers with high mass accuracy and resolving power are desirable. This contrasts 
with tandem quadrupole systems commonly used for targeted analysis but only 
resolving to unit mass. In terms of sensitivity, hybrid configuration of ion traps such as 
Qtraps, orbitraps
®
 or triple quadrupoles in MRM mode offers great sensitivity in 
particular for small molecules MSI. 
Table 1.5: Characteristic performances of different mass analysers for MSI. Adapted 
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PAF: Pixel acquisition frequency, TOF: Time of flight, FTICR: Fourier transform ion 
cyclotron resonance, MRM: Multiple Reaction Monitoring, MRP: Mass Resolving Power. 
 
1.3.5.1.  Quadrupole Mass Analysers 
A quadrupole mass spectrometer consists of an ioniser, an ion accelerator, and a mass 
filter consisting of four parallel metal rods. Two opposite rods have an applied potential 
of (U+Vcos(ωt)) and the other two rods have a potential of -(U+Vcos(ωt)), where U is 
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a direct current (DC) voltage and Vcos(ωt) is an alternative current (AC) voltage. The 
applied voltages affect the trajectory of ions travelling down the flight path cantered 
between the four rods. For given DC and AC voltages, only ions of a certain m/z pass 
through the quadrupole filter and all other ions are ejected from their original path 
(Hoffmann et al., 2001). A mass spectrum is obtained by monitoring the ions passing 
through the quadrupole filter as the voltages on the rods are varied. There are two 
methods: varying ω and holding U and V constant, or varying U and V with (U/V) 
fixed for a constant angular frequency, ω. Quadrupole mass analysers are low 
resolution systems often used for quantitation, with high reliability. However, their data 
collection at a nominal mass may be confounded by the presence of multiple species 
with the same average integer mass (Chernushevich et al., 2001). To improve 
specificity in the quantitative arena, triple quadrupole and tandem mass spectrometers 
have been developed. These allow Selected Reaction monitoring (SRM) where a 
precursor ion is selected by the first quadrupole, fragmented in the second and a 
particular product ion selected for detection in the third quadrupole. Quadrupole 
systems are limited in mass range (<4000 Da), and hence suitable for imaging most 
drugs but not large biomolecules. If further confidence in structural identity is required 
or large analytes of interest, mass analysers of higher mass accuracy are used (Steen et 
al., 2001). 
1.3.5.2.  Time of flight (TOF) analysers 
In a linear mode, a time of flight mass spectrometer measures the mass-dependent time 
it takes ions of different masses to move from the ion source to the detector. This 
requires that the starting time (the time at which the ions leave the ion source) is well-
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defined. Therefore, ions are either formed by a pulsed ionisation method (usually 
MALDI), or various kinds of rapid electric field switching are used as a 'gate' to release 
the ions from the ion source in a very short time (Wiley, 1956). In a reflectron mode, 
the ions leaving the ion source of a TOF mass spectrometer have neither exactly the 
same starting times nor exactly the same kinetic energies phenomena calls "chromatic 
aberrations". Various TOF spectrometer designs have been developed to compensate 
for these differences. A reflectron is an ion optic device in which ions in a TOF mass 
spectrometer pass through a "mirror" or "reflectron" and their flight is reversed. A 
linear-field reflectron allows ions with greater kinetic energies to penetrate deeper into 
the reflectron than ions with smaller kinetic energies. The ions that penetrate deeper 
will take longer to return to the detector if a packet of ions of a given m/z contains ions 
with varying kinetic energies, then the reflectron will decrease the spread in the ion 
flight times, and therefore improve the resolution of the time-of-flight mass 
spectrometer (Vestal et al., 2005). A curved-field reflectron ensures that the ideal 
detector position for the TOF mass spectrometer does not vary with m/z ratio. This also 
results in improved resolution for time-of-flight mass spectrometers. ToF analysers 
offer excellent m/z resolution, with high repetition rates, ideally suited for pulsed 
ionisation techniques like MALDI (Laiko, 2006). 
1.3.5.3.  Trapped-Ion Mass analysers 
This analyser employs similar principles as the quadrupole analyser mentioned above; 
it uses an electric field for the separation of the ions by m/z. The analyser is constructed 
of a ring electrode of a specific voltage and grounded end cap electrodes. The ions 
enter the area between the electrodes through one of the end caps. After entry, the 
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electric field in the cavity due to the electrodes causes the ions of certain m/z values to 
orbit in the space. As the radio frequency voltage increases, heavier mass ion orbits 
become more stabilised and the light mass ions become less stabilised, causing them to 
collide with the wall, and eliminating the possibility of travelling to and being detected 
by the detector (Stafford, 2002). The quadrupole ion trap usually runs a mass selective 
ejection, where selectively it ejects the trapped ions in order of increasing mass by 
gradually increasing the applied radio frequency voltage. This approach provides some 
unique capabilities, such as extended MS/MS experiments, very high resolution, and 
high sensitivity (Michalski et al., 2011).  
A relative new trapping analyser has been introduced by Makarov and co-workers 
called Orbitrap®. The Orbitrap® mass analyser is the first high-performance mass 
analyser which employs trapping of ions in electrostatic fields. Originating from an 
ideal Kingdon trap, Orbitrap® analyser can provide high performance analytical 
characteristics such as speed, mass accuracy and dynamic range, only when it is highly 
integrated to the ion introduction process (Zubarev et al., 2013 and Makarov et al., 
2000).  
1.3.5.4.  Fourier Transform Ion Cyclotron Resonance Mass Spectrometry 
(FTICRMS) 
In this research, FTICR was chosen as an ultra-high resolution mass spectrometry 
analyser for measuring steroids and drug distribution in the targeted tissues. FTICRMS 
offers a unique accurate mass measurement in contrast with most triple quadruple mass 
spectrometer that can only achieved integer mass accuracy leading to potential 
selectivity issues.   
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FTICRMS technique is determined by the cyclotron frequencies of ions trapped in a 
Penning trap. The m/z of the ions is calculated from this frequency in first 
approximation by the equation ώ=qB/m , where ω is the reduced cyclotron frequency in 
rad/s, q the elemental charge in Coulomb, B the magnetic field in T, and m the 
molecular weight in kg. In FTICRMS, the ions can be generated directly inside the ion 
trap or externally and then transported to the ion trap. The ion trap (or ICR cell) 
generally consists of two trap electrodes, two excitation electrodes, and two detection 
electrodes Figure 1.13  (Marshall et al., 1998). 
 
 
Figure 1.13: Representative FT-ICR-MS showing the ion trapping, detection and signal generation. 




The trap electrodes confer the parabolic trapping potential in order to confine the ions 
in an axial plane. After the trapping step (which can vary from milliseconds to a few 
hours), the ion cyclotron motion is then excited by the application of a Rf (radio 
frequency) excitation pulse on the excitation electrodes. As a result, the ions 
experience a net outward force which causes the ions to increase their cyclotron radius. 
Moreover, the ion motion also becomes coherent (Yin et al., 1992). The coherently 
orbiting ions induce a corresponding image charge in the detection electrodes. The ICR 
signal is measured by digitising the voltage difference between the two detection 
electrodes as a function of time. This signal is referred to an ICR transient. Fourier 
transformation of the time-domain transient results in the cyclotron frequency spectra, 
this frequency is then converted into mass spectra. Fourier transform mass 
spectrometers (FTMSs) offer several unique advantages including high mass resolving 
power and multistage MS/MS capabilities (Guan et al., 1994).  
FTICRMS has been gaining popularity in tissue imaging analysis due to the ability to 
trap and store ions while allowing additional ones to be introduced into the ion 
cyclotron resonance (ICR) cell. This phenomenon makes it possible to accumulate ions 
from multiple MALDI ionization events in the ICR cell during an imaging analysis 
prior to detection leading to an ultra-high resolution power. This increment in 
resolution (up to 2M) increases the selectivity of the mass accuracy down to sub-ppm 
levels allowing an almost unique monoisotopic mass measurement (Marto et al., 
1995). Continuous accumulation of selected ions (CASI
TM
) has been introduced by 
Bruker Daltonics showing very promising results with an increased in sensitivity up to 
10 times in comparison with the broadband acquisition mode. This continuous mode of 
operation successfully separates the targeted ions (e.g. drug, metabolite, etc.) from the 
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intense chemical background which is generated by MALDI of tissue, thereby 
lowering the limit of detection for the targeted species (Ruh et al., 2013). FTICRMS 
delivers a unique combination of high mass spectral resolution and tandem mass 
spectrometric capabilities. The resolution offered by FTICRMS allows the 
visualization of spatial details that remain hidden under lower mass spectral resolution 
conditions (Marshall et al., 1998) . 
1.3.6.  Data processing 
Specialised software programs are used to generate distribution images of ions of 
specific masses from MSI data. Each sample position/spot (or pixel) on the tissue 
irradiated by the laser, contributes a mass spectrum containing information about the 
species desorbed (Caprioli, 2007).
 
The relative intensity of a specific target molecule is 
plotted in each pixel, producing a molecular map. Several software packages have been 
used and mostly are commercially available, including Biomap® (Novartis, Basel, 
Switzerland) and FlexImaging® (Bruker Daltonics, GmbH) among others. The data 
collated can then be aligned with histological information, commonly using an adjacent 
tissue section.  
It should be again reiterated that the displayed image is of a specified mass window, 
with summed abundance within that window displayed as a 2D relative abundance 
image. To confirm that the image generated is representative of the distribution of a 
target mass the most effective method is to reanalyse the samples in MS/MS 
fragmentation mode. This allows the parent compound to be fragmented and then 
relative abundance distribution of the fragments ions mapped over the sample.  
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1.3.7.  Ion Suppression 
The term ion suppression was introduced originally by Buhrmann (Buhrmann et al. 
1996). The authors described it quantitatively as (100 - X)/(Y × 100), where X and Y are 
the unsuppressed and suppressed signals, respectively (Buhrman et al., 1996). Ion 
suppression occurs in the early stages of the ionisation process in the MALDI source. 
Disregarding sample cleanup, especially when complex matrices are involved, will lead 
to poor performance. The origin and mechanism of matrix effects are not fully 
understood. There are many possible sources for ion suppression, including the 
MALDI matrices, endogenous compounds from the tissue sections as well as 
exogenous substances, molecules not present in the original sample but from 
contamination with polymers during tissue embedding and fixation. Some other factors 
make a compound a prime candidate for inducing ion suppression, for example, 
concentration, mass, and physicochemical properties such as basicity and 
hydrophobicity (Goodwin, 2012). 
1.3.8.  Broadening the spectrum of MSI by on-tissue derivatisation 
It is an absolute requirement to effectively detect compounds directly from tissue 
sections by MALDI-MSI and the drug/analyte of interest must be ionised by the 
desorption and ionisation processes. However, not all drugs are amenable to ionisation 
as they lack chargeable moieties. Careful matrix selection and solvent composition can 
help to achieve the desired sensitivity, however, some drugs of interest are recalcitrant 
to these processes, e.g. many steroids are examples of difficult analytes to detect by 
MS. Derivatisation is a technique used in  chemistry  to transform a 
chemical compound into a product (the derivative) of similar chemical structure, called 
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a derivative. Generally, a specific functional group of the compound participates in the 
derivatisation reaction and transforms the precursor  to a derivative of 
distinct reactivity, solubility, boiling point or chemical composition. The new chemical 
properties that result can be used for quantification or separation of the precursor. 
Derivatisation has been extensively used as a strategy for improving the detection of 
poorly ionisable molecules such as steroids for both atmospheric pressure chemical 
ionisation (APCI) and ESI analysis in LC/MS analysis (Higashi et al., 2007; Higashi et 
al., 2004). However, MSI in combination with on-tissue chemical derivatisation 
(OTCD) is still in its infancy with few cases reported (Chacon et al., 2011; Manier et 
al., 2011).  
Chacon and co-workers have demonstrated the use of OTCD of a small molecule, 3-
methoxysalicylamine (3-MoSA). The molecule 3-methoxysalicylamine (3-MoSA) is a 
scavenger of levuglandins (LGs). LGs are highly reactive towards primary amines, and 
form adducts with proteins and DNA, a process linked to oxidative injury, 
inflammation and the progression of Alzheimer's disease. Therefore, molecules such as 
3-MoSA, which can scavenge LGs and prevent the formation of LG adducts, are of 
great interest. The study of the distribution of 3-MoSA on intact tissue by MALDI-MSI 
is very limited by matrix ion interference and low sensitivity. Derivatisation of 3-
MoSA with 1,1'-thiocarbonyldiimidazole (TCDI) resulted in a readily ionisable 
oxothiazolidine derivative. TCDI treatment of tissue from mice dosed with 3-MoSA 
allowed pharmacokinetic profilingof this drug in different organs (Chacon et al., 2011). 
Further OTCD approaches are required to broaden the spectrum of analytes currently 
readily detected by MALDI-MSI. 
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1.3.9.  Quantitation  
Imaging by mass spectrometry has been generally considered as a qualitative method 
though fundamentally, the signal generated by MSI is proportional to the relative 
abundance of the analyte. Therefore, with the use of properly controlled sample 
preparation it is possible to obtain quantitative data. The challenges arise in generating 
robustly prepared samples and achieving homogenous matrix application as both 
factors influence signal intensity. The application of a quantitation calibration curve 
onto vehicle control tissue, processed and analysed within the same experiment, is the 
simplest way to obtain quantitative information (Nilsson et al., 2010).  However, as 
localised ion suppression of analyte signal can vary across a complex tissue due to 
varying composition, the analysis may be improved by the use of an internal standard 
(e.g. stable isotope labelled analyte) within the matrix or applied to the tissue surface. 
The signal of the internal standard can be used to reflect the changes in ion extraction 
and ionisation efficiency at micrometre scale resolutions (Kallback et al., 2012). For 
whole body tissue analysis the use of tissue-specific correction factors can also prove 
useful (Hamm et al., 2012). Currently, data generated by MSI is cross-referenced to a 
gold-standard quantitative technique; drug concentrations measured by LC-MS/MS in 
adjacent tissue sections following homogenisation have been shown to be correlate 
well with data generated by MALDI-MSI in several studies (Reyzer et al., 2003). A 
quantitative method for elemental bio-imaging by laser ablation-inductive plasma MS 
(LA-ICP-MS) has been proposed by Becker and colleagues, using the ’matrix-
matched’ approach where quantitation is carried out using certified standards in the 
corresponding biological matrix; this approach compensates for any matrix ion 
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suppression effects (Becker et al., 2007). Such approaches can be anticipated to be 
more readily accepted by regulatory authorities.  
1.3.10.  MSI of steroids 
MS is widely used for steroid quantification in plasma. Regarding MSI, the distribution 
of cholesterol, chemically similar to steroids, has been imaged in brain (Malmberg et 
al., 2013) and in liver (Winograd et al., 2010), while corticosteroids and androgens 
have been detected in a non-biological matrix by cation-enhanced nanostructure-
initiator mass spectrometry (CA-NIMS) (Patti et al., 2010).
 
However, localisation of 
endogenous neutral steroids in biological tissues by MSI has not been yet reported. 
MSI of steroids is challenging, not only because of their relatively low abundance, but 
also because of their lack of either hydrogen donor or acceptor moieties, resulting in 
poor ionization yields during MALDI. Furthermore, steroids are susceptible to ion 
suppression by tissue components, such as lipids and proteins. Although steroids can be 
ionised by conventional ESI or atmospheric pressure chemical ionisation (APCI) 
(Singh G, 2000), detection in the low sub-pg range in tissues is largely out of reach, 
and these quantitative approaches do not offer two-dimensional imaging. For ESI, 
derivatisation (Higashi et al., 2004) enhances the ionisation efficiency of neutral 
corticosteroids, for example using Girard reagents (Higashi et al., 2007) . Similar 
approaches have allowed Girard P (GirP) derivatives of oxysterols to be detected with 
fmole sensitivity in rat brain homogenates using MALDI (Griffiths et al., 2011). The 
recent innovation of OTCD (Chacon et al., 2011; Manier et al., 2011)
  
has paved the 




1.4   Aims and hypothesis  
 Hypothesis 
We hypothesise that tissue imaging using mass spectrometry allows high-resolution 
dissection of tissue steroid levels, potentially at near cell-type-specific resolution, that 
will provide a step change in our understanding of the consequences of altered 
glucocorticoid metabolism. 
 Aims 
The overall aim of this Thesis is to optimise the MALDI-FTICR-MSI for steroid 
analysis and provide proof of principle for its utility for pharmacodynamics and for 
investigating the pathophysiology of disrupted glucocorticoid metabolism. The specific 
aims during this work were: 
Chapter 3: To develop and optimise a MALDI-FTICRMS MSI platform for detection 
of endogenous glucocorticoids in tissue. 
Chapter 4: To apply the optimised MALDI-FTICR-MSI platform for the assessment 
of the spatial distribution of endogenous steroids in murine and human tissue sections.  
Chapter 5: To monitor the effects of 11β-hydroxysteroid dehydrogenase-1 (11β-
HSD1) deficiency or inhibition on region-specific corticosteroids concentration in 
brain. 
Chapter 6: To apply the OTCD-MSI platform to measure the contribution of tissue-








Material and Methods 
2.1   Chemicals 
All chemicals used were analytical reagent grade and from Sigma-Aldrich (UK) unless 
otherwise stated. Isotope tracer  (
4
H-9,11,12,12)4-cortisol (d4F) (purity 98-99%),  (
3
H-
9,12,12)3-cortisol (d3F) and Internal standard (ISTD) corticosterone (
8
H- 
2,2,4,6,6,17α,21,21)8 (d8-CORT) (purity 95-97%) were from Cambridge Isotopes; MA, 
USA and 11DHC from Steraloids Inc (PA, USA), UE 2316, [4-(2-chlorophenyl-4-
fluoro-1-piperidinyl] [5-(1H-pyrazol-4-yl)-3-thienyl]-methanone and UE 2346 [4-(4-
chlorophenyl-4-fluoro-1-piperidinyl] [5-(1H-pyrazol-4-yl)-3-thienyl]-methanone were 
synthesised by High Force Ltd, York, UK (Sooy et al., 2010).
.
 Conductive indium tin-
oxide (ITO)-coated glass slides were from Bruker Daltonics (Bremen, GmbH). 
Solvents were glass-distilled HPLC grade (Fisher Scientific, Loughborough, UK). 4-
Chloro-α-cyanocinnamic acid (Cl-CCA) was synthesized in-house as explained in 
Appendix I (Jaskolla et al., 2008). 
2.2   Animals tissue 
All animals were housed in the Biological research facility, University of Edinburgh, 
Edinburgh, UK and studied under protocols approved by the UK home office. Licensed 
procedures were performed under the UK Animals (Scientific Procedures) Act, 1986 
by either Dr A Livingstone (PIL 60/5467) or Dr A McBride (PIL 60/1344) and under 
Project license PPL60/3962 JR Seckl Sept 2009. In all studies, animals were killed by 
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decapitation at 9.00 am; plasma was prepared from trunk blood, collected in EDTA and 
stored at -80˚C until analysis. Tissues were snap frozen in liquid nitrogen and stored     
(-80˚C).  
2.3   Sectioning of tissues 
Sections of tissues was carried out using cryostat cleaned to ensure the absence of 
optimum cutting temperature (OCT) mountant (Leica Microsystems Inc, Bannockburn, 
IL, USA) and tissues were embedded in gelatine solution (50%w/v). Rodent brain 
(coronal/horizontal); adrenal, kidney, testis, prostate and human biopsies (horizontal 
cryosections (10 µm) were cut and frozen (-80
o
C). For quantitation, a sampling 
protocol to combine MSI, histology and quantitation was used as previously described 
by Koeniger (Koeniger et al., 2011).
 
Briefly: (1) fifteen tissue sections (50 µm thick) 
were collected for confirmatory quantitation; (2) two adjacent sections were thaw 
mounted onto glass slides (Superfrost, Thermo Scientific, Braunschweig, Germany) 
and retained for histological examination; (3) four adjacent sections for MSI/LESA (10 
µm) were thaw mounted onto a conductive indium tin-oxide (ITO)-coated glass slides 
(Bruker Daltonics, Bremen, GmbH) pre-coated with Girard-T (GirT) reagent (0.15 
mg/cm
2
) and further sections for histology (x 2) and confirmatory quantitation (x 15) 
were harvested as above. Tissue sections for confirmatory quantitation were combined, 
weighed at room temperature (RT) and stored at -80˚C until LC-MS/MS analysis. 





2.4   Histological staining  
Cryosections were stained using haematoxylin and eosin as follows: Tissues were fixed 
in cold acetone (chilled with wet/ice for 60 min). After fixation, tissues were 
rehydrated with ethanol (EtOH) 70 % (3 min), then rinsed in distilled water (5 min), 
stained using haematoxylin (10 % alcoholic Harris hematoxylin solution) (6 min) and 
rinsed in running tap water for 20 min. Tissues were submerged in acid alcohol (70 % 
ethanol, 1 % hydrochloric acid) (1 second (s)) for decolourisation, rinsed well in tap 
water (5 min) and counterstained in Eosin (1% in water) for 15 s. Tissues were then 
dehydrated using EtOH 95 % (3 min) (twice) and finally EtOH 100 % (3 min). Tissues 
were then cleared in xylene (2 x 5 min), and mounted with cytoseal in a fume hood 
prior to histological evaluation. Tissue sections were examined using an optical 
microscope (40 X, Leica Microsystems Inc, Bannockburn, IL, USA) with CCD camera 
(Hitachi model 3969, Japan).    
2.5   On-tissue chemical derivatisation (OTCD) 
From -80
o
C, tissues were allowed to dry in a vacuum desiccator (20 min). ITO glass 
slides were coated with (GirT) solution (20 mg/mL) in methanol (approx. 10 mL per 
slide with a nitrogen flow of 7.5 L/min at a distance of 7 cm from the slide) using an 
artistic airbrush (Nozzle diameter 0.3 mm; AirArt, London, UK). Each manual pass 
took approximately 1 s and the process was repeated with 5-10 s between passes until a 
uniform coating of derivatisation reagent (0.15 mg/cm
2 
~ 2.1 mg per slide) (pre-coated 
slides). For post-coating, GirT (5 mg/mL) in methanol + 0.2 % v/v TFA containing 0.1 
µg of d8CORT (ISTD) was applied by an artist’s airbrush (AirArt, model highT40, 
London, UK) (4 mL per slide with a nitrogen flow of 5.5 L/ min at a distance of 10 cm 
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from the MALDI target). Each manual pass took approximately 1 sec and the process 
was repeated with 2-5 s between passes until a uniform matrix coating was achieved on 
the tissue section. For pre-coated, slide was sprayed with 3 mL of methanol+ 0.2 % v/v 
of trifluoroacetic acid (TFA) containing 0.1 µg of d8CORT (ISTD). Then, for both pre-
coated and post-coated, the slide was placed in a sealed container (reaction chamber) 
containing a saturated solution of potassium chloride to create a moisturising-controlled 
reaction environment. The tissue was incubated (60 min, 40 °C) in an oven or water 
bath and then allowed to cool and dry in a vacuum desiccator (RT, 15 min) to remove 
the condensed water prior to matrix deposition. For tissue homogenate/plasma analysis, 
the extract was re-constituted in 100 µL of GirT (5 mg/mL) in methanol and derivatised 
by incubation (60 min, 40 °C) in an oven or water bath. 
2.6   Matrix application 
Matrix (CHCA; 10 mg/mL) in acetonitrile (80 % + 0.2 % v/v TFA) was applied by a 
pneumatic TLC sprayer (20 mL per slide with a nitrogen flow of 7.5 L/ min at a 
distance of 20 cm from the MALDI target). Each manual pass took approximately 1 s 
and the process was repeated with 5-10 s between passes until a uniform matrix coating 
was achieved on the tissue section. The tissue section was then allowed to dry at RT 
and stored in a desiccator until analysis. 
2.7   Instrumentation for Mass Spectrometry 
MSI was performed using a 12T SolariX MALDI-FTICRMS (Bruker Daltonics, MA, 
US) employing a Smartbeam 1 kHz laser, with instrument control using SolariX 
control v1.5.0 (build 42.8), Hystar 3.4 (build 8) and FlexImaging version 3.0 (build 42). 
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On-tissue collision-induced dissociation was carried out by Liquid extraction surface 
analysis (LESA)-nanoESI-FTICRMS using Triversa nanomate
®
 (Advion, NY, USA) 
using software chip-soft version 3.0 (build 18). Cl-CCA synthesis was monitored using 
a ZMD single Quad (Micromass, Mancehester, UK) with MassLynx version 3.1 Build 
324. Confirmatory liquid chromatography-tandem MS (LC-MS/MS) analysis was 
performed using a triple-quadrupole linear ion trap mass spectrometer (QTRAP 5500, 
AB Sciex, Cheshire, UK) coupled with an ACQUITY ultra high pressure liquid 
chromatography (UPLC; Waters, Manchester, UK). Data was acquired using Analyst 
software version 1.5.1 Build 5218. 
2.8   MALDI-FTICR analysis  
2.8.1  MSI 
Optical images were taken using a flatbed scanner (Canon LiDE-20, Canon, UK). MSI 
analysis was performed using 250 laser shots, with a laser spot diameter of ~50 µm and 
laser power was optimized for consistent ion production. Ions were detected between 
m/z 250 and 1500, yielding a 1 Mword time-domain transient, and with a laser spot 
raster spacing of 100 – 300 µm unless otherwise stated.  For constant accumulation of 
selected ion (CASI
TM
) MSI analysis was conducted using 1000 laser shots with a 
frequency of 1000 Hz. Ions were detected at m/z 470 using an isolation window of 50 
Da, yielding a 2 Mword time-domain transient. MSI data were subject to vector 
normalization method (RMS) for broadband detection (250 to 1500 Da) mode and 
window normalization using d8CORT protonated mass at m/z 468.36726 with 0.9995 
as ICR noise reduction threshold. Mass precision was typically ± 0.025 Da. Internal 
calibration was performed using a (CHCA) matrix cluster ion at m/z 417.04834 
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(broadband) and d8CORT quasimolecular ion (CASI
TM
). Average abundances were 
determined by defining specific regions of interest (ROI). A measure of the average 
abundance was then assigned from the summed spectra. Neutral, derivatised steroids 
and drug-like molecules were monitored at the corresponding protonated mass 
described in the Table 2.1 
2.8.2  Tissue spotting 
CHCA (20 µL, 10 mg/mL in 6:4, ACN: H2O containing 0.2% TFA) was added to the 
sample extract and vortex-mixed and 1 µL applied onto a MALDI stainless steel plate. 
MALDI analysis was performed at 2 Mword time-domain transient in broadband mode 
(neutral steroids) and in isolation mode (470.3±50 Da) for 10 s at 500 laser shots at 800 
Hz for GirT-derivatised steroids. Corresponding ratios of ion intensity were calculated 










Table 2.1: Molecular weights and masses of ions of steroids and Girard-T derivatives 
Compound Mw m/z (M+H)+ 
Corticosterone (CORT) 346.219 347.222 
11-dehydrocorticosterone (11DHC) 344.199 345.206 
UE2316 389.080 390.084 





GirT-7ketocholesterol (GirT-7KC) 514.437 
GirT-Cortisol (GirT-F) 476.312 
GirT-Cortisone (GirT-E) 474.296 
GirT-Androstenedione(GirT-A4) 400.292 
GirT-dehydroepiandrosterone ( GirT-DHEA) 402.312 
GirT-testosterone (GirT-TESTO) 402.312 
GirT-dihydrotestosterone (GirT-DHT) 404.322 
GirT-d4Cortisol (d4F) 480.337 
GirT-d3Cortisol (d3F) 479.331 
GirT-d4Cortisone (d3E) 477.298 
GirT-7α,27-dihydroxy-4-cholesten-3-one (GirT-(VII)) 530.432 
GirT-7α-hydroxy-4-cholesten-3-one  one (GirT-(IV)) 514.444 
 
2.9 Liquid extraction surface analysis (LESA) 
Steroids within tissue sections were derivatised as previously described in section 2.5 
and analysed immediately using LESA-nanoESI-FTICRMS as follows: solvent 
(methanol: water, 50:50 with 0.1% v/v of formic acid); pick-up volume, 1.5 µL; 
dispense volume, 1.2 µL at 0.2 mm away for surface; droplet rest time (delay), 5 s; and 
aspiration volume of 1.4 µL at 0.1 mm away from surface. ESI-FTICRMS was 
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performed using the 12T SolariX dual source (ESI-MALDI) with SolariX control 
v1.5.0 (build 42.8). Ions were isolated at m/z 470.3±50Da (11β-HSD-1 manipulation 
studies) and m/z 470.3±20Da (deuterated tracer studies) for 30 s yielding a 2 Mword 
time-domain transient. Collision induced dissociation (CID) fragmentation was carried 
out at 28 eV. 
2.10  Statistical analysis  
Data are expressed as mean ± SEM and differences were analyzed using two-way 
ANOVA with Bonferroni’s post-hoc test. Statistical significance was accepted at 
p<0.05. Statistical calculations were performed using Statistica® version 8.0, StatSoft, 




Development and optimisation of a MALDI-
FTICRMS MSI platform for glucocorticoids 
 
3.1.  Introduction 
Mass spectrometry imaging (MSI) has emerged as a new modality that allows the rapid 
detection, localisation, and identification of many species, identified by the mass of the 
free ions in high vacuum, originating from the most complex biological sample 
surfaces (Caprioli et al., 1997). To date, the distribution of cholesterol, chemically 
similar to steroids, has been imaged in brain and in liver while corticosteroids and 
androgens have been detected in a non-biological matrix by cation-enhanced 
nanostructure-initiator mass spectrometry (Patti et al., 2010). However, localisation of 
endogenous neutral steroids in biological tissues by MSI is challenging, not only 
because of their relatively low abundance, but also because of their lack of either 
hydrogen donor or acceptor moieties, resulting in poor ionisation yields. Furthermore, 
in biological tissues, steroids are susceptible to ion suppression by more abundant 
molecules, such as lipids and proteins. Although steroids can be ionised by 
conventional electrospray or APCI, detection in the low sub-pg range in tissues is 
largely out of reach, and these quantitative approaches do not offer two-dimensional 
imaging. For electrospray ionization (ESI), derivatization enhances the ionisation 
efficiency of neutral corticosteroids, achieved for example using Girard reagents 
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(Higashi et al., 2007). Similar approaches have allowed Girard P (GirP) derivatives of 
oxysterols to be detected with fmole sensitivity in rat brain homogenates using MALDI 
(Griffiths et al., 2011) and have enhanced sensitivity for cholesterol analysis using N-
alkylpyridinium isotope quaternisation in analysis of human hair homogenate by 
(MALDI-FTICRMS) (Fuchs et al., 2007). The recent innovation of on-tissue chemical 
derivatization (OTCD) has paved the way for application of derivatisation techniques 
to MSI for investigation of tissue steroids (Chacon et al., 2011).  
In this chapter, the application and method development of OTCD for the detection of 
CORT and 11DHC, active product and inert substrate of the enzyme, 11β-HSD-1, in 
biological tissue sections will be described. MALDI-FTICRMS was used as the MSI 
platform of choice due to its unique selectivity and sensitivity achieved by its high 
mass resolution power. Tissue preparation, matrix selection, derivatisation screening, 
reaction conditions, deposition techniques and MS parameters were optimised to 










3.2.  Methods  
3.2.1.  Biological tissue sections 
Adrenal glands (horizontal section) from Sprague Dawley male rats (5-7 weeks, ~175-
200 g) and murine brains (horizontal sections) from C57Bl/6j (12 weeks) ~25-30 g 
mice were prepared as described in section 2.3.  
3.2.2.  Imaging of un-derivatised steroids in tissues 
3.2.2.1.  Comparison of responses of standards measured off- and on-tissue 
Standards of both CORT and 11DHC (10 µg 1 µg/µL) of each steroid were mixed with 
CHCA solution (10 µL of 10 mg/mL in 50:50 (acetonitrile: water) + 0.2 % v/v TFA) 
and 1 µL was spotted on a MALDI ITO slide (n=3) (standards off-tissue). Sample 
preparation was carried out using the standard dried droplet method. The sample 
(steroid standard) was mixed with the matrix solution, deposited on the ITO MALDI 
slide and dried. Following the same procedure, 1 µL of the (steroid: matrix) solution 
was spotted onto a murine mouse brain section (n=3) (Standards on-tissue) and 
analysed by MALDI-FTICRMS as described in section 2.8.2. 
3.2.2.2.  Adrenal gland and murine brain imaging 
MSI was performed on rat adrenal gland and murine brain tissue sections. After 
preparing a cryosection (10 µm), tissue was thaw-mounted on an ITO-MALDI slide 
and coated with CHCA as described in section 2.6. FTICRMS was used in broadband 
mode and heat maps of both CORT and 11DHC were generated extracting the ions of 
both steroids at m/z 345.20826 and 347.22385 respectively. 
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3.2.3.  Screening of matrices  
α-Cyano-4-hydroxycinnamic acid (CHCA, 4-chloro-α-cyanocinnamic acid (Cl-CCA), 
2,5-dihydroxybenzoic acid (DHB), 2-(4'-cydroxybenzeneazo) benzoic acid (HABA): 3-
indole acetic acid (IAA), ferulic acid and Buckminsterfullerene (C60) were screened as 
potential matrices for neutral corticosteroids. Matrix assessment was carried out by 
quantifying signal from spots of steroids. In this case, d8CORT (1 µg, 0.1 mg/mL) in 
methanol: water (1:1) (n=3 per matrix) was mixed with the selected MALDI matrices 
(300 μg, 10 mg/ml in 50:50 (acetonitrile: water) with 0.2 % TFA except for C60 where 
toluene was used. 1 µL was manually spotted on a MALDI stainless steel plate and 
allowed to dry at RT (dried-droplet technique) and analysed by MALDI-FTICRMS as 
described in section 2.8.2. 
3.2.4.  Derivatisation screening 
Derivatisation screening was performed off- and on-tissue using CORT and 11DHC as 
control standards. CORT (10 ng, 1 µg/mL) and ISTD (d8CORT) (10 ng, 1 µg/mL) were 
added to a 2 mL Eppendorf tube containing 100 µL of derivatisation reagents 
(aminoguanidine, dansyl chloride, sulfonyl chloride, isonicotinoyl chloride, ferrocene 
azide, dansyl hydrazine, GirT and GirP (5 mg/mL in methanol with 1% of TFA), the 
solution was mixed and allowed to react (3 h, 40 
0
C) using a rotating water bath. After 
derivatisation, an aliquot of 30 µL was mixed with of CHCA (50 µL, 10 mg/mL, 0.2% 
TFA); 1 µL was used for MALDI-FTICRMS analysis using a dried-droplet technique 




3.2.5.  Optimising on-tissue derivatisation conditions 
Optimisation of reaction conditions was performed using a control tissue section with 
spots (5 ng, 10 µg/mL; methanol: water (1:1) of d8CORT applied to the surface 
manually (n=3 per condition). CORT and 11DHC were also applied as spots to a 
tissue-free region as controls. Spots were allowed to dry, then GirT (1 µL; 5 mg/mL) in 
different solvent systems (methanol and ethanol with TFA 0.2 % v/v, formic acid (FA) 
0.2 %v/v, acetic acid (HA) 10 %v/v (freshly prepared)) was deposited on top. The 
MALDI glass slide was placed in the reaction chamber and incubated (20, 60 or 120 
min, 40 °C), then allowed to cool and dry in a vacuum desiccator (RT, 20 min). Matrix 
CHCA (10 mg/mL; (80 %)) in acetonitrile + 0.2 % v/v TFA) was applied by a 
pneumatic TLC sprayer (20 mL per slide) and allowed to dry (RT) and stored in a 
desiccator until MALDI-FTICRMS analysis as described in section 2.8.2. 
3.2.6.  Limits of Detection (LODs) of GirT derivatives of glucocorticoids 
applied to the surface of tissue  
LODs were assessed using standards (CORT, 11DHC) applied to slides "off-tissue" 
and deuterated standard (d8CORT) applied to the tissue (murine brain, kidney and 
liver) surface as spots "on-tissue" using a dilution series of both steroids in methanol to 
achieve a range of 10 g to 100 pg/spot for neutral steroids and 1 ng to 0.01 pg/spot for 
GirT-derivatives (n=3 spots per concentration). Matrix was applied and slides imaged 
by MALDI-FTICRMS as described in section 2.8.1. The ratios (CORT/11DHC) were 
estimated. The estimated LODs and LODs of GirT derivatives were estimated using the 
S/N (signal/noise) criteria of (S/N>3) for LOD and (S/N>10) for LOQ. 
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3.2.7.  Stability of derivatised steroids 
The GirT-CORT standard was prepared as reported previously by reaction of GirT and 
the corresponding steroid in a 1:1 molar ratio, in a 10 % v/v acetic acid solution in 
methanol. The reaction was incubated (3 h, RT). The derivative was extracted in 
toluene: dichloromethane (1:1) and the solvent evaporated to dryness. The residue was 
reconstituted in methanol, characterised using accurate mass measurement and storage 
until MALDI-FTICRMS analysis. On-tissue stability studies were performed using a 
control tissue section manually spotted with GirT-CORT standard solution (10 µg/mL, 
5 ng) in methanol: water (1:1). Spots (n=3, per time) were allowed to dry at RT. The 
matrix CHCA was applied using a pneumatic TLC sprayer (25 mL per slide) 
immediately after reaction (T= 0, 10, 20 and 30 min, RT) to evaluate the stability of the 
hydrazone derivative on the tissue. MALDI-FTICRMS analysis was performed as 
described in section 2.8.2. 
3.2.8.  Screening of matrix solvents for TLC-based matrix deposition 
methods  
Screening of solvents for the matrix was conducted in order to evaluate analyte 
extraction during matrix deposition by spray coating. Immediately after the 
derivatisation, matrix was applied using acetonitrile: water or methanol: water in 
proportions ranging from 1:1 to 9:1 with 0.2 % v/v TFA as solvents. Matrix deposition 
was performed as described in section 2.7. MALDI-FTICRMS analysis was performed 




3.2.9.  Optimisation of derivatisation reagent application and saturation 
studies 
Pre-coating and saturation studies were performed to assess diffusion of the GirT 
derivatives, ion suppression and reaction yields using adrenal gland sections. Adrenal 
gland sections (10 µm) were cut (horizontal) from frozen (-80 
o
C) as previously and 
thaw-mounted on an ITO-MALDI target previously coated (pre-coated) with GirT 
reagent (0.08, 0.15, 0.30 and 0.60 mg/cm
2
). Post-coating (controls) was carried out as 
described in section 2.5 with 2, 4, 6, 8 mL of a 5 mg/L of GirT. Steroids within tissues 
were derivatised followed matrix deposition a (section 2.6) described in section 2.5. 
MALDI-FTICRMS analysis was performed as described in section 2.8.1. 
3.2.10.  Sublimation as a matrix deposition methodology 
Sublimation was performed in Sublimation apparatus 8023 (Ace Glass, Vineland, NJ). 
A key component of the device was the flat bottom condenser to which the glass cover 
slips or MALDI plate inserts could be fixed using double sided thermally conductive 
tape (3M, St. Paul, MN). Matrix CHCA (300 mg) was added to the bottom section of 
the apparatus; the two pieces were assembled with an O-ring seal and connected to a 
direct drive vacuum pump (8 m
3
/h). After 15 min at reduced pressure, the condenser 
was filled with cold water (15 °C). After five additional min, heat was applied to the 
base of the sublimator via a heating mantle covered with a sand bath, the temperature 
was monitored using a thermocouple, and time was measured from the onset of heat 
application. The sublimation of the solid matrix gradually progressed upon application 
of heat. The variable voltage regulator was set to 200 V and the temperature of the 
heating mantle increased gradually from 25 to 120 °C over 25 min. The deposition of 
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matrix was visually observed to slowly move up the sides of the glassware to the level 
of the sample plate. Optimization of the amount of matrix that condensed onto the 
tissue was empirically determined by adjusting the following parameters: temperature 
at the condenser, amount of matrix, heat applied to matrix, and time of sublimation. 
The optimal amount of matrix recommended by Hankin et al., 2007 and Caprioli et al., 
2005 is 0.17-0.22 mg/cm
2
. Use of a period of 20–25 min from the onset of heat 
application resulted in a thin uniform layer of matrix. Adrenal gland tissue sections 
were coated with CHCA (n=4) with 0.18 mg/cm
2
. Adjacent tissue sections were post-
coated as described in section 2.5 as controls. After this time, the heat and condenser 
coolant were both removed, and the system was allowed to return to room temperature 
while still under vacuum. Once equilibrated (RT), the system was returned to ambient 
pressure, opened, and the sample plate was carefully removed from the sublimation 
condenser and transferred to a MALDI plate holder for analysis by MALDI-FTICRMS. 
After sublimation, one slide was placed in a recrystallisation chamber (same as for 
derivatisation, section 2.5) containing 3 ml, 1:1 methanol: water with 1 % v/v FA for 5 
s at 90 °C and then stored in a desiccator prior to MALDI-FTICRMS analysis as per 
section 2.8.1. 
3.2.11.  Tissue washing   
From -80 ◦C, control tissues (adrenal gland) were allowed to dry in a vacuum 
desiccator (20 min). The tissue contours were highlighted using a hydrophobic pen 
(Steindler, CT, USA) to hold the washing solution on top of the tissue sections. 
Targeted tissue sections were covered with chilled solutions of ammonium formate (5 
mM, pH4) and ammonium acetate (5 mM, pH7) using a glass pipette. The solution was 
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retained (3 s) and the content drained using a small glass pipette. This procedure was 
repeated ten times and then the tissues were allowed to dry in a vacuum desiccator (15 
min) prior on-tissue derivatisation as in section 2.5, followed by matrix application as 
















3.3.  Results  
3.3.1.  Characterisation of MALDI-FTICRMS spectra of neutral steroids  
Method development started with characterisation of the mass spectra of CORT and 
11DHC by MALDI-FTICRMS. Standards were manually applied onto a stainless-steel 
MALDI plate by the dried-droplet technique using CHCA as MALDI matrix. For both 
steroids, protonated masses [M+H]
+
 ions were the most abundant species detected at 
m/z 347.22889 and m/z 345.20385 respectively, in close agreement with the 
monoisotopic theoretical masses at m/z 347.22169 and m/z 345.20604 respectively. 
Fragment ions such as those formed by water loss [M-H2O+H]
+
 and alkaline (A) 
adducts [M+A]
+
 were not observed (Figure 3.1).  
 
Figure 3.1: MALDI-FTICRMS of neutral steroids standards. Both steroids showed their corresponding 
protonated masses [M+H]
+
 as the most abundant species detected at m/z 347.228 (CORT) and m/z 






3.3.2.  MALDI-FTICRMS of neutral steroids enriched in tissue 
homogenates 
Murine brain homogenates were enriched with steroid standards and compared with 
standards in matrix only for evaluation of the ion-suppression effects and specificity.  
When standards of steroids were added to murine brain homogenates followed by 
matrix application as described in section 2.6 the same spectra were observed as 
standards alone and interferences of isobaric ions from the matrix were not observed 
(Figure 3.2) 
 
Figure 3.2: MALDI-FTICRMS of neutral steroids standards spiked into a murine mouse brain. Both 
steroids showed their corresponding protonated masses [M+H]
+
 as the most abundant species detected at 
m/z 347.227 (CORT) and m/z 345.206 (11DHC). Interferences from isobaric ion were not observed.  
cps: count per second.  
The LODs on- and off-tissue were found to be ~ 30 ng (off-tissue) and 1µg (on-tissue) 
for both steroids, as the response factor for CORT and 11DHC was close to 1. 
However, the signal of the standard was considerably suppressed by the presence of 
tissue. These LODs were considered to be well in excess of the anticipated endogenous 
physiological levels (nM range). 
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3.3.3.  Tissue imaging of un-derivatised steroids in murine adrenal gland  
An attempt was made to detect endogenous CORT and its 11-dehydro metabolite 
directly from a tissue section by MALDI-MSI. Adrenal glands from Sprague-Dawley 
rats and murine brains were selected as representative tissue sections, with the adrenal 
gland anticipated to possess the highest levels of steroids at their sites of synthesis. 
Moreover, the adrenal gland is a good tissue to use as a control tissue section to detect 
diffusion, as it has defined histological zones where steroids would be expected to 
cluster. Initial attempts at imaging corticosteroids in rat adrenal gland, and murine 
brain, monitoring the [M+H]
+
 ions of the glucocorticoids of interest, yielded ions with 
mass accuracy of -3.2 ppm (CORT) and -18.3 ppm (11DHC) (Figure 3.3 (a-c)) but 
with signal/noise (S/N) values of 5 and 7 respectively, reflected in a poor quality MS 









Figure 3.3: MALDI-FTICR-MS imaging (MSI) of neutral steroids in rat adrenal gland sections. MSI of 
neutral glucocorticoids using α-cyano-4-hydroxycinnamic acid (CHCA) as matrix showed very low 
ionisation yields in both adrenal and brain tissue sections. Simulated theoretical isotopic distribution 
pattern of: (a) corticosterone (CORT); and (b) 11-dehydrocorticosterone (11-DHC). (c): MALDI-
FTICRMS spectra of adrenal gland of neutral corticosteroids of corticosterone at m/z 347.221 Da and 
11-dehydrocorticosterone at m/z 345.200 Da. (d) Histological image of adrenal gland stained with 
haematoxylin and eosin. MSI heat map distribution of: (e) CORT at m/z 347.222 Da; and (f) 11DHC at 
m/z 345.206 Da in rat adrenal gland. (g) Histological image of murine brain stained with haematoxylin 
and eosin. MSI heat map distribution of: (h) CORT at 347.222 Da; and (i) 11DHC at m/z 345.206 Da in 
murine brain. Signal intensity is depicted by colour as per the scale shown. cps: count per second. Scale 
bar (2 mm) for adrenal section and (5 mm) for brain section. 
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3.3.4.  Attempts to improve imaging of un-derivatised steroids 
To improve images of neutral steroids in tissues, a number of approaches were pursued 
to enhance their low intensity signal.  
3.3.4.1.  MALDI matrix screening  
Screening was performed using both standard and novel matrices, to identify reagents 
which may enhance energy transfer and facilitate desorption and ionisation efficiency. 
To improve the quality of the MS image, alternative matrices must possess better 
qualities in terms of spatial resolution (crystal size), sensitivity, noise, tolerance for 
contaminants and energy absorption compared with CHCA. In term of solid state 
characteristics, the alternative matrix should have a good covering capacity, 
homogeneity and fast crystallisation, also possess better vacuum stability and be more 
resistant to laser irradiation especially for high frequency lasers.  
Substantial differences in signal intensity were observed between matrices; the 
maximum signal intensity and desorption yield however was still achieved using 











































Figure 3.4: Screening of matrices for detection of neutral corticosteroids by MALDI-FTICR-MSI. A 
solution of d8-corticosterone (1µg) in of methanol: water (50:50) was spotted on a control tissue sections 
(brain) (n=3/matrix) using the dried-droplet technique. A best yield of ions was achieved using CHCA 
as a matrix. Data are mean ± SEM. cps: count per second. CHCA: α-cyano-4-hydroxycinnamic acid, 
2,5-DHB: 2,5-dihydroxybenzoic acid, CA: cinnamic acid, IAA: 3-indole acetic acid, FA: ferulic acid 
HABA: 2-(4'-hydroxybenzeneazo) benzoic acid,  C60: Buckminsterfullerene. 
 
As the best sensitivity was achieved using CHCA, the relationship of the desorption 
and ionisation mechanism and its chemistry was further investigated, with a view to 
proposing structural modifications which may be beneficial. In the CHCA core, the 
free carboxylic acid function is essential for good matrix performance. Also, it 
becomes possible that proton affinity (PA) may play a key role in the ionisation 
process. Matrices with lower PA have a faster proton transfer reaction constant leading 
to a more efficient ionisation. Proton affinities of some of the tested matrices were 
calculated based on the kinetic method (Brodbelt-Lustig et al., 1989). As shown in 
Table 3.1, the CHCA which had the lowest PA also led to the higher signal intensity 
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(Figure 3.5), confirming the hypothesis that matrices with lower PA have higher 
ionisation efficiency. 
Table 3.1: Proton affinity calculation of standard MALDI matrices  
Matrix PA (kJ/mol) 
CHCA 864 

















CHCA CHCAH  
)](()([)( HfHCHCARfHCHCAHRfHrHPA   
Figure 3.5: Proton affinity (PA) using the kinetic method.  Δr: Enthalpy of reaction. Δf: Enthalpy of 
formation. Adapted from (Brodbelt-Lustig et al., 1989). 
 
On this basis Karas and co-workers designed a halogenated cyanocinnamic acid 
derivative, the novel 4-chloro-α-cyanocinnamic acid (Cl-CCA), which possess a lower 
proton affinity (846 kJ/mol) than its hydroxyl analogue (864 kJ/mol). Use of this 
matrix had increased the signal of poorly ionisable peptides. To investigate if use of a 
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matrix with lower PA would be of benefit in imaging underivatised steroids, the Cl-
CCA matrix was synthesised and tested (Appendix I). Interestingly, the novel Cl-
CCA, demonstrated lower intensity signals in combination with steroids than CHCA 
(Figure 3.6), however, the background signal was noticeably lower in the low mass 






























Figure 3.6: Use of 4-chloro-α-cyanocinnamic acid (Cl-CCA) vs α-cyano-4-hydroxycinnamic acid as 
matrix for detection of neutral corticosteroids by MSI. d8-corticosterone (1µg) in of methanol: water 
(50:50) was spotted on a control tissue sections (brain) (n=3/matrix) using the dried-droplet technique as 
described in section 3.2.3. The greater intensity of signal of ions was achieved using CHCA as a matrix. 
Data are mean ± SEM. cps: count per second. 
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Figure 3.7: MALDI-FTICRMS spectra of neutral corticosteroids in a section of adrenal gland using 
CCA matrices. Corticosterone at m/z 347.215 Da and 11-dehydrocorticosterone at m/z 345.198 Da using 
(a) α-cyano-4-hydroxycinnamic acid (b) chloro-α-cyanocinnamic acid (Cl-CCA) as matrices. Signal 
intensity could not be improved by use of Cl-CCA; however, the matrix clusters contribution was 
noticeably lower. cps: count per second. CCA: cyanocinnamic acid. 
 
3.3.5.  MSI imaging of derivatised corticosteroids 
It is well known in approaches to analyse steroids by LC/MS that sensitivity can be 
improved using chemical derivatisation by the incorporation of readily charged or 
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steroids to readily charged derivatives may increase the proton affinity (or proton 
displacement, in negative ion-mode) leading to a more efficient ionisation.  
3.3.5.1.  Screening of derivatisation reagents 
Several derivatisation reagent were screened (Table 3.2) targeting both ketone at C3 in 









Figure 3.8: Molecular structure of corticosteroid core. Targetable derivatisation moieties: Α, β- 











Table 3.2: Potential derivatisation reagents 
















































































The screening was carried out by spotting experiments on- and off-tissue using a 
labelled corticosteroid (d8CORT) rather than endogenous steroids to avoid any 
background contribution. 
Poor desorption or ionization by MALDI analysis was found using derivatives 
targeting the primary (C21) alcohol moiety with acyl and sulfonyl chlorides. Screening 
derivatization reactions, targeting the α-β unsaturated ketone at C3 in the steroid A-
ring (Table 3.3) improved signal intensity in positive mode when the corticosteroids 
were converted to derivatives either permanently charged or easily protonated. In 
particular, formation of a quaternary ammonium derivative, by a hydrazine-type 
condensation reaction of the ketone at C3 using Girard-T (GirT) reagent (Figure 3.9) 
forming water soluble hydrazones group, greatly enhanced response up to 10
4
 fold 












































R1: OH ( Corticosterone): Mw 346.22                           


















 0.9 x 10
4
 0.1µg 
Aminoguanidine ND  ND  N/A 
Dansyl chloride ND  ND  N/A 
Sulfonyl chloride 2x 10
4
  1x 10
4





  5.4x 10
5
  4 ng 
Ferrocene azide ND  ND  N/A  
Dansyl hydrazine 8.1x 10
6
  6.7x 10
6
  0.2 ng  
Girard T 8.5 x 10
8
  8.7x 10
8
  1 fg 
Girard P 2.1x 10
7
  1.7x 10
7
  10 fg 
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In terms of reactivity, derivatisation was only observed at the C3 in the steroid A-ring 
as the π electrons are delocalised across the conjugated system leaving the carbonyl 
group more susceptible to a nucleophilic attack. Moreover, double or triple charged 
species were not detected suggesting that double or triple (in case of DHC) tagged 
derivatives were not formed to any significant degree.  
Upon derivatisation the average molecular weight of the CORT derivative was 460.4 
Da and for the corresponding 11DHC was 458.3 Da, in both cases, greater than the 
untagged steroid due to the introduction of the GirT tag. The monoisotopic masses of 
both GirT-derivatives were confirmed by accurate mass measurement with a mass 
deviation of ± 10 ppm from their theoretical values as it shown in Figure 3.10.  
Moreover, upon derivatisation, the ionisation of both derivatives was driven by the 
positive-charged quaternary amine tag, therefore similar intensities of responses were 
found for both steroids derivatives; the observed response factor (abundance of GirT-





Figure 3.10: Representative MALDI-FTICRMS of Girard T (GirT)-derivatives of corticosteroids 
standards at same amount (5 ng) each. Observed response factor was 1.07. Theoretical monoisotopic 
pattern (a: GirT-corticosterone (GirT-B).(b) GirT-11-dehydrocorticosterone (GirT-11DHC). C: Mass 
spectrum of GirT-(11DHC&CORT) derivatives (5 ng). cps: counts per second. 
 
3.3.5.2.  Optimisation of formation of Girard T derivatives 
GirT condensation is generally carried out using protic solvents in weak acid media at 
RT with reaction times around 10-18 h achieving 60-80 % of conversion of ketones to 
hydrazones. Recent studies have shown that the reaction can be carried out in 30 min at 
70 °C (Wu et al., 2010). However, this was not appropriate for the method developed 
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increase of water vapour in the reaction chamber and may also lead to diffusion of the 
water soluble GirT derivatives and ion suppression effects due to protein cleavage and 
tissue component degradation. Screening using different with MSI compatible solvents 
(ethanol/methanol) and acidic catalysts (formic acid, acetic acid and TFA) as described 
in section 3.2.6 was conducted.  The best signal intensity was achieved in 1 h at 40 °C, 
in a moisturizing environment using methanol/TFA as solvent/catalyst system (Figure 
3.11).  
 
Figure 3.11: Optimisation of time and catalytic conditions. A solution of d8-corticosterone (5 ng) in 
methanol: water (50:50) was spotted onto a control tissue section (murine brain (n=3)). The spots were 
allowed to dry, then solutions of Girard T (GirT; 0.5 µL, 5 mg/mL) applied using different solvent 
systems: Methanol or ethanol with HA, FA and TFA, respectively. Spots of reagent were deposited 
directly on top of the d8-CORT standard spots. The slide was placed in the reaction chamber and 
incubated (40
0
C for 20, 60 and 120 min). Matrix (CHCA (10mg/mL in 60:40 acetonitrile: water + 0.25 
%v/v TFA)) was applied to the tissue by a pneumatic TLC sprayer (20 mL per slide). The best signal 
intensity was achieved at 60 min using methanol/TFA as solvent/catalyst system. Data are mean ± SEM 


























Accordingly MALDI-FTICR parameters were optimised for maximum sensitivity of 
detection and quantification of GirT derivatives using CHCA as a MALDI matrix and 
following derivisation using the optimised reaction conditions (methanol/TFA solvent 
system at 40˚C for 60 min).  
3.3.5.3.  Limits of detection and quantitation of derivatised corticosteroids on 
tissue sections 
The LODs and LOQs were evaluated in different tissue sections by standard spotting 
experiment as described in section 3.2.7. Results are shown in Table 3.4. 
Table 3.4:  Limits of detection and quantitation of Girard T derivatives of 
corticosteroids by MSI 
 
LOQ: limit of quantitation; LOD: limit of detection; 11DHC: 11-dehydrocorticosterone-derivative, CORT: 
corticosterone-derivative ΔM:  Mass accuracy against the theoretical isotopic distribution. ppm = parts per million. 
 
LODs at pg levels were achieved in brain and liver sections with very good mass 
accuracy (less than 10 ppm). An improvement of approximately 10
4
-fold in signal 
intensity was achieved in comparison with non-derivatised steroids. However, higher 
values were found in kidney, possibly due to the high ion suppression caused by 
endogenous tissue composition and high levels of alkaline cations.  
 
11DHC CORT 11DHC CORT 11DHC CORT
Brain 5-10 0.5-1 1 0.1 3 2
Liver 12-15 12-15 1-2 1 2 3
Kidney 50-60 50-60 10 8-10 16 15




3.3.5.4.  Stability of Girard-T derivative 
As previously reported, proteolysis and tissue degradation during sample preparation 
may cause ion-suppression. With the optimized protocol in place, stability was 
evaluated temporally by assessing the intensity of signal from GirT-CORT applied on 
and off tissue sections as described in section 3.2.8. Only 13 % reduction in signal 
suppression/degradation was observed after 20 min at RT, within the necessary limit of 
tissue handling times before matrix coated (Figure 3.12). 
 
 
Figure 3.12: On-tissue stability of Girard T corticosterone (GirT-CORT). A solution of GirT-CORT (5 
ng) was spotted on a control tissue section in duplicate. Matrix (CHCA (10 mg/mL in 60:40 acetonitrile: 
water + 0.25 %v/v TFA) was applied to the tissue by a pneumatic TLC sprayer (6ml per slide) 
immediately after reaction (T=0) and after 10, 20 and 30 min at RT (n=3 per time point). The observed 
decline in signal intensity was less than the acceptable cut-off for stability of the original signal (20 %). 




























3.3.5.5.  Detection of endogenous steroids in adrenal glands following 
derivatisation with GirT 
After optimisation of the derivatisation reaction, a feasibility study was conducted to 
establish whether endogenous cortico steroids could be detected in biological tissue 
sections as their GirT- hydrazones with greater intensity than without derivatisation 
(section 3.3.3). Again rat adrenal glands were selected as a model tissue for method 
development, due to the anticipated high abundance of corticosteroids and well know 
distribution pattern. The on-tissue chemical derivatisation (OTCD) MALDI-MSI 
platform protocol was applied as summarised in Figure 3.13. Derivatisation reagent 
was applied using an artist’s air brush and ITO-slice with the tissue sections was 





Figure 3.13: On-tissue chemical derivatisation mass spectrometry imaging (OTCD-MSI) platform. 
Mass Spectrometry imaging workflow: after sectioning, tissue were coated with GirardT (GirT) by 
spray-based techniques, incubated in a temperature and humidity-controlled chamber and further coated 

























Figure 3.14:  Derivatisation reaction chamber. After coating with Girard T (GirT), slides were placed in 
a sealed container containing a moisturising-controlled solution (saturated potassium chloride) and 
incubated at 40
0
C for 60 min in a temperature-controlled oven. 
 
Both steroids were identified as hydrazone derivatives within adrenal tissue and 
molecular distribution maps were generated, showing GirT-CORT (m/z 460.317) and 
GirT-11DHC (m/z 458.301) in high abundance in the zona fasciculata/reticularis 
(Figure 3.15 b and a) respectively, with mass accuracy of ±5 ppm from their 
theoretical monoisotopic masses (Figure 3.15 d-f) and signal to noise ratios >100. 
Moisturising media 




Figure 3.15: Molecular imaging by MALDI-FTICR-MSI of corticosteroid derivatives prepared with 
Girard T reagent (GirT) in representative rat adrenal gland sections. Molecular regional distribution 
maps showed GirT-corticosterone (GirT-CORT; m/z 460.31713) and GirT-11-dehydrocorticosterone 
(GirT-11DHC; m/z 458.30139) in high abundance in the zona fasciculata/reticularis (site of 
glucocorticoids synthesis) with mass accuracy of ±5 ppm from their theoretical monoisotopic masses 
and (S/N) signal to noise ratios above 100. (a) Histological image of a cryosection of rat adrenal gland 
stained with haematoxylin and eosin ZG = zona glomerulosa; ZFR = zona fasciculata/reticularis). Heat 
map of GirT derivatives of: (b) GirT-CORT at m/z 460.31698 Da and (c) GirT-11DHC at m/z 458.30133 
Da, collated by MALDI-FTICRMS. Signal intensity is depicted by color on the scale shown. Scale bar 
(2 mm).  Simulated theoretical isotopic distribution pattern of: (d) GirT-CORT; and (e) GirT-11DHC. 
(f) Representative FTICRMS spectrum of corticosteroid hydrazones in rat adrenal gland, showing 
excellent agreement with theoretical mass. cps = counts per second.  
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In the adrenal gland, GirT derivatives yielded spectra dominated by the molecular ion 
(Figure 3.15, f) and high resolution MS was used to overcome the challenge of 
selecting specific analytes of interest from the many high abundance ions in the low 
mass range.  
Glucocorticoids were visualised and most abundant in the zona fasciculata and 
reticularis, the major site of glucocorticoid synthesis, with lower signal in the outer 
zona glomerulosa, where CORT is further metabolised to aldosterone. This suggested 
that unwanted diffusion of analytes was constrained by the tissue processing method. 
Spatial resolution of the laser is adjustable, but increasing the spatial resolution 
decreases sensitivity as the spot size sampled is smaller (Figure 3.16). In the adrenal, 
collecting data at 200 m resolution generated sufficient spatial information with 
adequate signal (signal/noise >100) as when the resolution was changed to 50 m a 
considerable decline in signal intensity was observed. 
 
Figure 3.16: Molecular imaging by MALDI-FTICR-MSI of corticosterone derivative prepared with 
Girard T reagent (GirT-CORT) in representative rat adrenal gland sections at different spatial resolution. 
Increasing the spatial resolution of the image caused a decline in signal intensity due to the smaller spot 
size. Heat map of GirT-CORT at m/z 460.317Da. (a) at 200 µm lateral resolution. (b) at 50 µm lateral 




3.3.5.6.  Confirmation of identity of molecular species by LESA  
Structural confirmation by fragmentation using LESA-electrospray ionisation (ESI)-
FTICR-MS followed by CID, allowed isolation of the precursor ions in the ICR cell, 
increasing both sensitivity and selectivity in comparison to MALDI. The experimental 
procedure can be found in section 2.9.  This process provided fragmentation patterns 
typical of GirT hydrazones (Figure 3.17), concordant with the structures of steroid 
hydrazones, extrapolating from GirP analogues, which may form a stable five member 
ring as previously reported. CID of the GirT derivatives generated a series of fragment 
ions characteristic of the loss of the quaternary amine tag [M-59]
+
 and carbon 
monoxide [M-87]
+
 of the derivatised group at m/z 399, m/z 371 (GirT-11DHC) and m/z 
401, m/z 373 (GirT-CORT), respectively. Also, a GirT-CORT selective fragment was 
observed at m/z 383 corresponding to the neutral loss of water at C11 of the m/z 401 





Figure 3.17: Liquid extraction surface analysis (LESA) with nanoESI-FTICR collision induced 
dissociation (CID) mass spectra of Girard T (GirT) derivatives of corticosteroids. CID mass spectra and 
proposed fragmentation patterns of GirT derivatives were in agreement with the structures of steroid 
hydrazones, extrapolating from Girard P (GirP) analogues. Precursors (a) at m/z 460.31692 Da (GirT-
corticosterone) and (b) at m/z 458.29727 Da (GirT-11-dehydrocorticosterone) (d) Proposed 
fragmentation patterns for GirT-CORT (c) and GirT-11DHC. cps = counts per second. Cell isolation 




















































































































3.3.5.7.  Solvent optimisation of method to detect endogenous steroids 
To further optimise the MSI platform specifically for detection of endogenous steroids 
in tissue, matrix solvents were screened to evaluate the extraction efficiency from the 
tissue surface. Due to solubility properties of the MALDI matrix, only methanol/water 
and acetonitrile/water in acidic media (TFA, 0.2 % v/v) were evaluated as solvents. The 
mixture 6:4 with 0.2 % v/v TFA has been used for all MSI experiments and therefore it 
was selected as a control solvent system. As shown in Figure 3.18, the highest signal 










































Figure 3.18: Screening of solvents using α-cyano-4-hydroxycinnamic acid (CHCA) for MALDI-
FTICR-MSI analysis of endogenous corticosteroids as Girard T (GirT) hydrazones extracted from rat 
adrenal gland tissue sections. The greatest signal intensity was achieved using acetonitrile: water 80:20 
as matrix solvent system during matrix deposition by pneumatic TLC sprayer (a) Gradient distribution 
of corticosterone GirT derivative (GirT-CORT) detected at [M]
+
; m/z 460.317 Da in rat adrenal gland. 
Lateral resolution was set at 150 µm. Signal intensity is depicted by colour as per the scale shown. Scale 
bar (2 mm). Methanol (MeOH): H2O I 5:5, III 6:4, V 8:2, VII 9:1. Acetonitrile (ACN): H2O II 5:5, IV 
6:4. VI 8:2. VIII 9:1. (b) Relative intensity of the GirT-CORT ion under different conditions. Data are 

















3.3.5.8.  Investigation of approaches to limit analyte diffusion 
Analyte delocalisation is a well-known problem in MALDI-MSI, caused primarily by 
the matrix co-solvent during application by spray-based techniques. Therefore a 
number of approaches were explored to limit this process. 
3.3.5.8.1. Saturation studies 
Studies were conducted to find out the amount of GirT generating the best and most 
rapid reaction yields on tissue, achieving completion for endogenous steroids 
conversion into the corresponding GirT hydrazones. This had to be balanced against 
using too much derivatisation reagent which could lead to ion suppression. Controlling 
the amount of reagent was crucial to achieve good MS images. The assessment was 
carried out using a rat adrenal gland. The derivatisation was carried out using GirT pre-
coated (pre-coated) MALDI slides and also applied by spray-based techniques (post-
coated) as previously described in section 3.2.10. The greatest signal intensity was 
achieved using 4 mL (post-coating) and 0.15 mg/cm
2 

































Figure 3.19: Optimisation of derivatisation reagent application for MALDI-FTICRMS of 
corticosteroids Girard T (GirT) hydrazones in adrenal gland tissue sections. Greatest intensities of signal 
were achieved by pre-coating with 0.15 mg/cm
2 
of GirT, without a significant analyte delocalisation 
being obvious. Higher concentrations of GirT in pre-coating deposition led to significant ion 
suppression. Gradient distribution of corticosterone GirT derivative detected at [M]
+;
 m/z 460.317 Da. 
After (a) Post-coating with I 2 mL, II 4 mL, III 6 mL, IV 8 mL of 5  mg/mL GirT solution. Pre-coating 
(b) with I 0.08 mg/cm
2
, II 0.15 mg/cm
2
, III: 0.30 mg/cm
2
, IV: 0.50 mg/cm
2
. Lateral resolution was set 
at 150 µm. Signal intensity is depicted by colour as per the scale shown. Scale bar (2mm). (c) Relative 
intensity of the GirT-corticosterone at [M]
+
 m/z 460.317 Da using pre-and post-coating experiments. 











3.3.5.8.2. Pre-coating of slides 
In order to control the undesired effects during derivatisation reagent application, pre-
coated slides were evaluated. ITO-slides were coated with different amounts of GirT 
and tissues were thaw-mounted and incubated them for derivatisation. Post coating (4 
mL of GirT (5 mg/mL solution in methanol + 0.2 %v/v TFA) was used as control 
condition and the spatial distribution of GirT-CORT was used to assess the 
delocalisation . Using pre-coated slides, the greatest signal intensity of GirT-CORT was 
achieved using 0.15 mg/cm
2
 of GirT reagent (Figure 3.19). Moreover, pre-coating 
yielded higher intensity signals than those detected with post-coating approaches. 
Overall analyte diffusion was not different during pre-coating at 0.15 mg/cm
2
 
compared with all post-coated conditions. However pre-coating slides with higher 
amounts (Figure 3.19 A III, VI) was associated with substantial ion suppression across 
the adrenal gland tissue section. 
3.3.5.9.  Application of matrix by sublimation 
In order to further control the analyte delocalisation during matrix application, 
sublimation was evaluated as deposition technique. Sublimation of matrix such as 














Figure 3.21: Glass sublimator used for MALDI matrix deposition. 
The finely dispersed coating of the organic MALDI matrices that result from 
sublimation was visually evident on the glass slides. An example of this is shown in 
Figure 3.22 where CHCA was applied by spraying or sublimation onto a sample 
section of rat adrenal gland. A close-up view of matrix deposited onto a glass cover 
slip is shown in Figure 3.22 B, D. As is shown in Figures 3.22 C,D, sublimation led 
to a smaller crystal size (sub-µm) compared with a standard spray-coating that can 
achieve crystal size around 10-20 μm (Figure 3.22 B). The matrix sublimed under 
reduced pressure (0.05 Torr) at temperatures between 120 °C and 140 °C without 
decomposition. The recommended coating of 0.18 mg/cm
2
 of matrix was thick enough 
to yield abundant ions upon laser irradiation. However, under these conditions, signal 
intensity of GirT-CORT was not enough to generate a MSI image of its distribution 
(Figure 3.23 B). This observation was supported by the fact that the signal in the area 
of the mass spectrum aligned with the mass of GirT-hydrazones was substantially 
suppressed in comparison with that obtained with spray-coating (Figure 3.23 DI).  
As sublimation is a very dry technique, recrystallisation was performed to increase the 




was still too low to produce a suitable MS image. Representative mass spectra are 
shown in Figure 3.23 DII. Therefore this approach was not pursued further. 
 
Figure 3.22: Comparison of TLC and sublimation as matrix application techniques. (a) Photograph (25 
x magnifications) of a rat adrenal gland tissue mounted on an ITO-MALDI glass slide and coated with 
CHCA matrix (4 mL) of 10 mg/mL of CHCA by a pneumatic TLC sprayer. (b) Optical microscope 
image of CHCA crystals (40 x magnifications). (c) Photograph (25 x magnifications) of an adrenal gland 
tissue on an ITO-MALDI glass slide and coated with CHCA matrix (2.74 mg/silde) by sublimation. (d) 











Figure 3.23: Sublimation of CHCA matrix for MALDI-FTICRMS analysis of corticosteroids GirT 
hydrazones in rat adrenal gland tissue. Signal of Girard T corticosterone (GirT-CORT) was completely 
suppressed by either sublimation or sublimation followed recrystallisation in comparison with a spray-
coated tissue section by TLC-sprayer. Gradient distribution of corticosterone GirT derivative detected at 
[M]
+
 m/z 460.3170Da (a) TLC-sprayer coated (Control). (b) Sublimation (0.18 mg/cm
2
). (c) 
Sublimation/recrystallisation from methanol: water 50:50 +1 %v/v formic acid 95 sec, 90˚C). 
(n=3/condition). Signal intensity is depicted by colour as per the scale shown. Scale bar (2 mm). (d): 
Representative MALDI-FTICRMS of Girard T (GirT)-derivatives during the sublimation studies. The 
signal of GirT-CORT at m/z 460.314 Da was substantially suppressed in sublimed tissue sections. (dI) 
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3.3.5.10. Tissue washing to limit ion suppression 
A tissue washing procedure was evaluated using ammonium formate and acetate as 
washing solutions to ameliorate ion suppression caused by inorganic salts and soluble 
proteins across the tissue surface. As shown in Figure 3.24, not only was the tissue 
morphology adversely affected by washing (Figure 3.24 A II, III), but also the signal 
intensity of GirT-CORT was substantially reduced (Figure 3.24 B II, III) in 
comparison with a control tissue (Figure 3.24 A I); therefore this approach was not 
pursued further. 
 
Figure 3.24: The effect of washing the tissue surface prior to MALDI-FTICRMS of corticosteroids as 
Girard T (GirT) hydrazones in rat adrenal gland sections. Results show that tissue washing caused 
alteration of tissue morphology and suppression of the signal intensity of endogenous corticosteroids 
imaged as GirT derivatives. (a) Representative optical images of washed tissue sections at 1200 dot per 
inch (dpi) resolution. I: Ammonium acetate washing (AmAc) pH=7 (n=3). II Ammonium formate 
washing (AmFor) pH=4 (n=2). III Un-washed control tissue sections (n=3). (b) Representative gradient 
distribution of GirT derivative of corticosterone detected at [M]
+
; m/z 460.317 Da. I: AmAc washing 
(n=3). II AmFor washing (n=3), III Un-washed controls (n=3). Lateral resolution was set at 150 µm. 













3.4.  Discussion  
The main focus of this chapter was the development and optimisation of a 
derivatisation technique for use to assess the spatial distribution of corticosterone and 
its 11-hydroxy metabolite in a biological tissue (adrenal gland) by MSI using a 
MALDI-FTICRMS platform. Either off and on tissue using pure standards, native 
corticosteroids were difficult to ionise in the MALDI process giving only low 
abundance [M+H]
+
 ions. The signal could not be improved by use of several novel 
MALDI matrices. Best ionisation yields were achieved by using the standard MALDI 
matrix, α-cyano-cinnamic acid (CHCA). Good sensitivity was also observed by using 
2, 5-dihydroxybenzoic acid (DHB), which is a favoured matrix for small molecule 
analysis, but the main drawback of this approach was the large crystal size, unsuitable 
for high spatial resolution imaging (Goodwin, 2012). 4-Chloro-α-cyano-cinnamic acid 
(Cl-CCA) was synthesised in-house, rationally-designed by (Jaskolla et al., 2008) to 
have a lower proton affinity (PA) and same wavelength absorption (very important for 
a successful matrix/analyte energy transfer and desorption) than its analogue. Cl-CCA 
showed suitable ionisation/desorption yields with a much cleaner total ion current 
(TIC) spectra in the mass range and can be used as a back-up MALDI matrix. However 
it was inferior to CHCA.  
It is hypothesized that PA is crucial for analyte incorporation into the matrix crystal 
lattice via ion-pair formation with positively charged functional groups. The final ion 
yield is the result of a complex interplay of analyte incorporation into the matrix 
crystals, ionisation and ion stability. The lower PA of Cl-CCA can be rationalised as 
follows: for both CHCA and Cl-CCA, the proton will be located either at the 
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carboxylic or at the cyano group. In both cases, the positive charge of [CHCA+H]
+
 can 
be delocalised over the whole conjugated Π-electron system promoted by the electron-
donating effect of the 4-OH group. This stabilisation of the protonated matrix molecule 
results in a larger PA. The charge delocalization is much less pronounced in the case of 
a 4-Cl functional group. This is substantiated by density functional theory (DFT) 
electron-density calculations which exhibit a loss of net positive charge in the para 
position for Cl-CCA because of the strong electron-withdrawing chloro substituent. 
However, further decrease the PA of the matrix by more or stronger electron-
withdrawing substituents, such as CF3 will fail because of the induced hypochromic 
shifts and the reduction of neodymium-doped yttrium aluminium garnet (Nd:YAG) 
laser absorption wavelength at 337 nm, used for MALDI analysis. 
The attempt to generate the molecular distribution map of neutral steroids in a rat 
adrenal gland failed, mainly because of the poor ionisation efficiency in MALDI due to 
the lack of either hydrogen donor or acceptor moieties in the molecular structure. After 
a screening of several derivatisation reagents, steroids were derivatised using a positive 
charged hydrazine (Girard-T reagent) as it showed the best results in terms of signal 
intensity. The OTCD reaction conditions were optimised to achieve the best sensitivity 
and reproducibility. Hydrazone formation by Girard reagents is a two-step reaction that 
involves condensation, which is normally achieved by using protic solvent in a weak 
acid media as catalyst. Derivatisation using methanol/TFA led to the highest yield after 
one hour incubation at 37 ºC in a moisturising environment. Due to the fact that TFA is 
a strong organic acid that can promote the backward reaction by hydrolysis, stability 
testing of GirT derivatives was performed and reassuringly degradation was not 
observed in the typical sample preparation period which is around 20 minutes.  
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Regarding matrix deposition techniques, both spray and dry coating techniques were 
evaluated. Spray coating using a pneumatic TLC sprayer accomplished the best analyte 
extraction from tissue sections. However, the main drawback of this technique is the 
diffusion effect caused by the matrix solvent and compounded here by the 
derivatisation process. The analyte delocalisation was controlled by the standardisation 
of all possible variables, such as nitrogen flow, distance from the MALDI target, time 
in between passes and solvent volume during manual-based deposition. This issue can 
also be solved by using automatic matrix deposition devices. Sublimation was 
evaluated as a dry-deposition technique which allow direct solid to gas phase transition 
in a reduced pressure environment. During sublimation, a substance, in this case, the 
MALDI matrix is recrystallised from its molecular gaseous state onto the cold MALDI 
glass target. The evenness of the coating on the condenser surface reflects the random 
Brownian motion of the released gaseous matrix molecules. Sublimation has 
previously been reported as a method matrix application of MSI by Hankin (Hankin et 
al., 2007). The finely dispersed coating of the organic MALDI matrices that result 
from sublimation was visually evident in comparison with spray-coating leading to 
sub-micron crystal sizes which are suitable for high resolution MSI. However, 
unfortunately signal intensity of GirT steroids was completely suppressed. Sublimation 
is a solvent-free technique and this may lead to poor analyte extraction from the tissue 
section. Sublimation followed by recrystallisation was also evaluated in order to 
increase the extraction from the tissue section without any success. Sublimation has 
been used for the analysis of non-polar compounds such as lipids in tissue section, but 
it has not yet been applied for the analysis of polar compounds by MSI. Upon 
derivatisation, the non-polar neutral steroids were converted to polar quaternary 
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hydrazones in which desorption/ionisation process is driven by the positive charged 
quaternary amine. Thus, sublimation may not be an adequate matrix deposition 
technique for very polar compounds when the matrix solvent plays a key role in 
compound extraction from tissue sections. In conclusion, spray-coated based 
techniques, has shown to be the most suitable deposition methodology for MSI of GirT 
steroids in the studied tissue sections. The fact that spray-based deposition techniques 
using CHCA as matrix led to crystal size in the sub 10 µm range, MSI can only be 
performed at > 10 µm spatial resolution.  
The quality of MSI results depends heavily on the choice and execution of sample 
preparation methods. Specific molecular classes often require different sample 
preparation treatments, such as optimised washing steps (Goodwin, 2012). Several 
washing methods have been tested using different buffers systems at different pH by 
pipette application of the solution onto the sample and subsequent removal by pipette. 
However, such washing led to undesired morphological changes, as the tissue was 
severely damaged. Moreover, a considerable loss of sensitivity was observed, so, the 
washing step was ruled out as part of the sample preparation procedure. 
In this chapter, an OTCD-MALDI-FITCRMS MSI platform was successfully 
developed and optimised to detect endogenous corticosteroids in a biological tissue 
section (rat adrenal gland). With MSI spatial distribution maps of endogenous steroids 
were generated adding molecular information at histology level that is impossible to 
achieve by using the standard tissue homogenisation approach. Having failed to 
generate molecular maps of native corticosteroids due to the lack of sensitivity, the 
signal was boosted (up to 10
4
-fold) by using tissue derivatisation. Sample preparation 
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conditions and MALDI-FTICRMS parameters were optimised to achieve the best 
possible sensitivity. Moreover, analyte diffusion was also controlled by using pre-
coated GirT slides to minimise analyte delocalisation. GirT hydrazone derivatives were 
















3.5.  Conclusion 
A MSI platform using a MALDI-FTICRMS was developed and optimised for spatial 
distribution analysis of endogenous and exogenous α-β unsaturated- keto steroids as 
Girard T hydrazones derivatives in biological tissue sections. In subsequent Chapters, 
this approach will be applied to answer questions about the distribution and turnover of 















Application of the MALDI-FTICR-MSI for 
the assessment of the spatial distribution of 
endogenous steroids in biological tissues 
 
4.1.  Introduction 
In chapter three a derivatisation reaction was established which allowed detection of 
glucocorticoids in a rat adrenal tissue where they are highly abundant. In principle this 
derivative should enable detection of GCs in multiple tissue types but also open up 
opportunities to detect other α- unsaturated steroids and oxysterols.  
4.1.1.  Androgens 
Sex steroids such as androgens play a key role in the stimulation and control of the 
development and maintenance of male characteristics in vertebrates acting by binding 
with androgen receptors (Labrie, 2004). In terms of the chemistry, most of the 
androgens contain a ketone group in the molecular structure. This allows the neutral 
androgens to be derivatised by Girard T reagents leading to the corresponding 
hydrazones derivatives. A general biosynthetic pathway of the principal androgens is 




Figure 4.1 Biosynthetic pathways and interconversion of the major androgens. The numbers refer to the 
enzymes involved in the reactions: 1=3β-hydroxy Δ5- steroid isomerase, 2 = 5-reductases, and 3 = 
17β-hydroxy steroid dehydrogenase. Adapted from (Longcope, 2003). 
 
In prostate tissue, direct determination of androgen levels provides a perspective on the 
organ that is not available via androgen serum levels. The principle prostatic 
androgens, primarily dihydrotestosterone (DHT) and secondarily testosterone, can be 
readily assayed in quick-frozen prostate biopsy cores or surgical specimens. Such 
assays have proved important in establishing (Bartsch et al., 2002) that DHT is a 
permissive factor in Benign Prostatic Hypertrophy (BPH) pathogenesis, a mechanism 






































chemoprevention, an explanation for the ‘escape’ of prostate cancer from castration 
therapy, prostate safety of testosterone replacement therapy, and insights into the cause 
of racial differences of prostate cancer (Schitz-Drager et al., 2007). However, 
compared with studies of circulating androgens, few studies of prostate tissue 
androgens are available. This is a major knowledge gap, because circulating androgen 
levels might not reflect the androgenic activity within the prostate gland and tissue 
homogenate does not provide distribution information within a specific cell 
population, ignoring the distinct compartments and functions within tissues or organs. 
Therefore, spatial distribution determination of prostate tissue androgens would be a 
valuable tool in androgen research and potentially in clinical diagnosis. 
4.1.2.  Oxysterols 
Going upstream in the steroid metabolic pathway, oxygenated derivatives of 
cholesterol (oxysterols) present a remarkably diverse profile of biological activities, 
including effects on sphingolipid metabolism, platelet aggregation, apoptosis, and 
protein prenylation (Brown et al., 2009). The most notable oxysterol activities centre 
on the regulation of cholesterol homeostasis, which appears to be controlled in part by 
a complex series of interactions of oxysterol ligands with various receptors, such as the 
oxysterol binding protein, the cellular nucleic acid binding protein, the sterol regulatory 
element binding protein, the LXR nuclear receptors, and the low-density lipoprotein 
receptor (Brown et al., 1999; Massey, 2006). 
In contrast to glucocorticoids, most of the oxysterols have the alcohol as the main 
functionality in the molecular structure. However, some physiological relevant 
oxysterols (IV, VII and IX) have the hydrazine reactive ketone moiety, so application 
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of the OTCD-MSI would be feasible (Figure 4.2). Identification of the endogenous 
oxysterols and elucidation of their enzymatic origins are topics of active investigation. 
Currently, endogenous oxysterols are being analysed by LC/MS using tissue 
homogenate, losing the histological information at molecular level. This is particularly 
important in tissues such as brain where oxysterols play different roles in different cell 
compartments in several CNS diseases, e.g. Alzheimer’s disease (van Reyk et al., 
2006). Therefore, spatial distributions of oxysterols would be beneficial in 
understanding the underlying biological mechanism. A representative formation 
pathway is shown in Figure 4.2. 
 
 
Figure 4.2: Metabolism of cholesterol (I) and 27-hydroxycholesterol (III) into 7α-hydroxy-3-oxo-4-
cholestenoic acid (7α-OH-4-CA) (IX). Based on previously described pathways in other tissues, the 
formation of 7α-OH-4-CA (IX) may proceed via an initial formation of 7α-hydroxycholesterol (II), 7α-
hydroxy-4-cholesten-3-one (IV), and 7α,27-dihydroxy-4-cholesten-3-one (VII) or via the formation of 
27-hydroxycholesterol (27-OHC) (III), cholestenoic acid (VI), and 7α-hydroxy-cholestenoic acid (VIII). 
There is considerable potential for crossover between the different pathways. CYP7A1, cholesterol 7α-
hydroxylase; CYP7B1, oxysterol 7α-hydroxylase; CYP27A1, sterol 27-hydroxylase; HSD3B7, 3β-
hydroxy-C27-steroid dehydrogenase/isomerase; 27-OHC, 27-hydroxycholesterol. Adapted from 
(Meaney et al., 2007). 
126 
 
In this chapter, the OTCD-MALDI-MSI platform will be explored:  
1) to identify and quantify glucocorticoids in tissues other than adrenal gland and also 
tissues derived from humans. 
2) to identify and quantify different classes of steroids and sterols in relevant 















4.2.  Methods  
4.2.1.  Screening of tissues for suitability to detect glucocorticoids 
Brain and liver tissues were obtained from C57BL/6j mice (6-7 weeks, male). 
Animals were from Harlan Olac Ltd (Bicester, UK) and killed as per section 2.2. 
Human term placenta from uncomplicated pregnancies was obtained and collected 
within 15–20 min of vaginal delivery or Caesarean section. Tissues were taken in 
compliance with the Human Tissue Act 2004 (HTA) under ethical approval. Tissue 
sectioning was carried out as described in section 2.3 and histological staining was 
performed as per section 2.4. On-tissue chemical derivatisation was carried out as 
described in section 2.5 and matrix was applied as per section 2.6. MALDI-FTICR-
MSI analysis performed as described in section 2.8.1 and the ions monitored of GirT-
CORT and GirT-11DHC as detailed in Table 2.1  
4.2.2.  Detection of androgens 
4.2.2.1.  Standards on-tissue 
Standards of both TESTO and DHT (10 µg, 1 µg/µL) of each steroid were mixed with 
CHCA solution (10 µL, 10 mg/mL in 50:50 (acetonitrile: water) + 0.2 % v/v TFA) 
using the standard dried droplet method as described in section 3.2.2.1. Then, 1 µL of 
the (steroid: matrix) solution was spotted onto a rat prostate section (n=3) and analysed 
by MALDI-FTICRMS as described in section 2.8.2. Ions monitored of GirT-TESTO 





4.2.2.2.  Imaging of androgens on prostate tissue sections 
Prostate tissues were obtained from Sprague Dawley male rats (5-7 weeks, ~175-200 
g). Animals were from Harlan Olac Ltd (Bicester, UK) and killed as per section 2.2 
and processed as 4.2.1. Ions of GirT-TESTO and GirT-DHT were monitored as 
detailed in Table 2.1. d8CORT was used as ISTD and a normalisation marker for heat 
map generation. 
4.2.3.  Detection of keto-oxysterols  
4.2.3.1  Standards on-tissue 
Standards of both 7α-hydroxy-4-cholesten-3-one (IV) and 7α,27-dihydroxy-4-
cholesten-3-one (VII) (10µg, 1µg/µL) were mixed with CHCA solution (10 µL, 10 
mg/ml in 50:50 (acetonitrile: water) + 0.2 % v/v TFA) using the standard dried droplet 
method as described in section 3.2.2.1. Then, 1 µL of the (steroid: matrix) solution was 
spotted onto a rat brain section (n=3) and analysed by MALDI-FTICRMS as described 








4.2.4.2.  Imaging of keto-oxysterols on rat brain tissue sections 
Brain tissues were obtained from Sprague Dawley male rats (5-7 weeks, ~175-200 g). 
Animals were from Harlan Olac Ltd (Bicester, UK) and killed as per section 2.2. 
Tissues were processed as per section 4.2.1. Ions of GirT-IV and GirT-VII were 
monitored as detailed in Table 2.1. d8CORT was used as ISTD and a normalisation 
















4.3.  Results 
4.3.1.  MSI of glucocorticoids  
4.3.1.1.  Murine liver 
Figure 4.3 shows the distribution of glucocorticoids in liver section as determined by 
MSI, with an unstructured pattern. Both CORT and 11DHC were detected as their 
hydrozone derivatives with high signal to noise ratios (S/N > 200) and good mass 
accuracy (<10 ppm).  The signal intensity of GirT-CORT was considerably higher than 
its inactive metabolite, as liver is rich in 11β-HSD1. Histological information could not 
be interpreted from an MS image, generated at 150 µm lateral resolution as the spatial 
resolution was not enough to differentiate cell types. 
 
Figure 4.3: Molecular imaging by MALDI-FTICR-MSI of corticosteroid hydrazones in representative 
murine liver sections. Molecular regional distribution maps showed corticosterone (GirT-CORT) and 
11-dehydrocorticosterone (GirT-11DHC) derivatives distributed across the section. Histological 
information could not be interpreted, as the spatial resolution was not enough to distinguish different 
cellular populations (a) Histological image of a cryosection of murine liver section stained with 
haematoxylin and eosin. Heat map of (b): GirT-11DHC at m/z 458.301 Da, (c): GirT-CORT at m/z 
460.317 Da collated by MALDI-FTICRMS. Signal intensity is depicted by color on the scale shown. 
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4.3.1.2.  Murine brain 
The OTCD MSI platform was applied to a murine brain section to generate regional 
distribution maps of corticosteroids. The analysis was focused on CORT and 11DHC, a 
product and substrate of the 11-HSD1 enzyme, respectively. Both steroids were 
detected as their hydrazone derivatives with good mass accuracy (± 5 ppm) against the 
corresponding monoisotopic molecular weights (Figure 4.4.E). Moreover, the S/N 
ratios for both corticosteroids derivatives were above 10, allowing reliable heat maps to 
be generated. Signals for corticosteroids were found with greatest intensity across the 
hippocampus, cortex and amygdala (Figure 4.4 C, D) in agreement with the 














Figure 4.4: Molecular regional distribution maps showed corticosterone (GirT-CORT) and 11 
dehydrocorticosterone (GirT-11DHC) derivatives primarily distributed in cortex, hippocampus and 
amygdale, co-localised with 11-HSD1 mRNA.(a) Histological image of a cryosection of murine brain 
section stained with haematoxylin and eosin. (b) In-situ hybridization (ISH) of 11β-HSD1 mRNA 
(Imaged gifted by Joyce Yau, University of Edinburgh). Heat map of (c) GirT-11DHC at m/z 458.300 
Da, (d) GirT-CORT at m/z 460.317 Da collated by MALDI-FTICR-MS. Signal intensity is depicted by 
color on the scale shown. Scale bar (2 mm) for imaging, histology and ISH. (e) Representative MALDI-
FTICRMS spectrum of GirT-11DHC and GirT-CORT in murine brain section. cps = counts per second. 
 
4.3.1.3.  Human placenta  
After successful generation of molecular maps of corticosteroids in murine tissues, a 
feasibility study was conducted on human tissues for potential translational 
applications. Human placenta was studied, as an 11-HSD2 rich tissue. Cortisol (GirT-
F) and cortisone (GirT-E) hydrazones were detected at m/z 476.312 and m/z 474. 296 
respectively, with good mass accuracy (< 5 ppm) (Figure 4.5 E). It can be extrapolated 









keto-steroids derivatives that contain one hydrazine tag. Thus, as shown in Figure 4.5, 
E (product) level (Figure 4.5 B) was higher than F (substrate) (Figure 4.5 C), each 
with a different distribution pattern. 
 
 
Figure 4.5: Molecular imaging by MALDI-FTICR-MSI of corticosteroid hydrazones in a representative 
human placenta section.(a) Histological image of a cryosection of human placenta sample stained with 
haematoxylin and eosin. Heat map of Girard T (GirT) derivatives of: (b) cortisol (GirT-F) at m/z 
476.312 Da (c) cortisone (GirT-E) at m/z 474.303 Da collated by MALDI-FTICRMS. Signal intensity is 
depicted by color on the scales shown. Scale bar (2 mm). Lateral resolution was set to 100 µm (e) 
Representative MALDI-FTICRMS spectrum of both GirT hydrazones in human placenta sample. cps = 








4.3.2.  Imaging of androgens 
4.3.2.1.  Standards 
The feasibility of derivatising androgens was tested by spotting experiments using 
testosterone (TESTO) and androstenedione (A4) as androgen standards. The predicted 
reaction of both androgens with GirT reagent is shown in Figure 4.6 and both 
derivatives were detected as hydrazone derivatives at m/z 402.312 Da for TESTO and 
m/z 400.302 Da for A4 with good mass accuracy (<10 ppm) against their corresponding 











































Figure 4.7: Representative MALDI-FTICRMS of Girard T (GirT)-derivatives of androgens standards (5 
ng). Observed quasimolecular ion at m/z 402.312 (GirT-testosterone) and at m/z 400.302 (GirT-
androstenedione). cps: count per second. 
 
4.3.2.2.  Imaging androgens in prostate 
The MSI platform was applied to a rat prostate tissue (an androgen-rich tissue) in order 
to establish if the technique was able to generate molecular maps of androgens in a 
biologically relevant setting. Figure 4.8 shown the distribution of testosterone (Figure 
4.8 B) and androstenedione (Figure 4.8 C) detected as GirT-hydrazone derivatives. On 
the contrary, dihydrotestosterone (5DHT) could not be detected. In line with 
glucocorticoids, androgens FTICR spectra were well-defined showing an excellent 
mass accuracy against the theoretical monoisotopic spectra (Figure 4.8 E). 
Intens 



































Figure 4.8: Molecular imaging by MALDI-FTICR-MSI of androgens as hydrazones derivatives in a rat 
prostate tissue section. (a) Optical image of a prostate cryosection. Heat map of GirT derivatives of: (b) 
Testosterone (GirT-TESTO) at m/z 402.324 Da, (c): Androstenedione (GirT-A4) at m/z 400.297 Da 
collated by MALDI-FTICRMS. (d): Heat map superimposition of GirT-A4 (green) and GirT-TESTO 
(blue). Signal intensity is depicted by color on the scale shown. Scale bar (2 mm). Lateral resolution was 
set to 100 µm. (e) Representative MALDI-FTICRMS spectrum of androgen derivatives in rat prostate. 
cps = counts per second. 
4.3.2.3.  Androgens and Glucocorticods 
As GirT reacts with all activated and non-activated ketone groups, an extended 
FTICRM spectra was generated to see the multiplex capabilities of the GirT 
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Figure 4.9: Representative extended MALDI-FTICRMS spectrum of androgens and glucocorticods 
derivatives in rat prostate. Testosterone (GirT-TESTO) at m/z 402.323 Da, Androstenedione (GirT-A4) 
at m/z 400.298 Da and 11-dehydrocoricosterone (GirT-11DHC) at 458.305 Da. cps = counts per second. 
 
4.3.3.  Imaging of oxysterols  
4.3.3.1.  Standards 
Oxysterol standards, 7α-hydroxy-4-cholesten-3-one (IV) and 7α,27-dihydroxy-4-
cholesten-3-one (VII) (Figure 4.2) were selected for a feasibility study to image 
oxysterols. These oxysterols shared the same ketone-reactive moiety as 
glucocorticoids, so, derivatisation reaction with GirT-hydrazine could be possible 
(Figure 4.9). Standard were derivatised as per in section 2.6.4 and analysed as 































detected as GirT derivatives with good mass accuracy (<10 ppm against their 



















Girard T (GirT)Keto-oxysterolds GirT derivatives  
Figure 4.10: Proposed reaction scheme for derivatisation of keto-oxysterols with Girard T (GirT) 
reagent. Ketone reactive-moiety (blue) 
 
Figure 4.11: Representative MALDI-FTICRMS of Girard T (GirT)-derivatives of keto-oxysterols 
standards (5 ng). Observed protonated masses at m/z 514.443 (GirT-IV) and at m/z 530.431 (GirT-VII).  
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4.3.3.2.  Imaging Oxysterols in Rat Brain 
It was proposed that the regional distribution of sterols with the hydrazine reactive 
motif may be measured in tissue by the OTCD-MSI platform (Section 4.3.3.1). In this 
example, molecular distribution maps of cholesterol metabolites (oxysterols) were 
successfully generated in a rat brain tissue section.  
Both oxysterols measured, 7α-hydroxy-4-cholesten-3-one (GirT-IV) and 7α, 27-
dihydroxy-4-cholesten-3-one (GirT-VII), were detected with an excellent mass 
accuracy of ± 2.5 ppm against their corresponding theoretical monoisotopic masses 
(Figure 4.141E). However, oxysterol IX could not be detected and MSI images were 
not generated. 
The two detected oxysterols shared the same pattern and were widely distributed across 
the striatum, hippocampus, cortex and cerebellum (Figure 4.11). The relative 
abundance of the keto-oxysterol identified as (GirT-IV) at m/z 514.444 was higher 












Figure 4.12 : Molecular imaging by MALDI-FTICR-MSI of oxysterols detected as Girard T (GirT) 
hydrazone derivatives in a rat brain section. Oxysterols were distributed with high abundance in the 
striatum, hippocampus, cortex and cerebellum. (a) Optical image of a cryosection of rat brain section. 
Heat map of oxysterols derivatives of: (b) 7α-hydroxy-4-cholesten-3-one (GirT-IV) at m/z 
514.443±0.025Da, (c) 7α,27-dihydroxy-4-cholesten-3-one (GirT-VII) at m/z 530.531±0.025Da by 
MALDI-FTICRMS. Signal intensity is depicted by color on the scale shown. Scale bar (10mm). Lateral 
resolution was set to 150 µm. (d) Representative MALDI-FTICRMS spectrum of (i) GirT-IV and (ii) 
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4.4.  Discussion 
In this chapter the application of the OTCD MSI platform to other physiological 
relevant keto-steroids was demonstrated in several tissue types. Girard reagents have 
been used to derivatise ketone-containing compounds such as (quinones, natural 
product, drug-like molecules and steroids) to form the corresponding hydrazone 
analogues. Upon derivatisation, neutral molecules are converted to positive-charged 
derivatives enhancing the detection during MS analysis. As it shown in Ch 3, the 
intensity of signal from neutral glucocorticoids was considerable enhanced upon 
derivatisation with GirT. In this chapter the application OTCD MSI platform was 
extended to other physiological relevant rodent and human tissues including human 
biopsies. Furthermore, molecular images were also generated for other keto-containing 
sterols such as androgens and oxysterols. 
The main advantage of using MSI over conventional tissue-homogenate analysis is the 
generation of molecular distribution maps across the tissue section of both targeted 
exogenous and endogenous compounds. Tissue-homogenate analysis involves 
averaging of the composition across the tissue section and in most cases the tissue is 
not homogenous, with many different histological features due to diverse cell 
populations. However in some cases, homogeneity can be assumed when the spatial 
resolution of an image is not enough to distinguish different cell types. At the spatial 
resolution used in this study (200-100 µm), ten to twenty times the size of an average 
mammalian cell (10 µm), and histological evaluation would be possible in tissue such 
as brain, adrenal gland and kidney. For example in brain, the cortex can be 
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differentiated from the hippocampus and in the kidney, distinction of the medulla and 
cortex can also be possible.  
Having generated the successful molecular maps of CORT and 11DHC in the adrenal 
gland, a number of tissues were evaluated as matrices for imaging glucocorticoids. In 
liver the steroids could be detected but this tissue appeared homogenous and therefore 
no particular advantage was gained by imaging. The size of the hepatocytes are much 
smaller than the laser spot size (50 µm) (Vind et al., 1992), using MSI approaches at 
low spatial resolution mode. In the liver, steroid distribution may be studied at cell or 
sub-cellular resolution using high resolution MALDI (stop size ~ 5 µm) or SIMS. 
However, increasing the spatial resolution dramatically decreases the sensitivity. 
Nonetheless relative abundance of glucocorticoids could be gleaned from this method, 
in a manner that avoids the losses and extensive processing required to handle tissue 
homogenate with subsequent LC-MS/MS. 
Imaging of adipose, another metabolic tissue was not successful. Adipocytes are small 
and again the tissue may appear homogenous with low resolution imaging, Adipose 
also had another disadvantage as during on-tissue derivatisation the tissue is exposed to 
a wet environment leading to a substantial tissue disruption and analyte delocalisation 
making MSI of derivatised steroids practically impossible. This may be due to its high 
lipid content. 
The method was applied to imaging these glucocorticoids in murine brain, where the 
levels of corticosteroid are lower than in the adrenal gland. The highest abundance in 
cortex, hippocampus and amygdala may reflect the higher expression of corticosteroid-
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binding receptors as well as of 11β-HSD1 in these brain regions (Moisan et al., 1990a). 
This approach is pursued further in Ch 5. 
The MALDI-MSI platform was also applied to human placenta tissue to evaluate the 
capability of the methodology of measuring human-counterpart corticosteroids, active 
cortisol and inactive cortisone. In the human placenta, the mRNA and protein for both 
11β-HSD-1 and -2 are primarily expressed in the syncytiotrophoblast (Benediktsson et 
al., 1997). It was demonstrated that the mRNA and protein levels of 11β-HSD2 
increases with advancing gestation promoting the inactivation of cortisol (Blum et al., 
1995). A sample of human placenta tissue biopsy collected at term showed higher E 
levels than the active F. This finding was in agreement with the current understanding 
of the physiology of the placenta as the pattern of placental cortisol-cortisone 
metabolism changes from preferential reduction (formation of cortisol from cortisone) 
early in pregnancy to oxidation assisted by oestrogens (conversion of cortisol to 
cortisone) near term.  
To further evaluate the advantage of MSI as a multiplex platform, the analysis was 
extended to androgens. In a rat prostate tissue section, testosterone and A4 were 
detected as hydrazone derivatives and the corresponding molecular maps were 
generated. These preliminary data open new avenues to study androgen metabolism 
and biomarkers at tissue-specific level in some important research areas such as testis 
development and prostate cancer. In particular prostate cancer, circulating levels of 
diagnostic biomarkers may not reflect the tissue microenvironment, therefore 
evaluation of  tissue-specific biomarkers would be beneficial (Corrie et al., 1985). 
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To further expand the applicability of the MSI platform to study sterol biology, 
molecular distribution map of oxysterols were generated in a rat brain tissue section. 
Oxysterols 7α-hydroxy-4-cholesten-3-one (IV) and 7α, 27-dihydroxy-4-cholesten-3-one 
(VII) were selected with chemical motifs allowing them to react with GirT. These 
oxysterols are the substrate and product of the sterol 27-hydroxylase (CYP27A1), allowing 
inferences to be drawn about the enzyme activity. This enzyme is located in the energy-
producing centres of cells (mitochondria), where it is involved in the pathway that 
breaks down cholesterol to form acids used to digest fats (bile acids) (Li et al., 2007). 
Sterol 27-hydroxylase plays a key role in maintaining normal cholesterol levels in the 
body. Accumulation of some oxysterols throughout the body, particularly in the brain 
and tendons has been proposed to lead to the signs and symptoms of cerebrotendinous 
xanthomatosis and cognitive impairment (Pannu et al., 2013). So knowing the 
molecular distribution could be valuable to understanding the underlying mechanism. 
However, as only detection was achieved, further development and validation must be 










4.5.  Conclusion  
In this chapter the potential for the application of MALDI-MSI with OTCD using 
Girard-T reagent to study diverse steroid and sterol biology has been demonstrated. 
Molecular map have been generated of glucocorticoids, androgens and oxysterols in 
several rodent tissue section, where analytes were selected with the appropriate 
chemical groups to react with Girard T. Indeed this could be expanded to include 
progesterone-type molecules as well. Furthermore, beyond murine and rat tissues, 
human samples have been successfully analysed showing good selectivity and 
sensitivity in detecting human steroids counterparts. MALDI-MSI is a powerfully 
multiplexed platform to study tissue molecular histology. Indeed, its ability to uncover 
biomolecular intratumour heterogeneity may grow to provide a valuable tool for 












Monitoring effects of 11β-hydroxysteroid 
dehydrogenase-1 deficiency or inhibition on 
region-specific corticosteroid concentrations 
in brain by MALDI/LESA-FTICRMS-MSI 
 
5.1. Introduction 
Measurement of plasma concentrations of steroid hormones has shown the intricate 
control of their secretion from endocrine glands. Recently, it has been recognised that 
steroid concentrations within tissues are also modulated locally by steroid-generating 
and inactivating enzymes. This has been confirmed in spontaneous human enzyme 
deficiency syndromes, recapitulated by genetic disruption in mice and using 
pharmacological inhibitors (Simpson et al., 1994). Dysregulation of steroid-
metabolizing enzyme expression is thought important in the pathophysiology of 
steroid-dependent disease, including breast cancer, prostate disease and obesity. 
Moreover, inhibitors of these enzymes have proved the reduction of steroid action in 
these disorders. A key limitation in the field of 'steroid intracrinology', however, is the 
inability to study steroid concentrations at tissue level, particularly in organs with 
region-specific expression of key-role enzymes, such as the brain. Up to now, the 
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inferences of the consequences of enzyme manipulation for local steroid concentrations 
therefore remain qualitative rather than quantitative.  
This chapter will focus on the role of 11β-HSD1, which is highly expressed in 
metabolically active tissues such as the liver, adipose, kidney, and brain and mainly 
converts inactive into active glucocorticoids (Chapman et al., 1997). The potential for 
therapeutic intervention has been demonstrated in rodent models where selective 11β-
HSD1 inhibitors lower plasma glucose, improve insulin sensitivity and in some studies 
reduce body weight in mice (Bujalska et al., 2008; Hughes et al., 2008; Webster et al., 
2007). In the brain, 11β-HSD1 mRNA expression and activity is mainly observed in 
the cerebellum, hippocampus and cortex (Moisan et al., 1990a). Higher levels are 
found in Purkinje cells in the cerebellum, CA3 pyramidal cells in the hippocampus and 
layer V neurons in the neocortex. Inhibition of 11β-HSD1 in brain is associated with 
improved memory (Sooy et al., 2010) but the consequences for local steroid 
regeneration in the brain sub-regions where 11β-HSD1 is expressed are uncertain. 
Furthermore, 11β-HSD1 can interconvert other keto substrates, including 7-keto and 
7α-hydroxycholesterol (Mitic et al., 2013), but it has been difficult to establish the 
equilibrium of these reactions in vivo. In this chapter, OTCD, in combination with MSI 
was applied, for the first time to quantify and validate the detection of CORT and 
11DHC and alternative substrates within sub-regions of murine brain, following 
manipulation of 11-HSD1. The aim of this chapter is to monitor the effects of 11β-
hydroxysteroid dehydrogenase-1 (11β-HSD1) deficiency or inhibition on region-




5.2.  Methods  
5.2.1.  Biomatrix 
The effect of deficiency of the 11β-HSD1 enzyme was studied in the following models: 
• C57BL/6j 11β-HSD1-/- mice (KO) and their wild-type (WT) littermates (male, 2-3 
months) were bred in-house. The genetically modified animals were genotyped using 
protocols described by (Morton et al., 2001) and obtained from in-house breeding 
colony  
• C57BL/6j mice (6-7 weeks, male) were from Harlan Olac Ltd (Bicester, UK) and 
studied after pharmacological inhibition of 11-HSD1 (n=6/group, killed 1h, 4hs and 
6hs after receiving UE2316 (25 mg/kg oral, in DMSO: PEG-400: saline (0.9 %w/v) 
(2:38:60)) or vehicle).  
In all studies, animals were killed by decapitation at 09:00 h, Plasma was prepared 
from trunk blood, collected in EDTA. Tissues were snap frozen in liquid nitrogen and 
stored (-80 ˚C).  
5.2.2.  MSI 
5.2.2.1.  Steroids 
Tissues were harvested as per section 2.2 and MSI performed as described in section 
2.8.1. The identities of ions of the steroid-GirT hydrazones were confirmed on-tissue 
by CID using LESA as described in section 2.9. The average spectral intensities of 
steroid derivatives in ROIs across the cortex, hippocampus and amygdala were 
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recorded using MSI, presented as ratios of CORT/11DHC and compared with those 
generated by LESA and LC-MS/MS. 
5.2.2.2.  UE2316 
Tissues were harvested as per section 2.2, matrix was applied as described in section 
2.6, analysed by MALDI-FTICR-MS as per section 2.8.1 and MS images generated 
using the quasimolecular ion of UE 2316 as per Table 2.1.  
5.2.3.  Approaches to validate quantitation  
5.2.3.1.  Extraction of steroids from whole brain 
Analysis was adapted from (Griffiths et al., 2011). In brief, murine brain (~300mg) was 
homogenised in methanol–acetic acid (100:1 v/v, 10 mL) using a mechanical 
homogeniser and assisted by ultrasonication. The supernatant was retained and the 
pellet formed followed centrifugation (5000 × g, 10 min, 4 °C), further extracted with 
methanol–acetic acid (100:1 v/v, 10 mL). The supernatants were combined and stored 
at -80 °C. The extract was reduced to dryness and re-dissolved (3 mL, 
methanol/dichloromethane/water (7:2:1, v/v)) and enriched with internal standard. 
d8CORT (5 ng). The sample, prepared in methanol/dichloromethane/water (7:2:1, v/v), 
was passed through a diethylaminohydroxypropyl Sephadex LH-20 (GE Healthcare, 
Sweden) anion-exchange column in its acetate form (7 × 0.4 cm). The column was 
washed with 2 mL of the same solvent, followed by 1 mL of 
methanol/dichloromethane/water (2:2:1, v/v), and the “flow-through” and “wash” 
combined, dried and re-dissolved in methanol–acetic acid (2 mL, 100:1 v/v) with the 
final addition of water (2 mL). The solution was passed through a Bond-elut (HLB, 2 g, 
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Waters, Manchester, UK) cartridge. After washing with water (2 mL), methanol–water 
(1:1, 3 mL) and hexane–ethyl acetate (5:1, 2 mL), the steroids were eluted with ethyl 
acetate (2 mL). The residue was evaporated, re-dissolved in 50:50 (methanol: H2O with 
0.1% of formic acid (FA)) and subjected to LC-MS/MS analysis as per section 5.2.3.3. 
Calibration curve was prepared as described in section 5.2.3.3  
5.2.3.2.  Extraction of steroids from plasma  
Analysis was adapted from Hughes (Hughes et al., 2010). The method consisted of the 
following: 500 µL (for HPLC), 50 µL (for MALDI) of plasma was transferred to 10 
mL glass tube; ISTD was then added (50 ng) to each sample followed the extraction 
with CHCl3 (3 x5 mL), the solutions were shaken (15min, centrifuged (3500 g, 50 min, 
4˚C)), the organic extracts were combined, retained and the plasma removed. The 
organic layers were dried under oxygen free nitrogen (OFN) at RT, submitted to LC-
MS/MS analysis as described in section 5.2.3.3.   
5.2.3.3.  Quantitative analysis of steroids by LC-MS/MS  
Solutions (0.1 mg/mL in methanol) of CORT and 11DHC were serially diluted with 
water (as simulated media) to prepare calibration standards (0.1-50 ng each steroid) 
with the addition of d8CORT (5 ng), and processed as tissue (section 5.2.2.2) and 
plasma (section 5.2.2.3). The final extracts were dissolved in (50:50) methanol: formic 
acid 0.1% v/v. Separation was achieved on an Inerstil ODS-3 100 x 2.1 mm, 3 µm (GL 
Sciences, Torrance, USA) column. Mobile phases, consisting of 0.1% v/v FA in H2O 
(A) and 0.1 % v/v formic acid in 90:10 (acetonitrile: methanol) (B), were used at a flow 
rate of 0.3 mL/min, with an initial hold of 3 min at 35 % B followed by a linear 
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gradient to 90 % B in 8 min and re-equilibration at initial conditions (2 min). Column 
and autosampler temperatures were 45 ˚C and 10 ˚C respectively. Electrospray 
ionisation was performed with an ion source voltage of 4500V, medium collision gas 
and source temperature 450
o
C. Data were acquired by multiple reaction monitoring at 
the following transitions (collision energy, declustering potential, cell exit potential): 
CORT m/z 347→121 (31,148,12 V); 11DHC m/z 345→121 (30,155,15 V); and 
d8CORT m/z 355→125 (32, 119,12 V). Peaks area ratios were calculated and 
interpolated onto a standard curve (peak area ratio vs amount) derived from data 
generated by corresponding calibration samples. 
5.2.4.  Extraction of UE2316 from whole brain 
Brain tissue (~150 mg) was homogenized in 5 mL of buffer (50:45:5 Hepes: Tris (0.1 
M): sodium lauryl sulphate (0.5%), pH 9.5 adjusted with sodium hydroxide (NaOH) 
containing 100 µg/mL of Protein K enzyme. UE2346 ([4-(4-chlorophenyl-4-fluoro-1-
piperidinyl] [5-(1H-pyrazol-4-yl)-3-thienyl]-methanone) was added (ITSD 100 ng) and 
homogenates were incubated in a rotating water bath (37˚C, 60 min). Samples were 
allowed to cool to RT and subjected to centrifugation (3500 g, 15 min, 4˚C). 
Supernatants were filtered through a 0.45 µm nylon (Millipore, Chesire, UK) filters and 
extracted with 3 x 5 mL of ethyl acetate. Organic layers were reduced to dryness under 
gentle stream of nitrogen at RT and residues were reconstituted in (acetonitrile: water 
50:50 containing 0.1 % formic acid) (100 µL) and samples were then submitted to LC-




5.2.4.1.  Quantitative LC-MS/MS UE2316 analysis  
Stock solutions of 1 mg/mL of UE 2316 and UE 2346 (ISTD) were obtained by 
dissolving 1.0 mg of corresponding analytes in 1 mL of methanol. Working standards 
of 5, 25, 100, 250, and 500 ng were prepared by serial dilution of the stock solution in 
methanol and were stored in vials at −20˚C protected from light. Standard curves were 
prepared using water as a simulated media and ion suppression was evaluated by 
standard addition experiments at 25 and 250 ng respectively using brain tissue from an 
untreated mouse. The final extract was dissolved in mobile phase (50:50) acetonitrile: 
formic acid 0.1% v/v. Separation was achieved on a Kinetex PFP column 100 x3 mm, 
2.6 µm (Phenomenex, Macclesfield, UK,). Mobile phases, consisting of 0.1% v/v FA in 
H2O (A) and 0.1% v/v formic acid in acetonitrile (B), were used at a flow rate of 0.35 
mL/min, with an initial hold of 2 min at 20% B followed by a linear gradient to 100% 
B in 10 min and re-equilibration at initial conditions (2 min). Column and autosampler 
temperatures were 40˚C and 10˚C respectively. Electrospray ionisation was performed 
with an ion source voltage of 5000V, medium collision gas and source temperature 450 
o
C. Data were acquired by multiple reaction monitoring of the following transitions 
(collision energy, declustering potential, cell exit potential): UE2316 m/z 391→177 
(31,148,12V) and UE2346 m/z 482→194 (35, 115,10V). Peaks area ratios were 
calculated and interpolated onto a standard curve (peak area ratio vs amount) derived 
from data generated by corresponding calibration samples.   
5.2.5.  Data analysis 
Data are expressed as mean ± SEM and differences were analyzed using two-way 
ANOVA with Bonferroni’s post-hoc test (MSI and LESA) and Student’s t-test (LC-
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MS/MS) as appropriate. Statistical significance was accepted at p < 0.05. A statistical 
trend is define as 0.05<p<0.1. For correlation analysis between MSI, LESA and LC-
MS/MS, Bland-Altman plots with 95% confidence intervals were used. Analysis was 
performed according to section 2.10. 
5.3.  Results  
5.3.1.  Studies of genetic manipulation of 11β-HSD1 
Endogenous CORT (Figure 1B, 1D) and 11DHC (Figure 1C, 1E) were successfully 
detected as GirT hydrazones by MSI in sections of murine brain from both wild-type 
(WT) and 11β-HSD1-/- mice. Corticosteroid derivatives were detected in highest 
abundance in the cortex, hippocampus and amygdala as demonstrated in Ch4.  In 11β-
HSD1-/- mice, the CORT/11DHC ratio was reduced in these regions of interest 
(Figure 5.1F). Absolute ratios (and magnitude of difference between 11β-HSD1-/- and 
WT mice) obtained by LC-MS/MS and LESA were similar to those determined by MSI 
(Figure 5.1F). Absolute measurements (Figure 5.1G) suggested the change in pattern 
between genotypes was driven by both increased amounts of 11DHC and reduced 








Figure 5.1: Effect of 11β-hydroxysteroid dehydrogenase type 1 deficiency on proportions of active and 
inactive glucocorticoids in regions of murine brain. Girard T (GirT) corticosteroid hydrazones 
(corticosterone (CORT) and 11-dehydrocorticosterone (11DHC)) were most abundant in the cortex, 
hippocampus and amygdala with lower CORT/11DHC ratios observed upon disruption of the enzyme 
primarily caused by an accumulation of 11DHC. (a) Histological image of cryosection of murine brain 
stained with haematoxylin and eosin with the outline of the MSI regions of interest (ROIs) (cortex; 
hippocampus, HPC; and amygdala, Am). (b, d) Heat map distribution by MALDI-FTICR-MSI of GirT-
CORT derivative at m/z 460.317 Da in wild type (WT) (b) and 11-HSD1
-/-
 (KO) (d) mice. (c,e) Heat 
map distribution by MALDI-FTICR-MSI of GirT-11DHC derivative at m/z 458.301 Da in WT (c) KO 
(e) mice. Signal intensity is depicted by color on the scale shown. Scale bar (2mm). cps = count per 
second. (f) CORT/11DHC ratios measured by MALDI-FTICR-MSI (MSI), LC-MS/MS and LESA in 
regions of interest in murine brain were lower in KO mice than WT (p<0.001 overall between 
genotypes). (g) Differences between genotypes in CORT/11DHC ratios were caused by an increase of 
11DHC and a trend ( 0.05<p<0.1) to a similar magnitude of reduction in CORT in 11-HSD1
-/-
 mice, 
measured in whole brain by LC-MS/MS. Statistical analysis was by two- way ANOVA for LESA and 
MSI and Student’s t-test for LC-MS/MS and absolute measurements (n=12). Data are mean ± SEM. 













































5.3.1.1.  CORT and 11DHC quantitation in plasma and brain by LC/MS  
Upon enzyme depletion, an average decline in the absolute level of CORT (~16 %) 
with a simultaneous increase (~50 %) with 11DHC level was observed in brain 
homogenate. However, no differences were observed in plasma levels as both WT and 
KO shown the same profile (Figure 5.2).  
 
Figure 5.2: Absolute quantitation of corticosterone (CORT) and 11-dehydrocorticosterone (11DHC) 
measured by LC-MS/MS of plasma and brain homogenate in 11-HSD1
-/- 
(KO) and WT mice. A decline 
in CORT and an increase of 11DHC levels were observed in KO mice brains homogenate. On the 
contrary, no difference were observed in plasma levels. Statistical analysis was by Student’s t-test 
(n=12). Data are mean ± SEM. *P<0.05.  
 
5.3.2.  Studies of pharmacological inhibition of 11β-HSD1 
The small molecule 11-HSD1 inhibitor UE2316 (Figure 5.3) was used to attenuate 
regeneration of active CORT in mice. MSI was initially used to establish which tissue 
had been exposed to drug, with specific reference to brain. MSI analysis of small drug-












































techniques the molecule must contain a readily ionisable moiety to be suitable for 
analysis. In this case, the murine 11β-HSD1 inhibitor (UE2316) studied has piperidinyl 
moiety which promotes the proton adduct formation leading to an efficient ionisation in 
MALDI. In contrast to steroids, derivatisation was not needed, as the sensitivity was 
enough to generate a suitable molecular map. MS images were successfully generated 
for UE2316 in murine brain section after time-dependent dosing study and the relative 
abundance obtained was validated using the standard tissue-homogenate LC-MS/MS 
platform described in section 5.2.3.1. 
 
Figure 5.3: Molecular structure of UE 2316. Piperidinyl moiety in red 
Following a single oral dose of UE2316, levels of the drug detected by MSI reached a 
maximum in brain one hour post-dose (Figure 5.43B, vehicle, Figure 5.4C-E, 
UE2316); the MSI data were confirmed by LC-MS/MS of drug in whole brain (Figure 
5.4F).  Therefore this time point was selected for subsequent analysis of changes in 
steroid levels. The regional distribution of glucocorticoids was similar in brains of 
vehicle and UE2316 treated mice (Figure 5.4H,J (CORT), 5.4I,K (11DHC)). 
Treatment with UE2316 reduced CORT/11DHC ratios measured by MSI in the cortex, 
hippocampus and amygdala (Figure 5.4L). Quantitative analysis by LC-MS/MS 



































































Figure 5.4:  Effect of pharmacological inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11β-
HSD1) with UE2316 in C57BL/6 mice. Girard T (GirT) derivatives (corticosterone (CORT) and 11-
dehydrocorticosterone (11DHC)) were mostly distributed across the cortex, hippocampus and amygdala, 
before and after enzyme inhibition, CORT/11DHC ratios showed a significant decline as a result of an 
increased 11DHC metabolite. (a) Histological image of horizontal cryosection of murine brain stained 
with haematoxylin and eosin. (b-e) MSI heat map distribution of m/z 390.084 Da representing UE2316 
in brain over a 1-6 h time course in mice receiving Vehicle (V) or UE2316 (D). (f) Amounts of UE2316 
in whole brain measured by LC-MS/MS demonstrated the same temporal pattern as those determined by 
MSI. (g) Histological image of coronal cryosection of murine brain stained with haematoxylin and eosin 
with the outline of the MSI regions of interest (ROIs) (cortex; hippocampus, HPC; and amygdala, Am). 
(h, j) MSI heat map of GirT-CORT at m/z 460.317 Da brain from mice receiving Vehicle (h) or UE2316 
(1h post dose) (j). (i, k) GirT-11DHC at m/z 458.301 Da in brain from mice receiving Vehicle (i) or 
UE2316 (k). Signal intensity is depicted by color on the scale shown. Scale bar (2mm). cps = count per 
second. (l) A significant decline (p<0.01, overall between groups) in CORT/11DHC ratios was observed 
across the ROIs by MSI in the brain after administration of UE2316, showing good agreement with data 
generated by LC-MS/MS in whole brain. (m) Absolute quantification of corticosteroids in brain tissue 
by LC-MS/MS showed that the differences in CORT/11DHC ratios were associated with an increase of 
11DHC and a trend to a decrease in CORT in UE2316-treated mice. Statistical analysis was performed 
using two-way ANOVA for MSI and Student’s t-test for LC-MS/MS and absolute measurements 
(n=12). Data are mean ± SEM. *P<0.05, ** and  P<0.01.  
 
 
5.3.3.  Agreement between methods of quantitative analysis 
Good agreement was observed between MSI and LC-MS/MS (Figure 5.5A) and 
between MSI and LESA (Figure 5.5B), in measuring the (CORT/11DHC) ratios across 
the range of values, although MSI-LESA demonstrated a negative bias using Bland-





Figure 5.5:  Agreement between MSI and alternative methods for measuring corticosteroids. Bland-
Altman plots with 95% confidence intervals for agreement for ratios of corticosterone to 11-
dehydrocorticosterone (CORT/11DHC) measured in wild type murine brain by: (a) MSI and LC-
MS/MS; (b) MSI and LESA.  
 
5.3.4.  Quantitation of alternative substrates of 11-HSD1 
The GirT derivative of 7-ketocholesterol was detected by MSI in brain sections (Figure 
5.6) and its abundance increased in mice with disruption (Figure 5.6B-D) or inhibition 
(Figure 5.65E-G) of 11β-HSD1. 





































Figure 5.6: MSI detection of 7-ketocholesterol, an alternative substrate for 11-HSD1. A significant 
increase in Girard T 7-ketocholesterol (GirT-7KC) intensity was observed across the whole brain in mice 
after disruption of 11-HSD1 (KO) and after administration of UE2316 (1 h post-dose). (a) Histological 
image of coronal cryosection of murine brain stained with haematoxylin and eosin. MSI heat map of 
GirT-KC at m/z 514.437 in (b) wild type (WT), (c) KO and brain from mice receiving (e) Vehicle (V) or 
(f) UE2316 (D). Quantification of MSI signal intensity for GirT-7KC across the whole brain for (d) wild 
type versus 11-HSD1
-/-
 mice and for (g) mice treated with vehicle or UE2316. Signal intensity is 
depicted by color on the scale shown. Scale bar (2 mm). cps = counts per second. Statistical analysis was 






























































5.4.  Discussion 
Neutral steroids were converted to positively charged hydrazone derivatives using 
Girard reagents T (GirT), enabling detection and quantitation by MALDI and LESA 
with FTICR-MSI. Validation was performed with LC-MS/MS. MSI demonstrated 
alterations in amounts of brain glucocorticoids (and 7-ketocholesterol, an alternative 
substrate) in mice with 11β-HSD1 deficiency, and allowed simultaneous 
pharmacokinetic/pharmacodynamic studies with an 11β-HSD1 inhibitor. A potent, 
selective and orally bioavailable piperidinyl-pyrazol inhibitor of 11β-HSD1 (UE2316) 
was used; UE2316 crosses the blood-brain barrier and displays potency across species 
(Ki: mouse, 162 nM,; rat, 80 nM) 
 
This novel application of OTCD coupled with MSI permits detection of poorly 
ionisable endogenous corticosteroid hormones within tissues, by generating 
permanently charged derivatives which yield intense signals upon MALDI-FTICR 
analysis. The spatial distribution of the substrate and product of 11-HSD1, 11DHC 
and CORT, in murine brain had been visualized in Ch4. Here quantitation of these 
analytes in brains from 11-HSD1 deficient mice allowed quantitative assessment of 
the consequences of regional activity of 11-HSD1 for local steroid levels, and the 
approach also allowed pharmacodynamic and pharmacokinetic assessment of an 11-
HSD1 inhibitor within the brain. This technique has the potential to be applied to other 





OTCD coupled with MALDI-FTICR-MSI was successfully applied in murine brain, 
where discriminating abundance of glucocorticoids in sub-regions was possible. As 
shown in Ch4, wild-type mice on a C57BL/6 background, the highest abundance of the 
glucocorticoids tested was again in cortex, hippocampus and amygdala and may reflect 
the higher expression of corticosteroid-binding receptors as well as of 11-HSD1 in 
these brain regions. 
 
To evaluate use of the technique to interpret biological variations 
in tissue steroid levels, proof-of-principle experiments were performed using brains of 
mice with 11-HSD1 deficiency or receiving pharmacological 11-HSD1 inhibitors. 
Changes in enzyme activity were quantified by CORT/11DHC ratios, which is 
appropriate since derivatives of both steroids possess similar ionisation yields and 
signal intensities, as previously demonstrated in section 3.3.5.1, when compared using 
post-processing vector normalization (RMS). An alternative approach would have been 
to incorporate a labeled steroid (e.g. d8CORT) in the matrix, allowing signal intensity 
to be normalised; this approach also offers the advantage of a further read-out of 
uniformity of matrix application but was not employed here. Disrupting or inhibiting 
11-HSD1 was anticipated to increase the CORT/11DHC ratio, as previously reported 
in homogenates of brain from 11-HSD1 deficient mice (Yau et al., 2007). This was 
indeed detected, and quantified in brain sub-regions, with an increase of the signal 
intensity of GirT-11DHC and a smaller decline in GirT-CORT levels across the cortex, 
hippocampus and amygdala with 11-HSD1 deficiency or inhibition. These brain 
regions have high abundance of 11-HSD1 mRNA, which when translated in protein, 




CORT in the brain is derived both from the circulation and from local 11-HSD1 
activity. The proportionate contribution of each source, however, is unknown. To date, 
this has been inferred for some tissues, imprecisely, from studies using arteriovenous 
sampling in combination with stable isotope tracers, by sampling interstitial fluid by 
microdialysis, or by quantifying steroid concentrations in whole tissue homogenates ex 
vivo (section 1.24). The MSI data here provides the novel insight into the role of the 
enzyme in tissues. In mice with 11-HSD1 deficiency, the CORT/11DHC ratio was 
unaltered in plasma but within specific regions of tissues, the local ratio of active and 
inactive steroid was altered. A ~16 % decline in active CORT with 11-HSD1 
deficiency in regions of the brain where 11-HSD1 is normally most highly expressed; 
suggesting the contribution of 11-HSD1 to the intracellular pool of CORT in these 
experimental conditions is relatively modest and the circulation contributes 
considerably to steroid availability. 
 
Lastly using MSI, it was possible to image alternative substrates of 11-HSD1, in this 
case 7-ketocholesterol. Previously it has been difficult to establish whether 11-HSD1 
predominantly reduces 7-ketocholesterol to 7-hydroxycholesterol or if oxidation 
dominates (Mitic et al., 2013).  Indeed, changes in the balance of circulating oxysterols 
are modest in 11-HSD1
-/-
 mice. By demonstrating accumulation of 7-ketocholesterol 
with 11-HSD1 deficiency, data obtained using MSI may suggest that reduction of 





5.5.  Conclusions 
MSI with on-tissue derivatisation is a powerful new tool to study the regional variation 
in abundance of steroids in brain tissue sections. This is the first technique capable of 
detecting and quantifying corticosteroids to <200 m resolution, and at physiological 
concentrations, allowing application within region-specific areas of murine brain. We 
have demonstrated its utility for measuring pharmacodynamic effects of small molecule 
inhibitors of 11-HSD1; in combination with pharmacokinetic imaging, this will 
facilitate screening of the disposition of such drugs being developed to treat 
Alzheimer's disease. This offers the prospect of many novel insights into tissue-specific 














dehydrogenase-1 turn-over using MSI with 
stable isotope tracer infusion  
6.1.  Introduction 
11β-HSD1 is widely expressed, including in the liver and adipose and brain (Seckl et 
al., 2001). Its main function is believed to be catalysing the regeneration of active 
glucocorticoids, cortisol (F) in humans and corticosterone (CORT) in rodents, from 
inactive cortisone (E) and 11-dehydrocorticosterone (11DHC) respectively, therefore, 
amplifying glucocorticoid receptor activation independently of the circulating level of 
active glucocorticoids. Its importance as a tissue-specific regulator of metabolism has 
been demonstrated using animal models (Masuzaki et al., 2003; Masuzaki et al., 2001). 
Tissue-specific dysregulation of 11β-HSD1 has been inferred in human obesity from 
indirect measurements (Rask et al., 2001; Tomlinson et al., 2002), therefore, 11β-
HSD1 has become an attractive target for ameliorating metabolic syndrome. Selective 
and potent 11β-HSD1 inhibitors have been developed with some evidence of success 
(Webster et al., 2007). However, key questions remain about the role of 11β-HSD1 in 
aetiology of metabolic disease and CNS in humans. It has been proved that inhibition 
of 11β-HSD1 in brain is associated with improved memory (Sooy et al., 2010) but the 
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consequences for local steroid regeneration in the brain sub-regions where 11β-HSD1 
is expressed are not known. Of pressing importance is understanding the magnitude of 
regeneration of cortisol within individual tissues; until this can be assessed, 
consequences and sites of dysregulation or enzyme inhibition remain uncertain. An 
idea persists that 11β-HSD1 may catalyse the dehydrogenase conversion of active to 
inactive under some circumstances (Bujalska et al., 2002; Hughes et al., 2012); thus, in 
vitro enzyme expression or activity driven by co-factor and substrate cannot be 
extrapolated in vivo. Studies measuring endogenous F and E (Kannisto et al., 2004) or 
dilution of stable isotope F tracer (Basu et al., 2004) in the hepatic vein suggest that 
there is substantial splanchnic F regeneration but this methodology does not distinguish 
activity in the liver from the contribution of visceral adipose tissue, which in vitro 
studies suggest is considerable (Katz et al., 1999b). Venous sampling has demonstrated 
local F regeneration in subcutaneous adipose tissue, but the errors associated with this 
method is wide (Basu et al., 2004).  
As the MSI platform was successfully applied to measure endogenous concentrations 
as ratios in mouse brain, in this chapter, we aimed to apply the OTCD-MSI platform to 
measure the contribution of tissue-specific cortisol regeneration primarily in the brain 
using a stable isotope tracer, 9,11,12,12[
2
H]4-cortisol (d4F). D4F is converted to 
9,12,12[
2
H]3-cortisone (d3E) by 11β-HSD2 in the kidney and d3E is converted to 
9,12,12[
2
H]3-cortisol (d3F) by 11β-HSD1(Andrew et al., 2002) (Figure 6.1). Unlike 
cortisol or d3F, d4F cannot be regenerated by 11β-HSD1. Using this approach the rate 
of cortisol turnover in the brain may be compared with that in adipose and liver 
alongside plasma. Furthermore, the effects of 11β-HSD1 deficiency on the region-
specific cortisol regeneration in metabolic tissues can be evaluated using genetically 
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modified mice and a selective inhibitor. In contrast with tissue homogenate 
approaches, with MSI it is possible to evaluate the regional turn-over within different 
compartment in brain tissues, where the consequences for local steroid regeneration in 
different sub-regions are still not known. 
 
 
Figure 6.1: Cortisol turnover at the tissue level using stable isotope tracers.  9,11,12,12[2H]4-cortisol       
(d4F)  is converted to d3-9,12,12[
2
H]3-cortisone (d3E) by 11β-HSD2 in the kidney and d3E is converted 
to 9,12,12[
2








































6.2.   Methods   
6.2.1.  Biomatrices   
The effect of the 11β-HSD1 activity enzyme on the cortisol turn-over was studied in 
the following models. Four groups of mice (n=3/group) were studied: 
• Group 1: C57Bl/6j from Harlan Olac Ltd (Bicester, UK) (male, 12 weeks), infused 
with d4F 1.75 mg/day for 6, 24 and 48 h termed “controls”. 
• Group 2: C57Bl/6 mice from Harlan Olac Ltd (male, 12 weeks) infused with vehicle 
(dimethylsulfoxide (DMSO): propylenglycol (PG) (50:50) termed “vehicle”. 
• Group 3: C57Bl/6j 11β-HSD1
-/-
 mice (male, 2-3 months) bred in-house and 
genotyped using protocols described by Morton (Morton et al., 2001), infused with 
1.75 mg/day of d4F for 48 h, termed KO. 
• Group 4: C57Bl/6 mice (12 weeks, male) from Harlan Olac Ltd infused with 1.75 
mg/day of d4F for 48 h and studied 1, 2, 4 h hours post-dose (HPD) of UE2316 (11β-
HSD1 inhibitor; 25 mg/kg oral gavage) or vehicle (DMSO: PG)  (50:50), termed 1 h 
(1HDP), 2 h (2HPD) and 4 h (4HPD) post-dose, respectively 
The d4F solution was administered at a rate of 1.03 µL/hr by subcutaneous surgical 
implantation of mini-osmotic pumps (ALZET model 1003 with a reservoir volume 
100µL, Cupertino, CA, USA). Pumps were primed overnight in saline solution prior to 
insertion. Animals were killed by decapitation and plasma was prepared from trunk 
blood, collected in ethylenediamine tetraacetic acid (EDTA) coated tubes. Tissues were 
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snap frozen in liquid nitrogen and stored (-80˚C) at cull as per section 2.2 and 2.3, 
respectively. 
6.2.2.  FTICRMS spectral characterisation of deuterated glucocorticoids 
(standard on tissue) 
On-tissue spectral characterisation of the tracers was performed using a control tissue 
section (murine brain) sectioned as per section 2.3 with spots (5 ng, 10 µg/mL; 
methanol: water (1:1)) of d4F and d3F applied to the surface manually (n=3). Spots 
were allowed to dry, then GirT (1µL; 5 mg/mL) in methanol: water (80:20) was 
deposited on top. The MALDI glass slide was placed in the reaction chamber and 
derivatised according to section 2.5. After derivatisation, matrix CHCA was applied as 
per section 2.6 and allowed to dry (RT) and stored in a dessicator until MALDI-
FTICRMS analysis. MSI was performed in full mass (230-1500 Da) (broadband mode) 
as described in section 2.8.2. Ions of GirT-d4F and GirT-d3F were monitored as detailed 
in Table 2.1. Ion intensities were recorded and response factors were calculated. 
6.2.3.  Detection of d4F and d3F in an infused murine brain (control) 
section  
Brain tissues were obtained from Group 1 as per section 6.2.1 (48 h time point). 
Tissue sectioning was carried out as described in section 2.3. OTCD was carried out as 
described in section 2.5 and matrix was applied as per section 2.6. MALDI-FTICR-
MSI analysis was performed as described in section 2.8.1 acquired in both broadband 




using an isolation window 
at 470±25Da in profiling mode. Ions of GirT-d4F and GirT-d3F were monitored as 
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detailed in Table 2.1. d8CORT was also monitored as ISTD for window normalisation 
marker as explained in section 2.8.1. 
6.2.4.  Structural confirmation of d4F and d3F in brain (control) sections 
from a mouse infused with d4F analysed by CID experiments using LESA-
nanoESI-FTIRMS. 
Brain tissues were obtained from Group 1 as per section 6.2.1 (48 h time point). 
Tissue sectioning was carried out as described in section 2.3. OTCD was carried out as 
described in section 2.5 and tissues were analysed immediately using LESA-nanoESI-
FTICRMS as described in section 2.9. Ions were isolated at m/z 470.3±20Da for 30 s 
yielding a 2 Mword time-domain transient. CID fragmentation was carried out at 28 eV 
and CID spectra recorded and fragments proposed. 
6.2.5.  Time-dependent  cortisol turn-over using stable isotope tracers in 
metabolic tissues 
6.2.5.1.  Plasma analysis 
Plasma analysis was performed as previously described by Stimson et al (Stimson et 
al., 2009). Plasma cortisol, d3F, d4F, CORT, and d3E were measured by LC/MS-MS. 
Epi-cortisol (500 ng) was added to 1.5 mL plasma and extracted using 15 mL 
chloroform. Samples were evaporated and then reconstituted in mobile phase (60% 
methanol and 40% 5 mmol/L ammonium acetate) before injection into a Thermo 
Finnigan LC-MS/MS, consisting of a TSQ Quantum Discovery Mass Spectrometer and 
a Surveyor Liquid Chromatogram using an Allure biphenyl column (50 mm × 4.6 mm 
× 5 μm; Thames Restek), with column temperature 25°C and mobile phase flow rate 
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0.5 mL/min. Ionization was achieved by positive electrospray. The precursor and 
product m/z and the collision energy used were as follows: EpiF (363→121),(35eV), 
d3F (366→121), (47eV), d4F (367→121), (39ev), CORT (346→121), (41eV), and d3E 
(364→164), (42eV). Compounds were quantified by the ratio of area under peak of 
interest to area under peak of internal standard against a standard curve. 
6.2.5.2.  Extraction of steroids from liver tissue   
The method was adapted from McInnes et al. (McInnes et al., 2004). Murine liver 
tissue (~300 mg) was homogenised in methanol–acetic acid (100:1 v/v, 10 mL) using a 
mechanical homogeniser and assisted by ultrasonication and enriched with internal 
standard, d8CORT  (ISTD) (5 ng).  The supernatant was retained and the pellet formed 
followed centrifugation (5000 × g, 10 min, 4 °C), further extracted with methanol–
acetic acid (100:1 v/v, 10 mL) and the supernatants combined and dried under oxygen 
free nitrogen (OFN) at RT, submitted for derivatisation as per section 2.5 and analysed 
by MALDI-FTICRMS as per procedure in section 2.8.2., using an isolation window of 
470.3±50 Da.  
6.2.5.3.  Whole brain analysis 
Extraction was performed as described in section 5.2.3.1 and analysis carried out as per 
section section 2.8.2., using an isolation window of 470.3±50 Da.  
6.2.5.4.  Extraction of steroids from adipose tissue  
The method was adapted from (Hughes et al., 2010).  Adipose samples (250 mg) were 
mechanically homogenised in ethyl acetate (1 mL), enriched with internal standard 
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(d8CORT, 5 ng), dripped onto chilled ethanol: glacial acetic acid: water (95:3:2 v/v) 
(10 mL) and stored at -80 ºC overnight. Samples attained 4 ºC, before being sonicated 
(8 x 15 s bursts) and centrifuged (3000x g, 30 min, 4 ºC). The supernatant was reduced 
to dryness under (OFN, 60ºC), methanol (10 mL) added and stored at -80 ºC overnight. 
To remove lipids, tissue extracts attained room temperature then hexane (10 mL) was 
added and mixed. The hexane layer was discarded and the remaining methanol 
removed by evaporation. Water (400 µL) and ethyl acetate (4 mL) were added to the 
dried steroidal extract,  the organic layer removed, dried and the residue derivatised as 
per section 2.5 and analysed by MALDI-FTICRMS as per procedure in section 2.8.2., 
using an isolation window of 470.3±50 Da. 
6.2.5.5.   MSI of deuterium labelled cortisol metabolites in murine brain  
Tissues were harvested as per section 2.2, OTCD was carried out as per section 2.5 and 
MSI performed as described in section 2.8.1. The ions of GirT-d4F, GirT-d3E and 
GirT-d3F and ISTD (d8CORT) were monitored according to Table 2.1. The average 
spectral intensities of GirT-d4F GirT-d3E and GirT-d3F in ROIs across the cortex, 
hippocampus and amygdala were recorded using MSI, presented as ratios of derivatised 
d4F/d3F and d3E/d8CORT (ISTD). An average value was calculated based on the 
weighted average. 
For tissue homogenate analysis, the average spectral intensities of the corresponding 
GirT-d4F, GirT-d3E, GirT-d3F, CORT and GirT-d8CORT ions (Table 2.1) were 
recorded and presented as ratios tracer/tracee ratios (TTR) of d4F/d3F, d4F/d8CORT and 
d3E/d8CORT as hydrazone derivatives respectively. The amount of d8CORT was 
normalised (d8CORT /mg tissue) across different tissues to allow intra-tissue 
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comparison. The intensities of GirT derivatives of deuterated steroids were corrected 
for any potential background monoisotopic contribution. 
6.2.6.  PK/PD study of UE 2316 using stable isotope tracer 
6.2.6.1.  Extraction and analysis of plasma UE2316  
150 µL of plasma was transferred to 10 mL glass tube; ISTD (UE 2346) was then 
added (50 ng) to each sample followed by extraction with ethyl acetate (3 x 5 mL), the 
solutions were shaken (15 min, centrifuged (3500 x g, 50 min, 4 ˚C)), the organic 
extracts were combined, retained and the plasma removed. The organic layers were 
dried under OFN at RT, submitted to LC-MS/MS analysis as described in section 
5.2.35. 
6.2.6.2.  Extraction and analysis of UE2316 in whole liver, adipose and brain  
Liver, adipose and brain (~150 mg) were homogenised in 5 mL of buffer (50:45:5 
Hepes: Tris (0.1 M): sodium lauryl sulphate (SDS) (0.5 %)) pH 9.5 adjusted with 
NaOH containing 100 µg/mL of Protein K enzyme. UE2346 was added (125 ng) and 
homogenates were incubated at 37 ˚C in a rotating water bath for 60 min. Samples were 
cooled down to RT and centrifuged (3500 x g, 15 min, 4˚C), supernatants were filtered 
through a 0.45µm nylon filter and extracted with 3 x 5 mL of ethyl acetate. Organic 
layers were reduced to dryness under gentle stream of nitrogen at RT and residues were 
reconstituted in acetonitrile: water (50:50 containing 0.1% formic acid) (100 µL) and 
samples were then submitted to LC-MS/MS analysis as per section 5.2.5. 
The amount of ISTD (UE2346) was normalised to allow comparison of UE2316 levels 
in different tissues. 
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6.2.6.3.  MSI of UE2316 in murine brain. 
Tissues were harvested as per section 2.2, matrix was applied as described in section 
2.6, analysed by MALDI-FTICRMS as per section 2.8.1 in broadband mode and MS 
images generated using the protonated mass of UE2316 as per Table 2.1 and 
normalised using vector normalisation (RMS).  
6.2.6.4.  MSI of deuterium labelled cortisol metabolites in murine brain  
Analysis was performed as described in section 6.2.5.5. 
6.2.6.5  MSI of UE2316 and its metabolites 
Tissues (Group 4 at 4HPD) were harvested as per section 2.2, matrix was applied as 
described in section 2.6, analysed by MALDI-FTICRMS as per section 2.8.1 in 
broadband mode and MS images generated using the protonated mass of UE2316 
metabolites at m/z 406.078681Da and m/z 404.06303Da, respectively. Data were 
normalised using vector window normalisation using the quasimolecular ion of 
UE2316. 
6.2.7.  Data analysis 
Data are expressed as mean ± SEM and differences were analysed using two-way 
ANOVA with Bonferroni’s post-hoc test and Student’s t-test as appropriate. Statistical 
significance was accepted at p < 0.05. A statistical trend is define as 0.05<p<0.1.  
The rate of appearance (Ra) of d3F was calculated using equation (1). 
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                  (1) 
TTR: Tracer/tracee ratio 
The tissue d3F regeneration corrected for changes in circulating contribution (plasma, 
P)  ( TTRT) was calculated using equation (2).  
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6.3.  Results 
6.3.1.  FTICR Spectra of deuterated glucocorticoids 
6.3.1.1.  Spectral characterisation 
Spectral characterisation was carried out by spotting experiments on a murine brain 
section using d4F and d3F (d3E is not commercially available). As previously shown in 
section 4.2.5 the human counterpart glucocorticoids reacted in the same way as the 
rodent counterpart with Gir-T. So, as expected, both labelled analogues formed the 
corresponding GirT-derivatives at m/z 479.331 Da for d3F and m/z 480.337 Da for d4F 
(Figure 6.2). Good mass accuracy (<10 ppm against their corresponding theoretical 
monoisotopic mass, m/z 479.331 Da for GirT-d3F and m/z 480.331 Da for GirT- d4F ) 
was observed for both derivatives (Figure 6.2). There was no need for correction of 
potential of M+D isotopomer contribution in d4F from d3F as both monoisotopic 
masses were well distinguished using HRMS (350.000 resolution power at 
400Da)
 
Figure 6.2: Representative MALDI-FTICRMS of Girard T (GirT)-derivatives of deuterium labelled 
glucocorticoid standards (5 ng). Observed ions at m/z 479.33066Da for GirT-d3F and m/z 480.33696Da 
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6.3.1.2.  Implementation of CASITM  for MSI 
In order to increase the sensitivity of the MSI detection by separating target ions from 
the background noise, continuous accumulation of selected ions (CASI
TM
) was 
invoked. A 48 h d4F infused brain tissue was analysed in full mass range and also with 
CASI
TM 
(Figure 6.3). As shown in Table 6.1 (S/N) ratios were boosted using CASI
TM
 
by 50 times (d4F) and 10 times (d3F) allowing a better sensitivity than detection by full 
mass, with a better mass accuracy.  
 
Figure 6.3: Molecular imaging by MALDI-FTICR-MSI of hydrazone derivatives of stable isotope tracer 
(d4F) and tracee (d3F) in representative murine brain sections. Molecular regional distribution maps show 
an increase in signal intensity by using continuous accumulation of selected ions (CASITM). Heat map 
using CASI
TM
 of (a) GirT-d4F at m/z 480.337 Da, (b) GirT-d3F at m/z 479.331 Da. Heat map in full 
mass. (c) GirT-d4F at m/z 480.337 Da, (d) GirT-d3F at m/z 479.331 Da collated by MALDI-FTICRMS. 
Signal intensity is depicted by color on the scale shown. Scale bar (2 mm). 
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6.3.1.3.  Detection of d4F and d3F using CASI
TM 
in a tissue section following 
in vivo administration of d4F 
After successfully detecting both deuterated cortisol analogues in a standard spotted 
tissue, the MSI platform was applied to murine brain section from a mouse treated with 
d4F in order assess feasibility of generating molecular maps of both tracer and tracee in 
a biologically relevant setting. In line with unlabelled glucocorticoids,  FTICR spectra 
of both steroids were well-defined showing an excellent mass accuracy (< 5 ppm) 
against the theoretical monoisotopic masses and good signal intensity (S/N above 50 
for both steroids) (Figure 6.4).  
 
Figure 6.4: Representative CASI
TM
-MALDI-FTICRMS of Girard T (GirT)-derivatives of labelled 
glucocorticoids in brain from a mouse infused with d4F for 48h. Observed molecular ions at m/z 479.330 
Da for GirT-d3F and m/z 480.336 Da for GirT-d4F were in agreement with the corresponding 
monoisotopic theoretical masses (m/z 479.331 Da for GirT- d3F and m/ z 480.331 Da for GirT- d4F). cps: 



















6.3.1.4.  Structural confirmation by CID experiments using LESA-nanoESI-
FTICRMS 
Structural confirmation by fragmentation was achieved using LESA-nanoESI-
FTICRMS, performed as described in section 2.10. This process provided 
fragmentation patterns typical of GirT hydrazones (Figure 6.5). These were concordant 
with the structures of steroid hydrazones, extrapolating from unlabelled rodent steroids, 
which shared the same five membered ring rearrangement as previously reported in 
section 3.3.5.6. CID of the GirT derivatives generated a series of fragment ions 
characteristic of the loss of the quaternary amine tag [M-59]
+ 
and carbon monoxide [M-
87]
+
 of the derivatised group at m/z 421, m/z 393 (GirT-d4F) and m/z 420, m/z 392 




Figure 6.5: Mass spectra of Girard T (GirT) derivatives of deuterium labelled cortisol following liquid 
extraction surface analysis with nanoESI-FTICR collision induced dissociation (CID). CID mass spectra 
and proposed fragmentation patterns were in agreement with the literature. Precursors (a) at m/z 
480.33711Da (GirT-d4F) and (b) at m/z 479.33074Da (GirT-d3F). Proposed fragmentation patterns (c): 
















































































































6.3.2.  Cortisol turn-over using stable isotope tracers  
6.3.2.1.  Tracer enrichment in plasma  
d4F was detected with very low signal intensity (S/N~8) after 6 h infusion of d4F 
(Figure 6.6A). The dehydrogenation metabolite (d3E) was also very low at this time 
point (S/N~6) (Figure 6.6B) as was regenerated active d3F (S/N~4) (Figure 6.6C). 
After 24 h of d4F infusion, the signal intensity of d4F, d3E and d3F increased (S/N>100) 
allowing regeneration to active steroid to be detected. This process continued to 
equilibrate until 48h infusion, inferred from absolute concentration of d4F, d3E and d3F 
in Figure 6.6A-C. Tracers were not detected in mice infused with vehicle. Upon tracer 
infusion, endogenous levels of CORT declined after 6 h infusion and became 
undetectable (below LOD, S/N< 3) after 24 and 48 h. Figure 6.6D shows the rate of 
appearance of d3F, derived from the d4F/d3F ratios using equation 1, which showed a 


































































































Figure 6.6: Concentration of circulating tracer and metabolites in plasma from wild-type mice. D4F and 
their metabolites d3E and d3F (tracee) continued to increase until 48 h d4F infusion and a considerable 
decline of CORT was observed after 6 h. Ra shown a time-dependent increase. Absolute concentration 
(a) d4F. (b): d3E and (c) d3F. (d) CORT and (e) Ra d3F. Statistical analysis was performed using two-
way ANOVA with Bonferroni's post-hoc test. Data are mean ± SEM (n=3). *** P<0.001 ,** P<0.01 and 












6.3.2.2.  Tracer enrichment in tissues 
To evaluate the tracer penetration into tissues (Figure 6.7A), total d3E production 
(Figure 6.7B) and d3F regeneration (Figure 6.7C) in tissues, analysis of liver, brain 
and adipose were conducted using tissue homogenate. For liver and adipose, 
performing MSI did not offer additional value as histological information cannot be 
obtained from these tissues in imaging mode at spatial resolution of 150 µm. 
Penetration of d4F in the liver and brain displayed a time-dependent increase reaching 
the highest levels at 48 h (Figure 6.7A) with a similar pattern observed for d3E (Figure 
6.7B). In adipose tissue both tracer and inert metabolite were only detected after 48 h 
and in lower abundances, with low S/N~7. Regarding d3F generation, (Figure 6.7C) 
levels peaked at 48 h for liver and brain, which in the latter was only detectable after 24 
h. In adipose, d3F was only observed after 48 h with a low S/N ration (~ 4). As 
previously found in plasma, endogenous levels of CORT in the liver declined after 6 h 
infusion and became undetectable (below LOD, S/N< 3) after 24 and 48 h (Figure 
6.7D). However, in the brain and adipose, the depletion of endogenous CORT was 
slower than plasma and liver as significant decline was only observed after 24 h and 
















































































































Figure 6.7: Estimation of (a) d4F,  (b) d3E, (c) d3F and (d) CORT normalised to ISTD (d8CORT) 
measured by MALDI-FTICRMS in tissues (liver, brain, adipose alongside plasma) from wild-type mice. 
A time-dependent increase in both tracer and metabolites amounts was observed for liver and brain after 
48 h infusion of tracer. In contrast, in adipose tracer and inert metabolite were only observed at 48 h with 
low S/N (~5). In liver levels of CORT declined after 6 h and became non-detectable (S/N<3) after 24 h. 
However, in brain and adipose, levels declined after 24 h and were still detectable after 48 h in the 
adipose. D8CORT intensity was normalized across tissues. Statistical analysis was performed using two-
way ANOVA with Bonferroni's post-hoc test. Data are mean ± SEM (n=3). *** P<0.001, ** P<0.01 and 






6.3.2.3.  Tracer enrichment in murine brain assessed by MSI 
In the brain, d4F (Figure 6.8A) and the inactive metabolite d3E (Figure 6.8B) were 
detected with very low signal intensity (S/N~4) after 6 h infusion of tracer. 
Regeneration to active d3F could not be observed or was below the LOD at this time 
point (Figure 6.8C). After 24 h, the signal intensity of d4F, d3E and d3F increased 
(S/N>50) representing production of d3E from plasma (Figure 6.8B) and allowing 
regeneration to active steroid to be detected (Figure 6.8C). 
 
Figure 6.8: Cortisol turnover assessed in tissues by measuring the proportions of active and inactive 
deuterium labeled cortisol as GirT derivatives in regions of murine brain by MALDI-FTICR-MSI. GirT-
d4F and the inactive metabolite GirT-d3E were effectively detected after 24 h. Regeneration of d3F was 
detectable by 24 h, but more readily after 48 h of infusion. Signal for d3F was most intense in the cortex, 
hippocampus and amygdala. Heat map distribution by MALDI-FTICR-MSI of (a) GirT-d4F at m/z 
480.331 Da (b) GirT-d3E at m/z 477.293 Da (c) GirT-d3F at m/z 479.331 Da.. Signal intensity is depicted 
by color on the scale shown. Scale bar (2 mm).  
 
As previously shown in Ch4 with corticosterone, d3F was detected in highest 
abundance in the cortex, hippocampus and amygdala (Figure 6.9). In all regions, the 
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6.9A), d3E (Figure 6.9B) and d3F (Figure 6.9C) with higher regeneration found in the 
hippocampus. Furthermore, as previously shown in tissue homogenate, CORT was 
depleted after 24 h in all brain regions (Figure 6.9D). Of note, tracers were detected in 
























































































Figure 6.9:  MALDI-FTICR-MSI in regions of interest in murine brain. (a) d4F/d8CORT (b) 
d3E/d8CORT (c) d3F/d8CORT  (d) CORT/d8CORT. Synthesis of d3E increased with time as well as d3F 
generation with higher levels found in the hippocampus; CORT was depleted after 24 h infusion. 
Statistical analysis was performed using two-way ANOVA with Bonferroni's post-hoc test. D8CORT 
intensity was normalized across tissues. Data are mean ± SEM (n=3). *** P<0.001, ** P<0.01 and  * 








6.3.2.4.  Cortisol regeneration in tissues 
Global d3F regeneration was estimated as TTR (d4F/d3F) ratios in plasma and tissue 
homogenates. Tissue-specific regeneration adjusted for the plasma contribution was 
calculated according to equation (2) and expressed as ᴧTTR(T). As shown in Figure 
6.10A, TTR displayed a time-dependent reduction with lowest levels observed in the 
liver. In the brain, TTR displayed lower levels in the hippocampus at 48 h (Figure 
6.10B) . Levels of ᴧTTR(T) in liver were higher than those found in the brain after 48 h 
(Figure 6.10C) and in both cases, a time-increase regeneration was found. In the brain 
higher regeneration was observed in the hippocampus. On the contrary, increment was 





































































































Figure 6.10: d3F regeneration measured as (a) TTR and (b) ᴧTTR(T) in tissues and in different regions 
across the brain as TTR (c) and (d) ᴧTTR(T) by MALDI-FTICRMS from wild-type mice. TTR (d4F/d3F) 
displayed a time-dependent decline pattern with lowest ratios found after 48 h. An increased of ᴧTTR(T) 
was observed with time in liver and brain with higher regeneration found in Liver after 48h. In the brain, 
d3F regeneration was observed across the brain with higher levels found in the hippocampus. Statistical 
analysis was performed using two-way ANOVA with Bonferroni's post-hoc test. Data are mean ± SEM 










6.3.2.5.  D3F regeneration in mice with genetic disruption of 11β-HSD1                          
After 48 h infusion, similar d4F levels were found in plasma of both WT and KO mice 
(Figure 6.11A). Nevertheless, d3F could not be detected or it was below the LOD of 
the methodology in the plasma (S/N<3) (Figure 6.11C). However, absolute levels of 
d3E were significantly higher in the KO than control mice (Figure 6.11B) and 













































Figure 6.11: Concentrations of (a) d4F (b) d3E in plasma from mice with genetic disruption of 11-
HSD1 (KO), after 48h d4F infusion. After disrupting the enzyme, d3E displayed a significant 
accumulation in plasma against controls while levels of d4F remained unchanged. Statistical analysis was 
performed using two-way ANOVA with Bonferroni's post-hoc test. Data are mean ± SEM (n=3). *** 
P<0.001. Ra=Rate of appearance. ND: No detectable. Control: Wild-type mice without drug 
 
In all the tissue the levels of d4F remained unchanged upon enzyme disruption (Figure 
6.12A). However, d3E accumulation was observed upon enzyme disruption in liver and 
brain, but not in adipose (Figure 6.12B). d3F regeneration was undetectable or below 
the LOD (S/N<3) in liver, brain and adipose tissues of the KO mice as ᴧTTR(T) was 
zero in all tissues (Figure 6.12C) . MSI analysis further confirmed the results on the 
brain homogenate as d3F was also undetectable.  


























































Figure 6.12: Estimation of levels of (a) d4F and  (b) d3E normalized to internal standard (d8CORT) and 
(c) ᴧTTR(T) in liver, brain and adipose tissue of mice with genetic disruption of 11-HSD1 (KO) 
following 48 h d4F infusion. D4F levels were unchanged upon disruption of the enzyme. D3E showed a 
significant accumulation in liver and brain in KO mice against controls with greater accumulation 
observed in the liver. However, changes were not observed in adipose tissue. D3F regeneration was not 
observed as ᴧTTR(T) was undetectable. as D8CORT intensity was normalized across tissues. Statistical 
analysis was performed using two-way ANOVA with Bonferroni's post-hoc test. Data are mean ± SEM 
(n=3). *** P<0.001 and * P<0.05. Control: Wild-type mice without drug. 
 
 
Figure 6.13: Cortisol turnover by measuring the proportions of active and inactive deuterium labeled 
cortisol and metabolites as GirT derivatives in regions of brain from mice with genetic disruption of 11-
HSD1 (KO) following 48 h d4F infusion. GirT-d3F could not be detected (S/N<3) after enzyme 
disruption in KO mice and accumulation of GirT-d3E was observed. Heat map distribution by MALDI-
FTICR-MSI of (a) GirT-d4F at m/z 480.331 Da (b) GirT-d3E at m/z 477.293 Da (c) GirT-d3F at m/z 
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6.3.3  PK/PD study of UE2316 using stable isotope tracers 
6.3.3.1  PK profile of UE2316 
After achieving significant d3F regeneration after 48 h, a time-dependent PK/PD study 
of the tissue specific effects of an 11β-HSD1 inhibitor (UE2316) was conducted. 
UE2316 was administered and mice were killed 1, 2, 4 h post-dose (HPD). As shown in 























Figure 6.14: UE2316 levels in plasma during time dependent PK study .Plasma drug levels reached a 
peak at 2 hour post-dose (HPD) and were declining by 4 h. Statistical analysis was performed using two-
way ANOVA with Bonferroni's post-hoc test. Data are mean ± SEM (n=3). **P<0.01.and *P<0.05.  
 
In other tissues tested, UE2316 amounts also reached a peak at 2HPD and declined at 
4HPD. In the liver, drug levels were higher than in the brain at peak level (2HPD). 
UE2316 was not detected in adipose tissue or the signal was below the LOD (5 nmol/g) 
(Figure 6.15). MS distribution maps clearly confirmed the pattern of drug distribution 



























Figure 6.15: Levels of UE2316 in brain and liver tissues during d4F infusion. Drug (UE2316) levels 
peaked at 2 hour post-dose (HPD) and declined after 4 h. Absolute levels of drug in the liver were higher 
than brain at 2HPD..Statistical analysis was performed using two-way ANOVA with Bonferroni's post-
hoc test. Data are mean ± SEM (n=3). *** P<0.001, ** P<0.01 and * P<0.05.  
 
 
Figure 6.16: MS image distribution of UE2316 in murine brain after dosing. Drug levels peaked 2 hour 
post-dose (HPD) and decline at 4HPD. Heat map distribution by MALDI-FTICR-MSI of UE2316 at m/z 
390.189 Da (a) Vehicle (b) 1HPD (c) 2HPD (d) 4HPD.. Signal intensity is depicted by color on the scale 
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6.3.3.2  Plasma PD assessment of glucocorticoid regeneration after UE2316 
treatment 
After a time-dependent pharmacological inhibition using a selective 11β-HSD1 
inhibitor PD was assessed by measuring the d4F/d3F and rate of appearance (Ra) of d3F. 
In the plasma, tracer levels were unaffected during the study (Figure 6.17A) but an 
accumulation of the d3E metabolite was observed at 2HPD (Figure 6.17B). D3F 




































































Figure 6.17: Plasma concentrations of (a) d4F (b) d3E (c) d3F and (d) rate of appearance (Ra) of d3F in 
during timed inhibition of 11-hydroxysteroid dehydrogenase type 1 by UE2316. An accumulation of 
d3E was found 2h post-dose (2HPD) while d4F levels remained unchanged. Levels of d3F and Ra 
decreased after 2HPD. Statistical analysis was performed using two-way ANOVA with Bonferroni's 
post-hoc test. Data are mean ± SEM (n=3).*P<0.05. 




6.3.3.3.  Tissue PD assessment of glucocorticoid regeneration after UE2316 
treatment 
PD was also evaluated in metabolic tissues and the brain. As is shown in Figure 6.18A 
no changes were observed in d4F levels in any tissues during the study. A simultaneous 
accumulation of the inert metabolite (d3E) was found (Figure 6.18B) peaking at 2HPD 
in all tissue expect in adipose and in brain, where levels remained unchanged after 
4HPD. Tracee (d3F) level declined upon enzyme inhibition in all tissue except in the 
adipose, with lowest levels found at 2HPD.  



























































Figure 6.18: Estimation of  (a) d4F (b) d3E  and (c) d3F  levels normalized to internal standard (d8CORT) 
in liver, adipose, brain and plasma. tissue during UE2316 treatment. D4F levels were unchanged while 
d3E levels showed a significant accumulation in liver and brain 2HPD with a greater magnitude in the 
liver d3E and d3F displayed a time-dependent increased pattern  upon pharmacological inhibition of the 
enzyme. D8CORT was normalized for all tissues. Statistical analysis was performed using two-way 





In the brain, molecular distribution maps (Figure 6.19) were generated and relative 
quantitation was conducted (Figure 6.20) for the tracer, tracee and the inert d3E 
metabolite. As shown in Figure 6.19C and 20C a decline in signal intensity of d3F was 
observed between 2 and 4 HPD primarily in the hippocampus and cortex in comparison 
with vehicle while the tracer levels were unchanged (Figure 6.19A and 20A). 
Furthermore, an accumulation of d3E was observed at 2HPD in both cortex and 
hippocampus but interestingly not in the amygdala (Figure 6.19B, 20B). 
 
Figure 6.19: Evaluation of changes in d4F, d3E and d3F following inhibition of 11-hydroxysteroid 
dehydrogenase type 1using UE2316 by MSI in murine brain. Signal intensity of GirT-d3F decline upon 
treatment with an accumulation of d3E metabolite primarily at 2HPD. No differences were observed in 
d4F levels during treatment. MS images of (a) GirT-d4F at m/z 480.331 Da (b) GirT-d3E at m/z 477.293 



































































Figure 6.20: MALDI-FTICR-MSI in regions of interest (ROI) in murine brain. (a) d4F/d8CORT (b) 
d3E/d8CORT  and (c) d3F/d8CORT. Levels of tracer were unchanged and removal of d3E  may have been 
impaired with time. On the contrary, d3F generation was suppressed after 2HPD. D8CORT intensity was 
normalized across tissues. Statistical analysis was performed using two-way ANOVA with Bonferroni's 










6.3.3.4.  Tissue-cortisol regeneration suppression in tissues upon 
pharmacological inhibition 
PD was assessed by calculation of the TTR (d4F/d3F) ratios on plasma and tissues. 
Tissue-specific PD measured as tracee (d3F) suppression during the pharmacological 
inhibition was calculated according to equation (2) and expressed as ᴧTTR(T).  
In plasma and in all tissues except in the adipose, TTR (d4F/d3F) ratios were 
significantly increased 2HPD after administration of the pharmacological inhibitor, 
indicative of lower d3F regeneration with the effect declined towards 4HPD as expected 
in the brain. (Figure 6.21A). ᴧTTR confirmed the pattern observed in the TTR as 
tissue-specific suppression of the d3F synthesis was found after correction for plasma 
contribution upon enzyme inhibition (Figure 6.21B). 
In the brain, region-specific PD was assessed by MSI. As shown in Figure 6.21C an 
increase was observed after 2 and 4 HPD in cortex and hippocampus, an indication of 
lower regeneration of d3F by 11β-HSD1. Interestingly, no significant changes were 






















































































Figure 6.21: Suppression of d3F regeneration measured as (a) TTR and (b) ᴧTTR (T) in tissues and in 
different regions across the brain as TTR (c) and (d) ᴧTTR(T) by MALDI-FTICRMS upon enzyme 
inhibition by UE2316. TTR (d4F/d3F) displayed a time-dependent increased pattern with higher ratios 
found at 2HPD except for adipose tissue. A decline of ᴧTTR(T) was observed with time in liver and brain 
with higher suppression found in the liver at 2HPD. In the brain, d3F synthesis suppression was observed 
across the brain with an exception of the amygdala with higher levels of ᴧTTR(T) found in the 
hippocampus. Statistical analysis was performed using two-way ANOVA with Bonferroni's post-hoc 







6.3.3.5.  UE2316 metabolism 
To further exploit the advantage of multiplexed analysis of MSI, metabolite 
identification was carried out in the liver and brain from mice treated with UE2316 
(4HPD). In the liver (using tissue homogenate), two potential phase II metabolites 
were observed at m/z 565.132 Da proposed as a metabolite formed by N-
glucuronidation (Metabolite I) and at m/z 521.011 Da as a further phase I metabolite 
formed by decarboxylation (Metabolite II) (Figure 6.22). 
 
 
Figure 6.22: Proposed metabolic pathway for UE2316 in the liver 
 
In the brain, two metabolites were potentially detected. From the molecular structure of 
UE2316, it is anticipated that the piperidine alpha hydrogens will be prompt to oxidise 
by phase I CYP450 enzymes leading to potential hydroxylation and further oxidised 
ketone products (Figure 6.23). Molecular distribution maps were generated for the 
theoretical monoisotopic masses of the proposed metabolites (Figure 6.23). A 
proposed hydroxylation product at m/z 406.079 Da Metabolite III) (Figure 6.24) was 
Metabolite II Metabolite I 




detected mainly distributed across the striatum and cortex. On the contrary, a further 
oxidised metabolite at m/z 404.063 Da (Metabolite IV) (possible ketone formation) 
was mainly found in the hippocampus and amygdala. The distinct distribution of each 
metabolite is clearly shown in Figure 6.24D. 
 
 
Figure 6.23: Proposed metabolic pathway for UE2316 in the brain 
 
Figure 6.24: Metabolite identification MSI in mouse brain of UE2316 4 hours post-dose. Proposed 
Phase I metabolites had different distribution across brain, with metabolite I mainly distributed in the 
striatum and cortex and metabolite II found in the hippocampus and amygdala. (a): Haemotoxylin  and 
eosin (H & E) histological staining. Molecular distribution maps of (b): Potential hydroxylation 
metabolite (Metabolite I) at 406.079 Da. (c): Ketonic metabolite at m/z 404.063 Da (Metabolite II). (d): 
Molecular superimposition maps of Metabolite I (blue) and Metabolite II (green). Scale bar (2 mm). 
HPC: hippocampus, Am: amygdala, St: Striatum. 
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6.4   Discussion 
The OTCD-MSI platform was successfully applied to measure the contribution of d3F 
regeneration at tissue-specific level using stable isotope tracer (d4F). As previously 
demonstrated with unlabelled corticosteroids, neutral tracer and their corresponding 
metabolites were converted to positively charged hydrazone derivatives using (GirT), 
enabling detection and quantitation by MALDI-FTICRMSI and structures were further 
confirmed by LESA. In Ch4, measurement of endogenous steroids had been achieved 
but this did not allow assessment of rates of tissue-specific regeneration of active 
glucocorticoids. For this, a stable-isotope tracer was employed.  
As previously performed for other steroids, the GirT derivatisation was evaluated for 
labelled cortisol (d4F) and (d3F) on-tissue spotted standards on a control brain with a 
successful outcome as both labelled derivatives were detected with an acceptable 
signal/noise (S/N>200) and good mass accuracy (<5ppm). As the ionisation was driven 
by the GirT-tag, the response factor between d4F and d3F was 1.04, in concordance 
with what already had been found for unlabelled corticosteroids in Ch5. Therefore, the 
deuterium atoms did not have any effect on either the derivatisation reaction or the 
efficiency of ionisation. Furthermore, preliminary detection of endogenous labelled d4F 
and d3F in an infused brain (d4F, 48 h) was achieved and structures confirmed by LESA 
shared the same fragmentation patterns as previously described for unlabelled 
analogues in section 3.3.5.6. Interestingly, the distribution of d3F during CASI
TM
 
optimisation was primarily located in the striatum and corpus callosum in contrast to 





After tracer infusion, the levels of d4F in the plasma reached around 349 ± 22 nM (24 h 
infusion) and 955 ± 54 nM after 48 h infusion, higher than endogenous levels of CORT 
(286 ± 29 nM) observed in vehicle-infused (DMSO:PG) mice. In humans, the normal 
physiological concentration of cortisol is ranging from (138-635nM, diurnal) and (83-
441nM, afternoon) (Aldhahi et al., 2004), therefore, during the study, physiological 
level of d4F was slightly exceeded.  In a biochemistry context, KM is the concentration 
of substrate at which half the active sites are filled. Thus, KM can provide a measure of 
the substrate concentration required for significant catalysis to occur and also an 
approximation of substrate concentration in vivo. The measured substrate (d3E) 
concentration at 48 h infusion was 536 ± 39 nM thus, in the range of KM values of 11β-
HSD1 (0.1-0.3µM (reduction). Furthermore the [S]/KM ratio was between 1.5-2, close 
to normal values at physiological concentration typically between 0.01 and 1.0. After 6 
h of d4F infusion, endogenous CORT was depleted in plasma from baseline levels 286 
± 29 nM (vehicle-infused) to 77±18 nM and ultimately not detected. This will have 
arisen through negative feedback suppression of ACTH by d4F and loss of stimulation 
of the adrenal cortex. 
 
As this is the first study conducted in rodent using d4F as a tracer, cortisol regeneration 
was compared to that observed in human studies. Followed d4F infusion, levels peaked 
at 955± 54 nM (tracer), 536 ± 39 nM (d3E) and 1257 ± 45 nM (d3F) in 48 h with 
cortisol turn-over higher than in humans as whole-body rate of appearance of d3F at 48 
h was lower (242 ± 25 nmol/h infused at 0.07 mg/h) than values found in human 
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studies at steady-state (~1 nmol/h infused at ~ 1 mg/h, corrected for body weight) 
(Andrew et al., 2005).   
Followed d4F infusion, the presence of tracer could be demonstrated after 6 h in 
plasma, liver and brain and after 48 h in adipose, these differences must reflect 
differences in access to tissues and indeed Hughes et al (Hughes et al., 2013) 
previously showed slow turnover of the adipose steroid pool in human adipose. D3E, 
the substrate for 11-HSD1 reductase, followed the same pattern as observed in d4F but 
with lower levels. The contribution of circulating substrate could not be subtracted, 
therefore levels of d3E measured as d3E/d8CORT in tissues account for total d3E in both 
tissues and circulating pools. Lastly d3F was readily detected in plasma and liver at 6 h, 
but it took 24 h to appear in brain, where it was located primarily in cortex, 
hippocampus and amygdala, the hippocampus being the more active region. Again in 
adipose, it took 48 h for d3F to de detected having a S/N~7 at this time point. 
Endogenous CORT was depleted (below LOD) from plasma and liver after 6 h. 
However, in the brain and adipose CORT levels were decreased after 24 h becoming 
undetectable (below LOD) in the brain after 48 h but not in the adipose as CORT was 
still detectable after 48 h infusion. 
In the liver, which is an 11β-HSD1-rich tissue, the turnover was higher as the d4F/ d3F 
ratios were lowest at all time points and showed a similar pattern as in the plasma. The 
blood contribution to apparent cortisol regeneration in tissues was estimated by 
subtracting the plasma TTR (d4F/ d3F) ratios expressed as ᴧTTR(T) (equation 2). In liver 
and brain local regeneration was observed, in contrast to adipose in which turn-over 
was not observed. In previous studies in humans it has been asserted that the measured 
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whole body rate of appearance reflects the splanchnic bed, of which liver 11-HSD1 
makes the greatest contribution (Andrew et al., 2005). Interestingly, unlike in humans, 
the tracer had not reached steady state during the time interval tested. A reason of this 
observation could be due to the minipump taking time to reach maximum infusion rate. 
Beyond plasma, target tissue availability of glucocorticoids is also regulated in blood 
by their plasma protein binding, largely to corticosteroid-binding globulin (CBG as 
well as albumin). CBG binds physiological glucocorticoids (F, CORT) with high 
affinity, but has low or minimal affinity for their inert 11-keto-forms (E, 11-
DHC) (Breuner et al., 2002). CBG may also act to deliver glucocorticoids to target 
cells. Binding to CBG and lower affinity proteins such as albumin ensures that only a 
small amount (2–5%) of physiological glucocorticoid is ‘free’ in the 
circulation (Rosner, 1990). Traditionally, steroid transport across the cell membrane 
was assumed to be a passive process following a concentration gradient. However, an 
increasing number of transporters of steroids have been identified, such as the organic 
anion transporter-3 in the adrenal (Atanasov et al., 2008), the multidrug resistance P-
glycoprotein in the central nervous system (Baker et al., 1991), and the glucocorticoid 
importer in the liver (Lackner et al., 1998). Particularly, in the brain, where d4F took 24 
h to be detected, the Mdr/p-glycoprotein/ABCB1 transporter acts particularly at the 
blood–brain barrier (but also on other membranes) to partially exclude specific 
corticosteroids from brain (as in many peripheral organs), although such membrane 
‘barriers’ are not absolute. Nonetheless p-glycoprotein minimises access of synthetic 
steroids like dexamethasone to the brain (Meijer et al., 1998) and appears responsible 
for the preferential access of corticosterone rather than cortisol to human cerebrospinal 
fluid (Karssen et al., 2001).  
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In the adipose some in vivo human studies (Lackner et al., 1998; Stimson et al., 2009) 
suggested that the slow rate of accumulation of d4F is determined by transport between 
plasma and intra-adipose steroid pools rather than by rapid enzymatic inactivation. This 
may reflect dissolution in triglyceride depots. This contrasts very markedly with the 
liver, in which d4F levels were detected after 6 h infusion with a considerable 
regeneration after 24 h. It is possible that in the adipose tissue the slow accumulation is 
a reflection of its relatively low blood flow ~3 ml/100 g adipose tissue/min (Katz et al., 
1999b) vs. ~400 ml/min in liver (Stimson et al., 2009). Furthermore, another in 
vivo study reported that adipose uptake of [
3
H]2-cortisol was approximately five times 
slower than that of sex steroids due to solubility in the triglyceride pool (only 12.7% 
uptake at 3 h) (Bleau et al., 1974).  
In term of the PK, there is no evidence that d4F and cortisol have different PK profile 
due to a “primary isotope effect” (Andrew et al., 2002), although their affinity for 
transporters has not been tested. The current data indicating slow turnover between 
plasma and tissue pools of cortisol are consistent with the intraadipose cortisol pool 
integrating the longer-term variations in circulating glucocorticoid concentrations. 
However, unless there are multiple pools of glucocorticoid within the adipose, with a 
cytosolic “free” pool that turns over more quickly than a triglyceride-bound pool, then 
it appears unlikely that intraadipose cortisol concentrations vary widely during acute 
changes in plasma cortisol. Thus, diurnal variation in intraadipose cortisol 
concentrations is likely to be small. This contrasts with other tissues, such as brain 
(Droste et al., 2008) and liver (Stavreva et al., 2009) where, at least in rodents, tissue 
concentrations vary even with ultradian (hourly) fluctuations in plasma glucocorticoids. 
It will be important to establish the rates of exchange between plasma and other 
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intracellular cortisol pools in other organs. 
After genetic disruption of 11β-HSD1, d3F generation was not detected in plasma or 
any tissues, suggesting that 11-HSD1 is the only enzyme carrying out this reaction. 
Furthermore, accumulation d3E was also observed upon enzyme depletion reinforcing 
the concept that 11-HSD1 acts primarily as a reductase in the tissues tested here.  
After a more modest intervention, pharmacological inhibition using an inhibitor 
selective for murine 11-HSD1 (UE2316), a similar pattern was seen. The circulating 
concentrations of drug achieved a peak in tissues after 2 h and declined towards 4 h 
after a single bolus. The blood concentrations achieved during the study were greater 
(3-23 times) than UE2316 Ki (162nM), predicting full enzyme blockage. The dose 
chosen was based on previous unpublished studied where ex vivo assessment of 
enzyme activity supported these magnitudes of enzyme inhibition in liver and brain, 
although this was not measured here. The absolute amounts in tissues were also above 
Ki as levels found in the brain were 278 ± 23 nmol/g and 1149 ± 81 nmol/g in the liver. 
In adipose, UE2316 was not detected, suggesting the drug could not reach the adipose 
tissue during the time of the study, in agreement with previous in vitro studies carried 
out by Webster et al. (unpublished).  Adipose is poorly perfused, and it takes more time 
for the drug to reach the tissue, perhaps explaining null or poor inhibitory effects.  This 
fits with lack of accumulation of d3E and no change in TTR (d4F/d3F) in adipose in the 
time course studied. 
As for most drug-like molecules like UE2316, the distribution is generally uneven 
because of differences in blood perfusion, tissue binding (e.g, because of lipid content), 
207 
 
regional pH, and permeability of cell membranes. Distribution equilibrium between 
blood and tissue is reached more rapidly in richly vascularised areas (e.g. liver), unless 
diffusion across cell membranes is the rate-limiting step. For interstitial fluids of most 
tissues, drug distribution rate is determined primarily by perfusion. For poorly perfused 
tissues (e.g. adipose), distribution was very slow, presumably due to moderate 
lipophilicity of UE2316 measured by its partition-coefficient (LogP) (3.8) 
(unpublished) which may lead to high drug/lipid affinity. Because fat is poorly 
perfused, equilibration time was long, especially in highly lipophilic drugs. 
Furthermore, the extent of drug distribution into tissues depends on the degree of 
plasma protein and tissue binding. In the bloodstream, UE2316 is mostly bound to 
plasma proteins (>80%) (unpublished) and only unbound drug is available for passive 
diffusion to extravascular or tissue sites where the pharmacologic effects of the drug 
occur. Therefore, the unbound drug concentration in systemic circulation typically 
determines drug concentration at the active site and thus efficacy. Like most 
hydrophobic drugs, UE2316 could reach the CNS via brain capillaries and 
cerebrospinal fluid (CSF). Although the brain receives about one sixth of cardiac 
output, drug penetration is restricted because of the brain's permeability characteristics. 
However, due to its moderate high LogP, UE2316 reached the brain readily 1h post-
dose. The reason is the blood-brain barrier, which consists of the endothelium of brain 
capillaries and the astrocytic sheath. The endothelial cells of brain capillaries, which 
appear to be more tightly joined to one another than those of most capillaries, may slow 
the diffusion of water-soluble drugs. The astrocytic sheath consists of a layer of glial 
connective tissue cells (astrocytes) close to the basement membrane of the capillary 
endothelium (de Vries et al., 1997). Also due to its LogP, UE2316 may enter the 
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ventricular CSF directly via the choroid plexus, and then passively diffuse into brain 
tissue from CSF.  
Again in vehicle treated mice, 1118 ±59 nM of d4F was achieved in the circulation and 
rates of appearance of d3F were lowered in the whole body, following administration of 
the inhibitor. This could be seen as the TTR (d4F/d3F) ratios increasing in plasma. The 
time course of change mirrored those of the drug concentrations, with a small delay.     
The most significant increase of TTR (d4F/ d3F) and ᴧTTR(T) ratios in brain and liver 
were observed 2-4 HDP, aligning with the peak in drug concentration at 2 h. 
Furthermore, tissue-specific suppression of d3F regeneration was also found after 
subtraction of the circulating pool contribution. 
There was a considerable decline in drug levels after 4HPD. The ratio of active to 
inactive steroid in liver and plasma responded quickly to the declining drug, but the 
brain levels were still altered 4HPD, suggesting buffering of this pool or long dwell 
time on the enzyme. As no compensation is possible from the adrenal gland, one 
hypothesis could be that the circulating d3F can be further metabolised by other 
enzymes. In adipose, levels of tracee were not altered, presumably due to the slow 
turnover and poor drug penetration in adipose tissue. Further experiments such as 
influence of H6PDH enzyme on cortisol regeneration and effects of tissue specific KO 
(e.g. liver, brain) would be beneficial to further understand the regulation at tissue-
specific level. 
In regards to UE2316 metabolism, standard pharmacokinetic assessments are generally 
carried out after the peak of the drug concentration is reached, in this case after 2HPD.  
209 
 
In the liver (homogenate), phase II metabolites were identified as potential 
glucuronidation derivatives (metabolite III and IV) potentially catalysed by UDP-
glucuronosyltransferase CYP enzymes. Based on the m/z Metabolite IV was proposed 
as a decarboxylation product of metabolite III potentially catalysed by cyp152 CYP 
450 family enzymes. In a tissue collected 4HPD two further metabolites were identified 
in the brain with different spatial distribution. The metabolite I was proposed as a phase 
I CYP450 potentially catalysed by (CYP2A6) sub-families through hydroxylation at 
the acidic 3-5 α-halogenated position of the piperidine ring and further oxidise to 
metabolite II by a potential P450 reductase (CYPOR). It is well documented (Gonzalez, 
1988) that the CYP 450 content in the brain in low (less than 1% found in the liver). 
However, several studies have shown that the levels of CYPs in specific neurons can be 
as high or higher than levels in hepatocytes (Miksys et al., 2002). Although it is 
unlikely that brain CYPs contribute to overall clearance of xenobiotics, they are able to 
metabolise a variety of compounds, including many drugs that cross the blood–brain 
barrier to produce their pharmacological effects within the brain. Given their highly 
localised expression and extreme sensitivity to environmental inducers, they may 
contribute substantially to much of the observed inter individual variation in response 
to centrally acting drugs. They may also be responsible for some of the variation seen 
in side effects and toxicities of drugs that enter the CNS (Miksys et al., 2002). 
Therefore, the different spatial distribution patterns observed in the MS images could 
be related with the enzymes’ localisation across the brain, but further work need to be 
performed in order to confirm this hypothesis. However, in order to fully confirmed all 
proposed metabolites structures, further characterisation analysis such as MS 
fragmentation and NMR must be carried out. 
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6.5   Conclusion 
In this Chapter, I confirmed that deuterated cortisol tracer with in combination OTCD-
MALDI-FTICR-MSI can usefully be employed to measure, for the first time, the 
region-specific turnover in the 11β-HSD pathway in mouse brain and to infer the 
regional activity of 11β-HSD1 isozyme. In this study, the data obtained with this novel 
tool provides new insight into the physiology of glucocorticoid metabolism in brain and 
metabolic tissues in rodents. In agreement with other human studies, data show slow 
11β-HSD1 activity in adipose may be due to lack of access of d3E  leading to low d3F 
generation. D3F regeneration was observed in the liver and moderate regeneration in 
brain primarily in the hippocampus and cortex where 11β-HSD1 expression is high. 
Furthermore, this work has also demonstrated that OTCD-MSI with deuterium cortisol 
labelling is a promising ex vivo high sensitivity, high resolution and multiple 
compounds detection label-free methodology that can potentially be used to assess the 
tissue–specific pharmacokinetic and pharmacodynamic profiles of novel 11β-HSD1 
inhibitors. This study has clearly shown the benefit of using MSI over conventional 









Overall summary and future perspectives 
 
7.1.  Overall summary 
In this thesis, a MSI platform using a MALDI-FTICRMS was developed and optimised 
for spatial distribution analysis of endogenous and exogenous α-β unsaturated- keto 
steroids as Girard T hydrazone derivatives in biological tissue sections. The application 
of MALDI-MSI with OTCD using Girard-T reagent to study diverse steroid and sterols 
biology has been demonstrated. Molecular maps have been generated of 
glucocorticoids, androgens and oxysterols in several rodent tissue sections, where 
analytes were selected with the appropriate chemical groups to react with Girard T. 
Furthermore, beyond murine and rat tissues, human samples have been successfully 
analysed. This platform was further validated using a biological proof of concept study 
in which detection and distribution of endogenous corticosteroids were achieved within 
sub-regions of murine brain, following manipulation of 11β-HSD1 enzyme.  
In this thesis it was also demonstrated that the MSI platform can usefully be used to 
measure the region-specific turnover in the 11β-HSD pathway in a mouse brain and to 
infer the activity of 11β-HSD1 isozyme using stable isotope tracers. The data obtained 
with these novel tools provide new insight into the physiology of glucocorticoid 
metabolism in brain and metabolic tissues in rodents. Furthermore, the methodology 
was used to assess the tissue–specific pharmacokinetic and pharmacodynamic profiles 
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of novel 11β-HSD1 inhibitors showing its benefit in the assessment of regional 
metabolite distribution in the mouse brain, impossible to achieve using the 
conventional LC/MS approaches in tissue homogenate. 
7.2.  Future perspectives 
MALDI-MSI is an emerging tool to enhance understanding of drugs, metabolites and 
endogenous compounds (lipids, proteins) directly in tissue sections. Its ability to co-
localise drug or metabolite distribution with histological information has been 
transformational in biochemistry and can be achieved at meaningful levels of spatial 
resolution.  
However, before MALDI-MSI is accepted as a quantitative tool a number of issues still 
need to be addressed, such as regional ion-suppression and reproducibility of sample 
preparation. In addition, industry and researchers will further develop and refine 
hardware and software to make the MSI approach more robust and easier to implement 
in a high-throughput capacity. Iterative technical improvements in ionisation and mass 
analysers will increase the sensitivity and speed of MSI experiments. Limitations of 
spatial resolution have to be addressed if cellular imaging is needed to allow specific 
assessment of steroid/drug trafficking across different organelles; techniques like SIMS 
or new developments in nanoSIMS may hold the key. Nano-structure initiator mass 
spectrometry (NIMS) (Yanes et al., 2009), laser ablation electrospray ionisation 
(LAESI) (Nemes & Vertes, 2010) and nano-DESI (Takats et al., 2004), amongst others, 
may also broaden the scope for application of the MSI in steroid biology. MSI can aid 
the refinement of clinical studies and an increasing use of in situ MSI for analysis of 
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clinical samples is predicted.  
In terms of MSI of steroids, the platform can be expanded to study progesterone and 
estrogens, but more challenging on-tissue derivatisation approaches have to be carried 
out in order to be able to detect the low physiological levels. In particular for estrogens, 
to reach the pM physiological concentrations, the LOD needs to be improved up to 100 
times of those achieved for glucocorticoids. The application of CASI
TM
 may hold the 
key as shown very promising results on derivatised glucocorticods and the fact that the 
ionisation is mostly driven by the GirT-tag other keto-steroids should follow the same 
desorption/ionisation mechanism.  
In case high spatial resolution is desirable (molecular histology), MALDI (up to 5 µm) 
or SIMS (up to 50 nm) can be used, nevertheless, the sampling area decreases inversely 
proportional with spatial resolution leading to a loss of sensitivity.  
As in MSI, achieving a better sensitivity can compromise spatial resolution, so the 
question to be answered (whole body/organ vs. profiling) is the determining factor in a 
successful MSI analysis. If spatial resolution is not needed, LESA can be used as it is 
one of most sensitive platforms, particularly, using FTICRMS as ions can be 
accumulated for a longer period of time than MALDI leading to better S/N ratios. 
In this thesis, it has been demonstrated for the first time that the spatial distribution of 
low levels steroids in biological tissue section (primarily in the brain) can be studied by 
tissue derivatisation followed MALDI-FTICRMS analysis. This is the first technique 
capable of detecting and quantifying corticosteroids to <200 m resolution, and at 
physiological concentrations, allowing application within region-specific areas of 
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murine brain. its utility for measuring pharmacodynamic effects of small molecule 
inhibitors of 11-HSD1; in combination with pharmacokinetic imaging was also 
demonstrated. This offers the prospect of many novel insights into tissue-specific 

















i.  Synthesis of 4-chloro-α-cyanocinnamic acid (Cl-CCA) 
ii.  Introduction  
MALDI has become an enabling technology for the fields of proteomics and 
metabolomics. Despite its widespread use, for example, in small molecule 
identification, a comprehensive model for the generation of free gas-phase ions has not 
yet been developed. All matrices in use today, such as CHCA, have been found 
empirically and stem from the early days of MALDI. By systematic and targeted 
variation of the functional groups of the α-cyanocinnamic acid core unit, 4-chloro-α-
cyanocinnamic acid (Cl-CCA) was selected and synthesised as previously described by 
Jaskolla and co-workers (Jaskolla et al., 2008). The key feature of the novel matrix is a 
lower proton affinity than its hydroxyl analogue which may enhance the proton transfer 
from a reactive protonated matrix species to the analytes of interest by increasing the 
ion formation via a chemical ionisation mechanism with proton. This increase in 
performance promises to have an impact on future analytical applications of MALDI, 







iii.  Methods 
iv.  Synthesis 
The synthesis was carried out as previously described by Jaskolla (Jaskolla et al., 
2008). Cl-CCA was synthesized by standard Knoevenagel condensation using 
cyanoacetic acid and 4-chlorobenzaldehyde with ammonium acetate as a catalyst 
(Figure APX1). Cyanoacetic acid (1eq), 4-chlorobenzaldehyde (0.9 eq) and 
ammonium acetate (0.15 eq) were refluxed, with stirring, in toluene (60 mL). After 
separation of the reaction water by a Dean Stark trap (4 h), the reaction mixture was 
allowed to cool (40°C) and filtered. The crude product was washed with distilled water 

























Figure  APX1: 4-chloro-α-cyanocinnamic acid synthetic scheme. Cl-CCA: (4-chloro-α-cyanocinnamic 









v.  LC/MS ( yield calculation) 
Separation was achieved on an Inerstil ODS-3 100 x 2.1 mm, 3 µm (GL Sciences, 
Torrance, USA) column. Mobile phases, consisting of 0.1% v/v formic acid (FA) in 
H2O (A) and 0.1% v/v FA in acetonitrile (B), were used at a flow rate of 0.3 mL/min, 
with an initial hold of 3 min at 5% B followed by a linear gradient to 95% B in 15 min 
and re-equilibration at initial conditions (3 min). ZMD single Quad with ESI source 
was used in negative ion mode. Data were acquired in broadband mode (50-500 Da). 
10 µL of a 0.1 mg/mL solution of the re-crystallised material was injected in the 
LC/MS system. 
vi.  Accurate mass determination 
Accurate mass measurement was performed using a 12T SolariX MALDI-FTICR-MS 
in broadband mode, covering a mass range of (98-1500 Da). Analysis was performed at 
2 Mword time-domain transient in broadband mode using negative ion mode at 500 
laser shots using 5 scans/spot. 
vii.  Nuclear magnetic resonance (NMR) characterisation 
5 mg of the final product was dissolved in 0.8 mL of deuterated dimethyl sulfoxide 















viii.  Results 
The overall yield of product, a colourless powder with needle shaped crystals, was ~60 
% assessed after three consecutive re-crystallisations. Accurate mass analysis detected 
an ion at 206.00167Da (Figure APX2) with a mass accuracy of 4.2 ppm against the 
expected Cl-CCA deprotonated monoisotopic quasimolecular ion. 
 






CNMR spectra were concordant with Cl-CCA structure with  
1
H 
NMR signals at (500 MHz, DMSO-d6, 25°C): δ = 8.3 (s, COOH), δ = 8.0-7.8 (d, 2H, J 


























3.15 (s, H2O) ppm (Figure APX3A) and 
13
CNMR  at δ =.164.36, 152.65, 139.49, 
131.11, 130.1, 128.89, 117.01, and 105.58.22 ppm (Figure APX3B)  
 
Figure 1.12: MALDI-FTICR-MS of 4-chloro-α-cyanocinnamic acid (Cl-CCA) cps: count per second.  
 
 
Figure APX3 :  (a): 
1
HNMR and (b): 
13
CNMR spectra of 4-chloro-α-cyanocinnamic acid (Cl-CCA) 







ix.  Conclusion 
The chlorine analogue of CCA, Cl-CCA, was successfully synthesised and 
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